+

US20020058674A1 - Systems and methods for treating a mucosal surface - Google Patents

Systems and methods for treating a mucosal surface Download PDF

Info

Publication number
US20020058674A1
US20020058674A1 US09/886,012 US88601201A US2002058674A1 US 20020058674 A1 US20020058674 A1 US 20020058674A1 US 88601201 A US88601201 A US 88601201A US 2002058674 A1 US2002058674 A1 US 2002058674A1
Authority
US
United States
Prior art keywords
piston
amines
mucosal surface
irm compound
irm
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US09/886,012
Inventor
John Hedenstrom
Michael Jozwiakowski
Mark Martinez
Kenneth Phares
Kenneth Trofatter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
3M Innovative Properties Co
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/479,578 external-priority patent/US6245776B1/en
Priority claimed from US09/676,339 external-priority patent/US6486168B1/en
Application filed by Individual filed Critical Individual
Priority to US09/886,012 priority Critical patent/US20020058674A1/en
Assigned to 3M INNOVATIVE PROPERTIES COMPANY reassignment 3M INNOVATIVE PROPERTIES COMPANY ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: PHARES, KENNETH R., MARTINEZ, MARK, JOZWIAKOWSKI, MICHAEL J., HEDENSTROM, JOHN C., TROFFATER, JR., KENNETH
Publication of US20020058674A1 publication Critical patent/US20020058674A1/en
Assigned to 3M INNOVATIVE PROPERTIES COMPANY reassignment 3M INNOVATIVE PROPERTIES COMPANY RE-RECORD TO CORRECT THE LAST NAME OF THE FIFTH ASSIGNOR, PREVIOUSLY RECORDED ON REEL 012378 FRAME 0329, ASSIGNOR CONFIRMS THE ASSIGNMENT OF THE ENTIRE INTEREST. Assignors: PHARES, KENNETH R., MARTINEZ, MARK, JOZWIAKOWSKI, MICHAEL J., HEDENSTROM, JOHN C., TROFATTER, KENNETH JR.
Priority to US10/238,662 priority patent/US6706728B2/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2210/00—Anatomical parts of the body
    • A61M2210/14—Female reproductive, genital organs
    • A61M2210/1475—Vagina

Definitions

  • the present invention relates to systems and methods for treating a condition associated with a mucosal surface, such as the vaginal part of the cervix.
  • the systems and methods may involve an immune response modifier (IRM) compound chosen from imidazoquinoline amines, imidazopyridine amines, 6,7-fused cycloalkylimidazopyridine amines, imidazonaphthyridine amines, oxazoloquinoline amines, thiazoloquinoline amines, 1,2-bridged imidazoquinoline amines, and pharmaceutically acceptable salts thereof.
  • the invention provides systems and methods which are particularly advantageous for topical application to the cervix for treatment of cervical conditions such as cervical dysplasias including dysplasia associated with human papillomavirus (HPV).
  • HPV human papillomavirus
  • the present invention is also directed to medicament delivery arrangements and methods of use. Some aspects of the invention are directed to the delivery of a pharmacological agent to a selected location with minimal delivery to regions surrounding the selected location. In some optional embodiments the invention is particularly advantageous for topical delivery of a pharmacological agent to the uterine cervix.
  • An IRM compound may be selected from the group comprising imidazoquinoline amines, imidazopyridine amines, 6,7-fused cycloalkylimidazopyridine amines, imidazonaphthyridine amines, oxazoloquinoline amines, thiazoloquinoline amines 1,2-bridged imidazoquinoline amines, and pharmaceutically acceptable salts thereof.
  • Methods for preparing such IRMs and pharmaceutical compositions containing them are disclosed in, for example, U.S. Pat. Nos.
  • IRM interferon-derived cytokines
  • IFN interferon
  • IL-1 tumor necrosis factor
  • IL-6 up regulation of cytokines such as, for example, tumor necrosis factor (TNF), IL-1 and IL-6 also have potentially beneficial activities and are believed to contribute to the antiviral and antitumor properties of these compounds.
  • Topical administration of a pharmacological agent to a tissue surface can provide localized therapeutic benefit without concomitant systemic effects.
  • topical application is often difficult or impossible due to the anatomical location of the tissue.
  • application of the agent to a general anatomical region that includes or surrounds the target tissue may be an alternative to direct topical application.
  • this alternative disadvantageously carries with it the possibility of irritating tissues surrounding the target tissue.
  • regional application typically requires use of a greater volume or concentration of the agent to achieve a therapeutic result equivalent to that achieved by direct application to the target tissue.
  • the uterine cervix is one example of a target tissue to which it is difficult to apply a topical agent. Relative to a standing position, the cervix is typically located at the uppermost portion of the vaginal cavity. However, while the cervix is located at the uppermost portion of the vaginal cavity, age, the stage of the estrous cycle, pregnancy, and other factors cause variability of the location of the cervix between different women and in the same woman at different stages of life.
  • Cervical dysplasia is an example of a pathological condition that can be effectively treated by direct delivery of medication to the surface of the cervix where the abnormal cells are typically found.
  • most currently available applicators for vaginal drug delivery are inadequate for applying a medication to the surface of the cervix.
  • an applicator that is less than optimal is not an acceptable option.
  • vaginal applicators are for application to the vaginal cavity generally and not for direct application to the cervix.
  • the length and configuration of the applicators are insufficient to ensure delivery of an agent to the uppermost portion of the vaginal cavity. Delivery to the middle or lower portion of the vagina does not ensure that an agent will reach the cervical tissue in the upper portion of the vagina.
  • gravity tends to drain agents away from the cervix. Normal discharge and flow of fluids, both menstrual and non-menstrual, also drain away from the cervix.
  • any applicator that is not capable of repeatedly delivering an appropriate amount of agent to the uppermost end of the vaginal cavity risks less than optimal treatment.
  • One aspect of the invention includes a system for treating a condition associated with a mucosal surface.
  • the system comprises an immune response modifier (IRM) compound chosen from imidazoquinoline amines, imidazopyridine amines, 6,7-fused cycloalkylimidazopyridine amines, 1,2-bridged imidazoquinoline amines, and pharmaceutically acceptable salts thereof.
  • IRM immune response modifier
  • the system also comprises an applicator device for applying the IRM compound to the mucosal surface.
  • Another aspect of the invention includes a system comprising an immune response modifier (IRM) compound chosen from imidazoquinoline amines, imidazopyridine amines, 6,7-fused cycloalkylimidazopyridine amines, imidazonaphthyridine amines, oxazoloquinoline amines, thiazoloquinoline amines, 1,2-bridged imidazoquinoline amines, and pharmaceutically acceptable salts thereof.
  • the system also includes an applicator device for applying to the mucosal surface the IRM compound.
  • the IRM compound may be 1-(2-methylpropyl)-1H-imidazo[4,5-c]-quinolin-4-amine, or 4-amino- ⁇ , ⁇ -dimethyl-2-ethoxymethyl-1H-imidazo[4,5-c]quinoline-1-ethanol or 2-propyl[1,3]thiazolo[4,5-c]quinolin-4-amine.
  • the system may be used for treating a condition associated with the mucosal surface on a cervix, optionally, the vaginal part of the cervix.
  • exemplary conditions associated with the mucosal surface include cervical dysphasia and cervical intraepithelial neoplasia.
  • the applicator device may comprise a hollow tube and a piston slidably received within the tube.
  • Yet another aspect of the invention includes a method for treating a condition associated with a mucosal surface.
  • the method comprises providing an immune response modifier (IRM) chosen from imidazoquinoline amines, imidazopyridine amines, 6,7-fused cycloalkylimidazopyridine amines, imidazonaphthyridine amines, oxazoloquinoline amines, thiazoloquinolines amines, 1,2-bridged imidazoquinoline amines, and pharmaceutically acceptable salts thereof.
  • the method also includes providing an applicator device for applying to the mucosal surface the IRM compound.
  • the method further includes applying the IRM compound to the mucosal surface with an applicator device.
  • the method may involve inserting the applicator device into the vagina, positioning a distal end of the applicator device adjacent to the vaginal part of the cervix, and applying the IRM compound to the vaginal part of the cervix.
  • At least some of the embodiments disclosed herein provide medicament application systems and methods suitable for topical administration of an agent to a target tissue.
  • the systems and methods could be advantageous for intravaginal delivery of a pharmacological formulation.
  • some embodiments provide effective topical application of a pharmacological agent to the cervix for treatment or prevention of conditions including, for example, cervical dysplasia.
  • FIG. 1A is a top view of a treatment system including an applicator device and a container containing an IRM compound packaged together;
  • FIG. 1B is a top view of a treatment system with several pre-filled cartridges of the IRM compound
  • FIG. 2 is an exploded perspective view of components of a intravaginal delivery device
  • FIG. 3 is a proximal end-on view of an exemplary intravaginal delivery device
  • FIG. 4 is a longitudinal cross-section view of an exemplary intravaginal delivery device taken through line 4 - 4 with the pushing member retracted proximally;
  • FIG. 5 is a longitudinal cross-section of an exemplary intravaginal delivery device with the pushing member advanced distally;
  • FIG. 6 is a close-up view of the proximal end of the intravaginal delivery device illustrated in FIG. 5;
  • FIG. 7 is a close-up view of the distal end of the intravaginal delivery device illustrated in FIG. 5;
  • FIG. 8 is an exploded perspective view of components of an optional alternative embodiment of an intravaginal delivery device according to the invention.
  • FIG. 9 is a longitudinal cross-section view of the intravaginal delivery device of FIG. 8 with the pushing member retracted proximally;
  • FIG. 10 is a longitudinal cross-section view of the intravaginal delivery device of FIG. 8 with the pushing member distally advanced;
  • FIG. 11 is a close-up view of the distal end of the intravaginal delivery device illustrated in FIG. 10;
  • FIG. 12 is a close-up view of the proximal end of the drug delivery device of FIG. 10;
  • FIG. 13 is a perspective view of an alternative proximal end for an intravaginal delivery device
  • FIG. 14 is a perspective view of another alternative proximal end for an intravaginal delivery device
  • FIG. 15 is a longitudinal cross section view of an exemplary intravaginal delivery device pre-filled with a formulation
  • FIG. 16 is a graph comparing imiquimod transport across hairless mouse skin from three pharmaceutical formulations each containing 5% imiquimod;
  • FIG. 17 is a graph comparing imiquimod transport across hairless mouse skin from four pharmaceutical formulations containing varied concentrations of imiquimod and isostearic acid;
  • FIG. 18 is a graph comparing mean serum imiquimod concentration in rats after a single intravaginal dose of Formulation A or Formulation B;
  • FIGS. 19A and 19B provide bar graphs of the pharmacokinetic comparison of imiquimod in rats after vaginal dosing of Formulation A or Formulation B.
  • the present invention may be, in part, directed to medicament applicators and methods for delivery of a pharmacological agent to a selected location.
  • the dispensers may be particularly suited for intravaginal delivery of a pharmacological agent.
  • the disclosed dispensers may provide for topical application of the pharmacological agent to an itravaginal location, such as the cervix, for treatment of conditions including, for example, cervical dysplasia.
  • the dispensers may be used to deliver a pharmacological agent in a frequency and amount necessary to obtain a desired treatment result.
  • the term “pharmacological agent” includes any agent or combination of agents that can be used to diagnose, treat, cure, ameliorate, prevent or otherwise manage a condition of a patient.
  • condition refers to any infectious, non-infectious, pathological, physiological, biochemical or other state of a patient's body that can be treated according to the invention.
  • proximal and distal are relative terms.
  • proximal refers to a location nearest the user (for example, the user's hand that is operating the dispenser) and the term “distal” refers to a location farthest from the user.
  • distal refers to a location farthest from the user.
  • the proximal end of the delivery device will be nearest to or grasped by the hand of the user and the distal end of the instrument will be located nearest to the tissue site at which the agent will be applied.
  • a “mucosal associated condition” means an inflammatory, infectious, neoplastic or other condition that involves a mucosal surface or that is in sufficient proximity to a mucosal surface to be affected by a therapeutic or prophylactic agent topically applied to the mucosal surface.
  • the term “treat”, and derivatives such as “treatment”, “treating”, etc., are used herein generically to indicate administration of a pharmacological agent for any reason to a patient and is not intended to distinguish a preventative, therapeutic, diagnostic, palliative or other procedure.
  • the term “therapeutically effective amount” means the amount of an agent administered to provide a desired therapeutic effect, such as cytokine induction, antiviral or antitumor activity.
  • a “therapeutically effective amount” includes a single dose of an agent used in a course of therapy over a period of time to achieve a desired therapeutic effect.
  • Some optional embodiments of devices and methods of the invention may be advantageous for delivering an agent to the uterine cervix through the vagina to treat (i.e., prevent, diagnose, ameliorate, etc.) a cervical condition.
  • the dispensers of the invention may be particularly advantageous for delivering an immune response modifier (IRM) to the cervix for a cervical condition.
  • IRM immune response modifier
  • Examples of immune response modifiers suitable for the invention include those disclosed in, for example, U.S. Pat. Nos.
  • IRMs suitable for the invention include 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine (imiquimod) and compounds and formulations such as disclosed in co-pending U.S. Ser. No. 09/479,578 and PCT Publication WO 00/06577. The entire disclosure of each of these patents and applications are incorporated herein by reference.
  • the “user” of the disclosed dispensers include health care providers who apply the agent to a patient or the patient themselves for self-administration of the agent.
  • the dispensers can provide for accurate delivery of a predetermined amount of the pharmacological agent to a selected location with reduced likelihood of inadvertent delivery to surrounding tissues.
  • a predetermined amount is a therapeutically effective amount for a single dose.
  • Accurate application of the agent to a selected location can advantageously reduce the amount of the agent necessary to achieve a therapeutic result while minimizing the possibility of irritation to tissues adjacent to the selected site of application.
  • the dispenser may reduce undesired side effects caused by an agent.
  • delivery of an agent is desired only to the cervix, such as for a cervical condition
  • delivery of the agent to locations other than the upper portion of the vaginal cavity can unnecessarily expose the lower vaginal cavity and other surrounding tissues to the agent. This not only exposes non-targeted tissues to the agent, but also to potential tissue irritation that can be caused by the agent or other components in a pharmacological formulation.
  • the intravaginal dispensers may optionally provide for accurate delivery of a volume of an agent (or formulation thereof that is smaller than volumes typically used for administering other intravaginal medications.
  • the intravaginal dispensers may provide for delivery of about 0.01-10 ml, in other optional embodiments about 0.5 to 4 ml and typically about 1.0 ml.
  • the dispensers can be pre-filled with a therapeutically effective amount of a particular agent or filled by the user at the time of administration.
  • the dispensers can be configured to receive the agent from a source of the agent (e.g., aluminum tube, plastic tube, etc.) that can mount to the dispenser for filling.
  • a source of the agent e.g., aluminum tube, plastic tube, etc.
  • Some optional dispensers may typically provide for a fixed maximum volume of the agent.
  • the dispensers can have incremental markings for filling with amounts less than the maximum volume of the dispenser.
  • a pre-filled dispenser may be provided to eliminate the possibility of filling the delivery device with an incorrect amount of the agent.
  • the dispensers may be pre-filled with a formulation including an amount of immune response modifier (IRM) compound for a single treatment.
  • IRM immune response modifier
  • the dispenser whether pre-filled or not, may be packaged in an outer wrap, such as a foil wrap, which maintains sterility and can act as a moisture barrier.
  • the dispenser may be formed through known methods including injection molding processes that form a plastic applicator from polymer materials such as high density polyethylene, low density polyethylene, linear low density polyethylene, or polypropylene.
  • FIG. 1A shows a treatment system 400 including an applicator device 10 and a container 401 of a formulation packaged together in packaging 402 .
  • the device 10 could be configured to be filled with formulation contained in the container 401 by placing them in flow communication with one another.
  • FIG. 1B shows a treatment system 400 where the formulation is a contained in pre-filled cartridges 401 a - 401 d capable of being loaded in the dispensing device 10 one at a time.
  • FIG. 2 is an exploded perspective view of components of device 10 including elongate tube 3 having a delivery end 4 , an operating end 5 and a lumen 6 passing therethrough.
  • Operating end 5 can include handle arrangement 7 such as opposing flanges 8 a and 8 b for holding device 10 during use.
  • elongate tube 3 may have a length dimension of about 6 cm to about 24 cm, typically, about 10 cm to about 18 cm.
  • Pushing member 11 may be slidably received within lumen 6 of elongate tube 3 and may include a pushing end 12 and a driving end 13 .
  • Pushing end 12 may include a platform 14 for placement of a user's thumb or finger to distally advance pushing member 11 within lumen 6 .
  • Piston 15 may be mountable to driving end 13 of pushing member 11 and may have a distal tip 16 opposite end 17 .
  • a cap 18 may be removably mounted to the distal end 4 of device 10 using known arrangements such as threads or friction fit, for example.
  • FIG. 3 is a distal end view of device 10 and FIG. 4 is a longitudinal cross-section of device 10 taken through line 4 - 4 of FIG. 3.
  • piston 15 is shown mounted to the driving end 13 of pushing member 11 and located at a first position that provides a chamber 20 for containing or receiving a predetermined amount of a pharmacological agent.
  • chamber 20 will provide for a volume of a pharmacological agent of about 5 ml to 0.1 ml, typically about 2 ml to 0.5 ml and optionally about 1.0 ml.
  • the driving end 13 of pushing member 11 may be removably nested into bore 19 of piston 15 .
  • the driving end 13 of pushing member 11 may pull free from bore 19 and piston 15 will not be retracted proximally with pushing member 11 .
  • This optional aspect may prevent aspiration of an agent after expulsion of the agent from chamber 20 and may also prevent aspiration of tissue into the delivery end 4 of tube 3 if pushing member 11 is retracted proximally.
  • lumen 6 may include a stop 40 , such as protuberance 41 which may protrude into lumen 6 to prevent proximal retraction of piston 15 .
  • the position of stop 40 may provide a fixed maximum volume of chamber 20 to contain a predetermined amount of an agent. This stop can advantageously prevent a user from exceeding a particular dose of an agent if the device 10 is filled with the agent by the user prior to use.
  • Cap 18 is shown mounted at delivery end 4 .
  • Cap 18 can be friction fit to the external surface 35 of delivery end 4 .
  • cap 18 can include a stem 18 a which is friction fit into the distal end 1 of lumen 6 .
  • Distal end 1 of lumen 6 could alternatively have female threads (not shown) which can threadedly receive male threads (not shown) which can be present on the exterior surface of stem 18 a.
  • Cap 18 can also include a tab 18 b which provides for easier gripping of cap 18 when removing from tube 3 .
  • Cap 18 could optionally include texturing, such as knurls, ridges, etc., to facilitate removal. Markings, such as a raised arrow, can optionally be added to the cap 18 to indicate the direction to unscrew for removal to contribute to the ease of use of the device.
  • pushing member 11 has been distally advanced to a position that would cause expulsion of a pharmacological agent from chamber 20 .
  • the distal tip 16 of piston 15 protrudes beyond the distal end 4 of elongate tube 3 .
  • distal tip 16 can be convex shaped or domed outwardly to further ensure complete expulsion of an agent from chamber 20 .
  • FIG. 6 is a close-up view of an optional embodiment of a proximal end 2 of delivery device 10 .
  • platform 14 of pushing member 11 forms a shoulder 25 at the junction with the pushing end 12 of pushing member 11 .
  • shoulder 25 may affirmatively stop by abutting against the operating end 5 of elongate tube 3 which may indicate complete delivery of a pharmacological agent from chamber 20 of device 10 .
  • FIG. 7 is a close-up of an optional embodiment of a distal end 1 of delivery device 10 .
  • the distal end of chamber 20 of lumen 6 may include a converging taper 30 .
  • the external surface 31 of piston 15 may also have a converging taper 32 that may extend to distal tip 16 .
  • the corresponding converging tapers 30 and 32 may facilitate complete delivery of a pharmacological agent contained within chamber 20 when pushing member 11 is advanced distally.
  • Piston 15 also may include a sealing ring 33 such as circumferential flange 34 which may fit snugly against lumen 6 to assure that a significant portion, preferably all, of the pharmacological agent is removed from lumen 6 as piston 15 is advanced distally.
  • lumen 6 may have at least two different diameters, a lumen diameter L D and a delivery diameter D D .
  • a typical lumen diameter L D may be about 5 to about 15 mm and a typical delivery diameter may be about 2 to about 10 mm.
  • the length of elongate tube 3 can be about 12-20 cm, L D can be about 10 mm and D D can be about 6 mm.
  • the external surface 35 of distal end 1 of elongate tube 3 may also have a converging taper 36 to facilitate insertion of the distal end 1 of device 10 into the vagina.
  • converging taper 36 may also ensure that all of the dispensed agent remains at the site of delivery.
  • the vaginal wall surrounding the distal end 1 can drape closely around the distal tip 1 to wipe off any of the agent remaining on the tip as compared to applicators having a square-ended (i.e., right cylinder) tip or square-ended tip with rounded corners.
  • the user can place the thumb and middle finger proximal to flanges 8 a and 8 b of handle arrangement 7 to hold device 10 at a selected location while the user's index finger is placed on platform 14 to distally advance pushing member 11 such that distal tip 16 of piston 15 expels the pharmacological agent from chamber 20 to deliver the agent to an intravaginal location, such as the mucosal surface of the cervix.
  • FIG. 8 is an exploded perspective view of the components of an optional alternative embodiment of an intravaginal delivery device 100 .
  • delivery device 100 may include a proximal end 101 , a distal end 102 and a longitudinal axis X-X passing therethrough.
  • Elongate tube 103 may have a delivery end 104 , an operating end 105 and a lumen 106 passing therethrough.
  • a cap 108 can be slidably or threadedly mounted to distal end 102 of device 100 as described above for cap 18 of device 10 .
  • the operating end 105 of elongate tube 103 may include a handle arrangement 107 including tip 118 to facilitate handling of device 100 during use.
  • lip 118 may extend continuously around the circumference of the operating end 105 .
  • lip 118 need not be continuous and, in other embodiments, lip 118 can be omitted.
  • Pushing member 111 can be slidably received into lumen 106 and may include a pushing end 113 , driving end 114 and a shaft 115 extending therebetween.
  • the pushing end 113 can include a platform 116 for placement of a user's thumb or finger to distally advance pushing member 111 during use.
  • Platform 116 can have a concave surface 117 to better conform to the tip of a user's finger or thumb.
  • Piston 120 can be fixedly mounted to driving end 114 of pushing member 111 or driving end 114 can be removably nested into bore 122 a at end 122 .
  • Piston 120 may include a distal tip 121 .
  • distal tip 121 can be convexed distally or domed outwardly to further ensure complete expulsion of the agent.
  • FIG. 9 is a longitudinal cross-section view of device 100 showing chamber 130 for containing or receiving a predetermined amount of a pharmacological agent when pushing member 111 is proximally retracted within lumen 106 of elongate tube 103 .
  • FIG. 10 illustrates that when pushing member 111 is distally advanced, the distal tip 121 of piston 120 may extend beyond the distal end 102 of elongate tube 103 .
  • FIG. 11 is a close-up view of the distal end 102 of the view of device 100 illustrating that chamber 130 may include a converging taper 131 at the distal end 102 of lumen 106 .
  • the optional converging taper 131 of chamber 130 may be configured to match with a corresponding converging taper 132 in a distal portion of piston 120 .
  • the converging surfaces 131 and 132 may facilitate complete expulsion of a pharmacological agent contained within chamber 130 .
  • Piston 120 also can include a sealing ring 133 such as circumferential flange 134 which may fit snugly against lumen 106 to ensure complete expulsion of the agent as piston 120 is advanced distally.
  • the external surface 135 of the distal end 102 of elongate tube 103 may be tapered 136 for reasons discussed above.
  • lumen 106 can include a stop 140 such as protuberance 141 which may protrude into lumen 106 to prevent proximal retraction of piston 120 .
  • the position of stop 140 may provide a fixed maximum volume of chamber 130 to contain a predetermined amount of an agent.
  • FIG. 12 is a close-up view of an optional embodiment of a proximal end 101 of device 100 of FIG. 10 illustrating that when pushing member 111 is fully advanced distally, platform 116 of pushing end 113 may be recessed within the operating end 105 of elongate tube 103 . This feature reduces the likelihood that some or all of the pharmacological agent dispensed from chamber 130 will be aspirated back into the chamber 130 after delivery by inadvertent proximal retraction of pushing member 111 after the pharmacological agent has been expelled.
  • the operating end 105 of elongate tube 103 and the pushing end 113 of pushing member 111 can be constructed to provide audible and/or tactile feedback to the user when expulsion of the agent is complete.
  • the operating end 105 of lumen 106 can include a projecting surface 145 such as ridge 146 at a location proximal to platform 116 when pushing member 111 is fully advanced distally.
  • Platform 116 may be sized such that as platform 116 is pushed distally past ridge 146 a click can be heard and the movement past ridge 146 creates a tactile click to inform the user of complete expulsion of the agent.
  • Ridge 146 may also act to “lock” pushing member 111 in the distally advanced portion and may prevent proximal retraction of pushing member 111 .
  • lumen 106 in addition to lumen diameter L D and delivery diameter D D , lumen 106 also has a diameter P O at operating end 105 .
  • Lumen 106 thus may have a taper 150 extending between diameter P O and L D .
  • the length of elongate tube 103 is about 15 to about 17 cm, L D is about 11-15 mm and D D is about 7-12 mm.
  • the region of elongate tube 103 shown as having parallel sides (see e.g., FIG. 9) extending from the proximal end to the distal end, can alternatively have a converging taper from the proximal end to distal end.
  • This may advantageously provide for filling the delivery device with a pharmacological agent from the proximal end of elongate tube rather than the distal end. That is, without a taper as just described, attempting to push the piston into place distally along a non-tapered tube, after loading the formulation could be hindered by air that can be trapped between the piston seal and wall of the lumen.
  • a gap may be maintained between the piston and the wall that may allow for air to escape as the piston is advanced distally.
  • Such a taper could occur gradually over the length of the elongate tube, or there can be an abrupt taper near where the piston is to be placed for setting a predetermined volume at the distal end of the elongate tube.
  • FIG. 13 illustrates another optional embodiment of the operating end of an elongate tube suitable for an intravaginal delivery device 10 , 100 according to the invention.
  • the operating end 201 of elongate tube 200 may include a configuration which provides an indicator 203 of the orientation of device 200 around longitudinal axis X-X.
  • opposing sides 204 and 205 are linear giving the operating end an oval cross-sectional configuration.
  • lip 206 may extend around the perimeter of the operating end 201 . It will be appreciated, however, that the lip may be completely absent or discontinuous around the perimeter.
  • FIG. 14 illustrates another optional embodiment of the operating end of an elongate tube 300 suitable for an intravaginal delivery device according to the invention.
  • the operating end 301 of elongate tube 300 may include a configuration which also provides an indicator 303 for the orientation of device 300 around longitudinal axis X-X.
  • Operating end 301 may include corners 304 a - 304 d.
  • the walls 305 a - 305 d of operating end 301 between corners 304 a - 304 d form a converging taper moving from operating end diameter P O to lumen diameter L D .
  • the proximal aspect of each of walls 305 a - 305 d may include a concave void 306 a - 306 d extending distally into the surface of the walls 305 a - 305 d, respectively.
  • the platform 350 of the pushing member (not visible) may have a distally concave surface 351 and four corners 352 a - 352 d configured to mate with the corners 304 a - 304 d of walls 305 a - 305 d.
  • a lip or flanges may or may not be present around the proximal edge of the operating end 301 as described for device 10 and 110 .
  • the intravaginal delivery device may provide for accurate delivery of a volume of an agent that is less than the volumes typically used for other vaginal medications.
  • Many vaginal applicators are designed to deliver about 5 ml of an agent and the application is not localized but rather it is delivered to the vaginal cavity in general.
  • the applicator 10 may be pre-filled with a product P to eliminate the possibility of incorrect filling of the applicator.
  • structure such as stops in the device, may set a maximum volume that can help to eliminate the chance of exceeding a predetermined dosage.
  • any of the above-mentioned applicators may have a length sufficient to allow the distal end of the applicator to be located at, or very close to, the cervix while a portion of the applicator passes through the vagina and proximal end is positioned outside the vagina.
  • the length of the applicator may be configured to assure delivery of an IRM compound to the uppermost end of the vaginal cavity while the proximal end is outside the vagina.
  • the length of the applicator may be sufficient to accommodate anatomical variability among women, so that treatment of women with longer vaginal cavities will not be compromised.
  • the intravaginal delivery device could be held at the proximal end between the thumb and middle finger and the platform of the pushing member depressed (i.e., advanced distally) with the index finger to deliver the agent.
  • the pushing member may be pre-positioned within the lumen of the elongate tube, ready for use.
  • the distal end of the elongate tube can include female threads to fit with male threads of a medicament source, such as an aluminum tube, to provide a threaded seal while transferring the medicament from the source to the chamber of the delivery device.
  • the dispensers can be packaged in an overwrap pouch that provides for asepsis as well as a moisture barrier.
  • the overwrap pouch can be made from any material suitable for protecting the pharmacological agent such as foils or foil laminates (e.g., a metal and plastic layer).
  • the overwrap can protect against moisture loss from the formulation or oxidation of the formulation.
  • the applicator device could be part of a system or component used in a method involving additional parts or components.
  • the systems and methods include an immune response modifier (IRM) compound to treat or prevent conditions associated with a mucosal surface.
  • IRM immune response modifier
  • the IRM compound could be in a formulation which can be applied to the mucosal surface of the cervix to treat cervical conditions including cervical dysplasias such as cervical intraepithelial neoplasia.
  • the certain formulations may be used for application of an IRM compound to a mucosal surface.
  • the formulations can enhance therapeutic efficiency of the IRM by facilitating mucosal permeation or increasing the duration of contact of the IRM with the mucosal surface.
  • the pharmaceutical formulation may contain a preservative system that renders the formulations suitable for packaging in multiple-use containers.
  • IRM compounds of the present invention have demonstrated significant immunomodulating activity.
  • Some optional immune response modifier compounds of the invention include 1H-imidazo[4,5-c]quinolin-4-amines defined by one of Formulas I-V below:
  • R 11 is selected from the group consisting of alkyl of one to ten carbon atoms, hydroxyalkyl of one to six carbon atoms, acyloxyalkyl wherein the acyloxy moiety is alkanoyloxy of two to four carbon atoms or benzoyloxy, and the alkyl moiety contains one to six carbon atoms, benzyl, (phenyl)ethyl and phenyl, said benzyl, (phenyl)ethyl or phenyl substituent being optionally substituted on the benzene ring by one or two moieties independently selected from the group consisting of alkyl of one to four carbon atoms, alkoxy of one to four carbon atoms and halogen, with the proviso that if said benzene ring is substituted by two of said moieties, then said moieties together contain no more than six carbon atoms;
  • R 21 is selected from the group consisting of hydrogen, alkyl of one to eight carbon atoms, benzyl, (phenyl)ethyl and phenyl, the benzyl, (phenyl)ethyl or phenyl substituent being optionally substituted on the benzene ring by one or two moieties independently selected from the group consisting of alkyl of one to four carbon atoms, alkoxy of one to four carbon atoms and halogen, with the proviso that when the benzene ring is substituted by two of said moieties, then the moieties together contain no more than six carbon atoms; and
  • each R 1 is independently selected from the group consisting of alkoxy of one to four carbon atoms, halogen, and alkyl of one to four carbon atoms, and n is an integer from 0 to 2, with the proviso that if n is 2, then said R 1 groups together contain no more than six carbon atoms;
  • R 12 is selected from the group consisting of straight chain or branched chain alkenyl containing two to ten carbon atoms and substituted straight chain or branched chain alkenyl containing two to ten carbon atoms, wherein the substituent is selected from the group consisting of straight chain or branched chain alkyl containing one to four carbon atoms and cycloalkyl containing three to six carbon atoms; and cycloalkyl containing three to six carbon atoms substituted by straight chain or branched chain alkyl containing one to four carbon atoms; and
  • R 22 is selected from the group consisting of hydrogen, straight chain or branched alkyl containing one to eight carbon atoms, benzyl, (phenyl)ethyl and phenyl, the benzyl, (phenyl)ethyl or phenyl substituent being optionally substituted on the benzene ring by one or two moieties independently selected from the group consisting of straight chain or branched chain alkyl containing one to four carbon atoms, straight chain or branched chain alkoxy containing one to four carbon atoms, and halogen, with the proviso that when the benzene ring is substituted by two such moieties, then the moieties together contain no more than six carbon atoms; and
  • each R 2 is independently selected from the group consisting of straight chain or branched chain alkoxy containing one to four carbon atoms, halogen, and straight chain or branched chain alkyl containing one to four carbon atoms, and n is an integer from zero to 2, with the proviso that if n is 2, then said R 2 groups together contain no more than six carbon atoms;
  • R 23 is selected from the group consisting of hydrogen, straight chain or branched chain alkyl of one to eight carbon atoms, benzyl, (phenyl)ethyl and phenyl, the benzyl, (phenyl)ethyl or phenyl substituent being optionally substituted on the benzene ring by one or two moieties independently selected from the group consisting of straight chain or branched chain alkyl of one to four carbon atoms, straight chain or branched chain alkoxy of one to four carbon atoms, and halogen, with the proviso that when the benzene ring is substituted by two such moieties, then the moieties together contain no more than six carbon atoms; and
  • each R 3 is independently selected from the group consisting of straight chain or branched chain alkoxy of one to four carbon atoms, halogen, and straight chain or branched chain alkyl of one to four carbon atoms, and n is an integer from zero to 2, with the proviso that if n is 2, then said R 3 groups together contain no more than six carbon atoms;
  • R 14 is —CHR x R y wherein R y is hydrogen or a carbon-carbon bond, with the proviso that when R y is hydrogen R x is alkoxy of one to four carbon atoms, hydroxyalkoxy of one to four carbon atoms, 1-alkynyl of two to ten carbon atoms, tetrahydropyranyl, alkoxyalkyl wherein the alkoxy moiety contains one to four carbon atoms and the alkyl moiety contains one to four carbon atoms, 2-, 3-, or 4-pyridyl, and with the further proviso that when R y is a carbon-carbon bond R y and R x together form a tetrahydrofuranyl group optionally substituted with one or more substituents independently selected from the group consisting of hydroxy and hydroxyalkyl of one to four carbon atoms;
  • R 24 is selected from the group consisting of hydrogen, alkyl of one to four carbon atoms, phenyl, and substituted phenyl wherein the substituent is selected from the group consisting of alkyl of one to four carbon atoms, alkoxy of one to four carbon atoms, and halogen; and
  • R 4 is selected from the group consisting of hydrogen, straight chain or branched chain alkoxy containing one to four carbon atoms, halogen, and straight chain or branched chain alkyl containing one to four carbon atoms;
  • R 15 is selected from the group consisting of: hydrogen; straight chain or branched chain alkyl containing one to ten carbon atoms and substituted straight chain or branched chain alkyl containing one to ten carbon atoms, wherein the substituent is selected from the group consisting of cycloalkyl containing three to six carbon atoms and cycloalkyl containing three to six carbon atoms substituted by straight chain or branched chain alkyl containing one to four carbon atoms; straight chain or branched chain alkenyl containing two to ten carbon atoms and substituted straight chain or branched chain alkenyl containing two to ten carbon atoms, wherein the substituent is selected from the group consisting of cycloalkyl containing three to six carbon atoms and cycloalkyl containing three to six carbon atoms substituted by straight chain or branched chain alkyl containing one to four carbon atoms; hydroxyalkyl of one to six carbon atoms;
  • R S and R T are independently selected from the group consisting of hydrogen, alkyl of one to four carbon atoms, phenyl, and substituted phenyl wherein the substituent is selected from the group consisting of alkyl of one to four carbon atoms, alkoxy of one to four carbon atoms, and halogen;
  • X is selected from the group consisting of alkoxy containing one to four carbon atoms, alkoxyalkyl wherein the alkoxy moiety contains one to four carbon atoms and the alkyl moiety contains one to four carbon atoms, hydroxyalkyl of one to four carbon atoms, haloalkyl of one to four carbon atoms, alkylamido wherein the alkyl group contains one to four carbon atoms, amino, substituted amino wherein the substituent is alkyl or hydroxyalkyl of one to four carbon atoms, azido, chloro, hydroxy, 1-morpholino, 1-pyrrolidino, alkylthio of one to four carbon atoms; and
  • R 5 is selected from the group consisting of hydrogen, straight chain or branched chain alkoxy containing one to four carbon atoms, halogen, and straight chain or branched chain alkyl containing one to four carbon atoms;
  • Preferred 6,7 fused cycloalkylimidazopyridine amine IRM compounds are defined by Formula VI below:
  • m is 1, 2, or 3;
  • R 16 is selected from the group consisting of hydrogen; cyclic alkyl of three, four, or five carbon atoms; straight chain or branched chain alkyl containing one to ten carbon atoms and substituted straight chain or branched chain alkyl containing one to ten carbon atoms, wherein the substituent is selected from the group consisting of cycloalkyl containing three to six carbon atoms and cycloalkyl containing three to six carbon atoms substituted by straight chain or branched chain alkyl containing one to four carbon atoms; fluoro- or chloroalkyl containing from one to ten carbon atoms and one or more fluorine or chlorine atoms; straight chain or branched chain alkenyl containing two to ten carbon atoms and substituted straight chain or branched chain alkenyl containing two to ten carbon atoms, wherein the substituent is selected from the group consisting of cycloalkyl containing three to six carbon atoms and
  • R y is hydrogen or a carbon-carbon bond, with the proviso that when R y is hydrogen R x is alkoxy of one to four carbon atoms, hydroxyalkoxy of one to four carbon atoms, 1-alkynyl of two to ten carbon atoms, tetrahydropyranyl, alkoxyalkyl wherein the alkoxy moiety contains one to four carbon atoms and the alkyl moiety contains one to four carbon atoms, 2-, 3-, or 4-pyridyl, and with the further proviso that when R y is a carbon-carbon bond R y and R x together form a tetrahydrofuranyl group optionally substituted with one or more substituents independently selected from the group consisting of hydroxy and hydroxyalkyl of one to four carbon atoms,
  • R 2 6 is selected from the group consisting of hydrogen, straight chain or branched chain alkyl containing one to eight carbon atoms, straight chain or branched chain hydroxyalkyl containing one to six carbon atoms, morpholinoalkyl, benzyl, (phenyl)ethyl and phenyl, the benzyl, (phenyl)ethyl or phenyl substituent being optionally substituted on the benzene ring by a moiety selected from the group consisting of methyl, methoxy, and halogen; and
  • R S and R T are independently selected from the group consisting of hydrogen, alkyl of one to four carbon atoms, phenyl, and substituted phenyl wherein the substituent is selected from the group consisting of alkyl of one to four carbon atoms, alkoxy of one to four carbon atoms, and halogen;
  • X is selected from the group consisting of alkoxy containing one to four carbon atoms, alkoxyalkyl wherein the alkoxy moiety contains one to four carbon atoms and the alkyl moiety contains one to four carbon atoms, haloalkyl of one to four carbon atoms, alkylamido wherein the alkyl group contains one to four carbon atoms, amino, substituted amino wherein the substituent is alkyl or hydroxyalkyl of one to four carbon atoms, azido, alkylthio of one to four carbon atoms, and morpholinoalkyl wherein the alkyl moiety contains one to four carbon atoms, and
  • R 6 is selected from the group consisting of hydrogen, fluoro, chloro, straight chain or branched chain alkyl containing one to four carbon atoms, and straight chain or branched chain fluoro- or chloroalkyl containing one to four carbon atoms and at least one fluorine or chlorine atom;
  • Preferred imidazopyridine amine IRM compounds are defined by Formula VII below:
  • R 17 is selected from the group consisting of hydrogen; —CH 2 R W wherein R W is selected from the group consisting of straight chain, branched chain, or cyclic alkyl containing one to ten carbon atoms, straight chain or branched chain alkenyl containing two to ten carbon atoms, straight chain or branched chain hydroxyalkyl containing one to six carbon atoms, alkoxyalkyl wherein the alkoxy moiety contains one to four carbon atoms and the alkyl moiety contains one to six carbon atoms, and phenylethyl; and —CH ⁇ CR Z R Z wherein each R Z is independently straight chain, branched chain, or cyclic alkyl of one to six carbon atoms;
  • R 27 is selected from the group consisting of hydrogen, straight chain or branched chain alkyl containing one to eight carbon atoms, straight chain or branched chain hydroxyalkyl containing one to six carbon atoms, alkoxyalkyl wherein the alkoxy moiety contains one to four carbon atoms and the alkyl moiety contains one to six carbon atoms, benzyl, (phenyl)ethyl and phenyl, the benzyl, (phenyl)ethyl or phenyl substituent being optionally substituted on the benzene ring by a moiety selected from the group consisting of methyl, methoxy, and halogen; and morpholinoalkyl wherein the alkyl moiety contains one to four carbon atoms;
  • R 67 and R 77 are independently selected from the group consisting of hydrogen and alkyl of one to five carbon atoms, with the proviso that R 67 and R 77 taken together contain no more than six carbon atoms, and with the further proviso that when R 77 is hydrogen then R 67 is other than hydrogen and R 27 is other than hydrogen or morpholinoalkyl, and with the further proviso that when R 67 is hydrogen then R 77 and R 27 are other than hydrogen;
  • Preferred 1,2-bridged imidazoquinoline amine IRM compounds are defined by Formula VIII below:
  • Z is selected from the group consisting of:
  • R D is hydrogen or alkyl of one to four carbon atoms
  • R E is selected from the group consisting of alkyl of one to four carbon atoms, hydroxy, —OR F wherein R F is alkyl of one to four carbon atoms, and —NR G R′ G wherein R G and R′ G are independently hydrogen or alkyl of one to four carbon atoms;
  • R 8 is selected from the group consisting of alkyl of one to four carbon atoms, alkoxy of one to four carbon atoms, and halogen,
  • Suitable thiazolo- and oxazolo-quinolinamine and pyridinamine compounds include compounds of Formula IX:
  • R 19 is selected from the group consisting of oxygen, sulfur and selenium
  • R 29 is selected from the group consisting of
  • R 39 and R 49 are each independently:
  • R 39 and R49 form a fused aromatic, heteroaromatic, cycloalkyl or heterocyclic ring;
  • X is selected from the group consisting of —O—, —S—, —NR 59 —, —C(O)—, —C(O)O—, —OC(O)—, and a bond;
  • each R 59 is independently H or C 1-8 alkyl
  • Suitable imidazonaphthyridine and tetrahydroimidazomaphthyridine IRM compounds are those of Formulae X and XI below:
  • A is ⁇ N—CR ⁇ CR—CR ⁇ ; ⁇ CR—N ⁇ CR—CR ⁇ ; ⁇ CR—CR ⁇ N—CR ⁇ ; or ⁇ CR—CR ⁇ CR—N ⁇ ;
  • R 110 is selected from the group consisting of:
  • R 210 is selected from the group consisting of:
  • each R 310 is independently selected from the group consisting of hydrogen and C 1-10 alkyl
  • each R is independently selected from the group consisting of hydrogen, C 1-10 alkyl, C 1-10 alkoxy, halogen and trifluoromethyl,
  • B is —NR—C(R) 2 —C(R) 2 —C(R) 2 —; —C(R) 2 —NR—C(R) 2 —C(R) 2 —;
  • R 111 is selected from the group consisting of:
  • R 211 is selected from the group consisting of:
  • each R 311 is independently selected from the group consisting of hydrogen and C 1-10 alkyl
  • each R is independently selected from the group consisting of hydrogen, C 1-10 alkyl, C 1-10 alkoxy, halogen and trifluoromethyl, and pharmaceutically acceptable salts thereof.
  • the substituents R 11 -R 111 above are generally designated “1-substituents” herein.
  • the preferred 1-substituents are alkyl containing one to six carbon atoms and hydroxyalkyl containing one to six carbon atoms.
  • the 1-substituent is 2-methylpropyl or 2-hydroxy-2-methylpropyl.
  • the substituents R 21 -R 211 above are generally designated “2-substituents” herein.
  • Optional 2-substituents are hydrogen, alkyl of one to six carbon atoms, alkoxyalkyl wherein the alkoxy moiety contains one to four carbon atoms and the alkyl moiety contains one to four carbon atoms, and hydroxyalkyl of one to four carbon atoms.
  • the 2-substituent is hydrogen, methyl, butyl, propyl hydroxymethyl, ethoxymethyl or methoxyethyl.
  • n is preferably zero or one.
  • the amount of an IRM compound that will be therapeutically effective in a specific situation will depend on such things as the activity of the particular compound, the mode of administration, the particular formulation and the condition being treated. As such, it is not practical to identify specific administration amounts herein; however, those skilled in the art will be able to determine appropriate therapeutically effective amounts based on the guidance provided herein, information available in the art pertaining to these compounds, and routine testing.
  • the pharmaceutical formulations described below can be used for topical administration of an IRM. Many of the formulations provided are particularly advantageous for topical administration to a mucosal surface. In some embodiments, the formulations can affect the pharmacokinetics of the IRM such that reduced concentrations of the IRM provide similar pharmacodynamic affects as that of other formulations having a greater IRM concentration.
  • a pharmaceutical formulation of the invention includes an IRM, a fatty acid, a preservative system and an optional viscosity enhancing agent such as a carbomer.
  • the IRMs can be prepared using methods previously described in the patents listed in the background section above as well as U.S. Pat. Nos. 4,988,815; 5,367,076; 5,175,296; 5,395,937; and 5,741,908, the disclosures which are incorporated herein by reference. Unless otherwise specified, all percentages are weight percentages based on the total composition weight.
  • the amount of an IRM present in a pharmaceutical formulation of the invention will be an amount effective to treat a targeted condition, to prevent recurrence of the condition, or to promote immunity against the condition.
  • the amount of IRM is preferably about 0.1% to about 9% by weight based on the total formulation weight.
  • the IRM amount does not exceed about 5% by weight and most preferably is about 0.1 to about 3% by weight for mucosal surface applications.
  • a pharmaceutical formulation of the invention is an oil in water emulsion.
  • the oil component of the formulation includes an IRM and a fatty acid.
  • the fatty acid is present in the formulation in an amount sufficient to solubilize the IRM. This is generally about 2% to about 45%, typically about 10% to about 30%, and preferably about 15% to about 18% based on the total weight of the formulation.
  • Fatty acids such as isostearic acid are suitable for the formulations.
  • the IRM can be solubilized in linear chain carboxylic acids of six to eight carbon atoms.
  • a pharmaceutical formulation of the invention can also include an emulsifier such as a non-ionic surfactant.
  • Suitable surfactants include, for example, polysorbate 60, sorbitan monostearate, polyglyceryl-4 oleate, polyoxyethylene(4)lauryl ether, etc.
  • surfactants such as Poloxamers (e.g., Pluronic F68 available from BASF, Ludwigschafen, Germany) and sorbitan trioleate (e.g., Span 85 available from Sigma Chemical Co., St. Louis, Mo.), alone or in combination, are preferred.
  • the non-ionic surfactant is typically present in an amount of about 0.5% to about 10% of total formulation weight. In preferred embodiments, the total emulsifier content does not exceed about 5% of total formulation weight, and is more preferably about 3.5% of total formulation weight.
  • a formulation of the invention can also include a viscosity enhancing agent such as a carbomer, preferably having mucoadhesive properties.
  • the carbomer can be present in an amount of about 0.1% to about 8%, preferably about 0.5% to about 4%, more preferably about 0.5 to about 3%, and most preferably about 1.0% of total formulation weight.
  • Suitable carbomers include polyacrylic acids such as Carbopol 934P, Carbopol 971 P, Carbopol 940 and Carbopol 974P available from B. F. Goodrich.
  • a preferred carbomer is Carbopol 974P.
  • the formulation can also include a chelating agent.
  • the chelating agent functions to chelate metal ions. If present, unchelated metal ions can suppress gel formation by suppressing ionization which facilitates gel formation in a carbomer containing formulation.
  • An optional chelating agent is disodium ethylenediaminetetraacetate (EDTA) in a concentration of about 0.0001 to about 0.5%, typically about 0.0005 to about 0.1% per total formulation weight.
  • EDTA disodium ethylenediaminetetraacetate
  • a preservative such as methylparaben, sorbic acid, propylene glycol, etc. can also be added.
  • methylparaben and sorbic acid are each provided at concentrations of about 0.05% to about 0.3%, preferably about 0.15% of total formulation weight and propylene glycol is present in amounts up to about 30%, preferably about 5%. It was discovered that this combination of preservatives advantageously meets the Preservation Effectiveness Test (PET), 1997 European Pharmacopeia, Test 5.1.3 Efficacy Antimicrobial Preservation—Topical Preparations—A Criteria. This renders the formulation suitable for use in a multi-dose dispenser without adversely affecting the stability of the formulation.
  • the methylparaben and sorbic acid can be solubilized in propylene glycol prior to adding to the formulation.
  • the remainder of the pharmaceutical formulation can be comprised of water to provide a formulation that can be washed away from the mucosal surface by normal physiological clearing mechanisms.
  • the carbomer In addition to providing mucoadhesive properties to the formulation, the carbomer also increases viscosity by forming a stabilizing gel. Many factors, such as the amount of oil phase, the drug load, and the amount of carbomer used will affect the pH at which gelation occurs. In some formulations, the presence of metal ions and surfactants increases the pH at which the carbomer will form a gel. Thus, in the absence of a chelating agent, or in the presence of increased surfactant levels, the pH at which the carbomer will gel can be increased. Thus it may be necessary to add an organic or inorganic base or other substance to facilitate gel formation. Suitable inorganic bases include, for example, KOH, NaOH, etc.
  • the pH for a pharmaceutical formulation of the invention is typically about pH 3.0 to about pH 7.0, preferably about pH 4.0 to about pH 6.0.
  • the compositions can be applied topically, particularly to non-cornified epithelial surfaces such as mucosal surfaces.
  • Mucosal surfaces include mucosal membranes such as buccal, gingival, nasal, tracheal, bronchial, gastrointestinal, rectal, urethral, ureteral, vaginal, cervical, uterine, etc.
  • the therapeutic affect of the IRM may extend only to the superficial layers of the mucosal surface or to tissues deep to the surface.
  • the disclosed IRMs can be topically applied to the vaginal or supravaginal region of the cervix for treatment of dysplastic conditions such as cervical intraepithelial neoplasia.
  • the above described formulations are particularly advantageous for cervical application of an IRM for a period of time sufficient to obtain a desired therapeutic effect without undesired systemic absorption of the IRM.
  • the Papanicoulaou Test (Pap smear) is the screening test which has been accepted since the 1950s as the method to detect abnormal cells of the cervix, including inflammation and dysplasia, which includes cervical cancer. This screening test has been widely adopted in industrialized countries and has had a profound impact on mortality associated with cervical cancers. An abnormal Pap smear prompts close observation for disease progression with the potential for the therapeutic interventions of destruction or excision of cancerous or pre-cancerous tissues. These excisional treatments are expensive, uncomfortable and associated with failure rates which range from 2 to 23% and with higher failure rates reported for the more advanced lesions. Failure rates have recently been documented to approximate 10% following laser treatment.
  • the etiologic agent for cervical cancer was originally thought to be the herpes virus. However, there was a gradual shift from this focus on herpes virus to the human papillomavirus (HPV) when it was shown that the cytopathic effects of HPV in experimental systems very closely mimicked what was seen in human disease. Improved experimental methods over the recent past have allowed the characterization of a full spectrum of HPV subtypes, which has resulted in the conclusion that the high risk HPV types (e.g., HPV 16, 18, and less frequently 31, 33, 35, 45) are very likely the exclusive initiating factor (i.e., oncogenic agent) for cervical dysplasia and subsequent cancers.
  • HPV human papillomavirus
  • HPV transformation of the normal cell to a dysplastic cell is associated with the HPV encoded oncoproteins (E6 and E7) from the high risk genotypes binding the cell's tumor suppressor gene products p53 and Rb resulting in disruption of the cell cycle control mechanism in which p53 and Rb play an important role.
  • HPV encoded oncoproteins E6 and E7
  • HPV encoded oncoproteins E6 and E7
  • HPV is isolated from approximately 93% of cervical tumors, which has further strengthened the generally accepted conclusion that HPV infection is the most important initiating agent for cervical cancer.
  • CMI cell-mediated immune
  • the cell-mediated immune response (Th-1-Type Response) appears to be effective in controlling tumor progression. Regression of intraepithelial lesions is accompanied by a cellular infiltrate consisting of CD4 + T-CELLS, CD8 + T-CELLS, natural killer cells (NK) and macrophages. This inflammatory infiltrate was usually associated with tumor regression which is in contrast to women who lack the ability to mount this inflammatory response and who experience disease progression. In addition, patients with a defect in cell-mediated immunity have increased cervical cancer rates, whereas those with defects in the production of antibody do not exhibit the same susceptibility.
  • the inventors foresee the topical application of IRMs for the non-invasive treatment of cervical conditions including cervical intraepithelial neoplasia (CIN).
  • CIN cervical intraepithelial neoplasia
  • IRM intravaginal application of a herein disclosed IRM.
  • the IRM can be applied via a dosing formulation or dispenser which ensures contact of the IRM with the mucosal surface of the cervix for a period of time sufficient to provide the desired therapeutic effect.
  • Any of the dispensers (i.e., applicators) described herein and/or shown in the drawings could be used to apply the IRM.
  • an IRM can be formulated as a suppository and administered intravaginally using a suppository applicator.
  • a suitable suppository applicator includes known cardboard tube applicators for dispensing medications to the vaginal cavity.
  • Formulations according to the invention can also be administered using a barrel type applicator, such as those described herein and/or shown in the drawings.
  • An example of a suitable barrel type applicator can be found in U.S. Pat. No. 5,282,789, the disclosure of which is incorporated herein by reference.
  • an IRM can be administered directly to the cervical mucosa.
  • the IRM can be topically applied to the cervical mucosa by using a direct cervical applicator, as previously described or using a cervical cap.
  • a direct cervical applicator as previously described or using a cervical cap.
  • Suitable cervical cap is found in U.S. Pat. No. 4,858,624, the disclosure of which is incorporated herein by reference.
  • Suitable IRM formulations for direct cervical applications are disclosed above and in the Examples below.
  • an IRM formulated pursuant to any of formulations A-J in the Examples below can be placed into the concave region of the cervical cap which is then applied directly over the cervix. These formulations might also be applied with other types of applicator devices including those shown in the drawings and described herein.
  • the IRM is formulated to include a viscosity agent, such as a carbomer, to enhance the residence time of the IRM on the cervix.
  • PK Systemic exposure
  • TNF- ⁇ tumor necrosis factor- ⁇
  • IFN- ⁇ interferon- ⁇
  • IL-1RA interleukin-1 receptor agonist
  • IL-6 interleukin-6
  • NTT neopterin
  • 2′5′ oligoadenlyate synthetase (2′5′ AS) 2′5′ AS
  • Statistical tests to evaluate AE's and demographics, laboratory tests, vital signs and ECG's were Fisher's Exact, Wilcoxon Rank-Sum and Kruskall Wallis Tests respectively. Cytokine changes between dose groups were compared using Wilcoxon Rank-Sum and changes from baseline were evaluated using Spearman Rank Correlation.
  • This example describes a novel formulation for a vaginal application, that is a stable formulation, with a high viscosity, and well preserved to pass the EP preservative effectiveness test (PET) criteria.
  • PET EP preservative effectiveness test
  • Table 2 The w/w % of ingredients of this formulation (Formulation B) are shown in Table 2 below.
  • Imiquimod was dissolved in isostearic acid with Span 85.
  • Pluronic F68, EDTA, Carbopol 974P, propylene glycol, sorbic acid, and methylparaben were dissolved in water.
  • sodium hydroxide was added to achieve a pH of about 5.2.
  • the pH range for this formulation can be about 4.8 to 6.0.
  • FIG. 16 is a graph of the results of imiquimod penetration studies of Formulations A and B, of Examples 1 and 2, using hairless mouse skin according to the procedure described in U.S. Pat. No. 5,238,944, the entire disclosure of which is incorporated herein by reference.
  • hairless mouse skin was removed from female hairless mice that were 5 to 7 weeks old (available from Charles River). The skin was maintained on ice until used. The mouse skin was mounted on a diffusion cell of the type shown in U.S. Pat. No. 5,238,944. The mouse skin was mounted with the epidermal side up between upper and lower portions of the cell which are held together by means of ball joint clamp.
  • the portion of the cell below the mounted skin was completely filled with 0.1 N HCl receptor fluid such that the receptor fluid contacted the skin.
  • the receptor fluid was stirred using a magnetic stir bar and a magnetic stirrer.
  • the cell was then placed in a constant temperature (31° C.) chamber.
  • the chamber utilized a heat exchanger coupled to a constant temperature bath, with a fan to circulate air.
  • the receptor fluid was stirred by means of a magnetic stirring bar throughout the experiment to ensure a uniform sample and a reduced diffusion barrier layer on the dermal side of the skin.
  • the entire volume of receptor fluid was removed and immediately replaced with fresh receptor fluid.
  • the withdrawn receptor fluid was analyzed for imiquimod content by conventional high pressure chromatography as follows:
  • Detector UV at 258 nm; Mobile Phase: 25/75 acetonitrile/water containing 1% triethylamine, 0.2% 1-octane sulfonate with the pH adjusted to 2.0 with H 3 PO 4 ; Stationary Phase: C8 Zorbax RX-C8 5 ⁇ ; Flow Rate: 2 ml/min; Run Time: approximately 10 minutes.
  • Table 4 below provides the imiquimod concentration, isostearic acid concentration, viscosity, pH and steady state rate ( ⁇ g/hour) of Formulations C-F across nude mouse skin.
  • Serum was analyzed by HPLC for imiquimod. Mean serum imiquimod concentrations versus time are depicted in FIG. 18. The time to achieve maximum serum concentrations of imiquimod (T max ) was similar (1 hr) for both formulations. However, the maximum imiquimod concentration (C max ) for Formulation B was approximately 1.6 times greater than for Formulation A and the respective area under the curve versus time (AUC) was 3.3 times greater (FIGS. 19A and 19B). Based upon these data, the rate and extent of absorption of imiquimod was greater from Formulation B than from Formulation A.
  • An oil phase was prepared as follows. Imjquimod (20.0 g) was slowly added with stirring to isostearic acid (3000 g). The mixture was stirred and heated, as necessary, up to 55° C. to facilitate dissolution of the imiquimod. After dissolution was complete the heat was turned off. Sorbitan trioleate (200 g) was added and thoroughly mixed. Carbomer 974 was slowly added with mixing. The mixing was continued until the carbomer was uniformly dispersed in the oil phase. The oil phase was then allowed to cool to a temperature of less than 30° C.
  • An aqueous phase was prepared as follows. Sorbic acid (30.0 g) and methylparaben (40.0 g) were added with stirring to propylene glycol (1000 g). The resulting mixture was stirred and heated gently ( ⁇ 45° C.) until a solution was obtained. The heat source was removed. Polaxamer 188 (500 g) was added to the solution. The resulting mixture was stirred until the polaxamer was thoroughly wet. The resulting slurry was then added to a solution of edetate disodium (10.0 g) in purified water (13950 g). The resulting mixture was stirred until a clear solution was obtained.
  • a sodium hydroxide solution was prepared by dissolving sodium hydroxide pellets (50 g) in purified water (1000 g).
  • the imidazoquinoline amines, imidazopyridine amines, 6,7-fused cycloalkylimidazopyridine amines, and 1,2-bridged imidazoquinoline amines of the present invention can be beneficial for treating mucosal associated conditions including cervical dysplasias.
  • the disclosed pharmaceutical formulations can be particularly advantageous for topical application of an IRM to a mucosal surface.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A system for treating a condition associated with a mucosal surface, the system comprising an immune response modifier (IRM) compound chosen from imidazoquinoline amines, imidazopyridine amines, 6,7-fused cycloalkylimidazopyridine amines, imidazonaphthyridine amines, oxazoloquinoline amines, thiazoloquinoline amines, 1,2-bridged imidazoquinoline amines, and pharmaceutically acceptable salts thereof and an applicator device for applying the IRM compound to the mucosal surface. This system of IRM compounds and applicator may be used to treat conditions associated with mucosal surfaces such as cervical dysphasia and cervical intraepithelial neoplasia.

Description

  • This application is a continuation-in-part (CIP) of co-pending application Ser. No. 09/676,339 filed Sep. 29, 2000, which is a continuation of application Ser. No. 09/479,578 filed Jan. 7, 2000 (now U.S. Pat. No. 6,245,776), which claimed priority to application Ser. No. 60/115,253 filed Jan. 8,1999. This application also claims the benefit of priority of the provisional application No. 60/213,420 filed Jun. 22, 2000. In addition, the disclosure of each of the above mentioned applications is incorporated herein by reference.[0001]
    • DESCRIPTION OF THE INVENTION FIELD OF THE INVENTION
  • The present invention relates to systems and methods for treating a condition associated with a mucosal surface, such as the vaginal part of the cervix. In particular, the systems and methods may involve an immune response modifier (IRM) compound chosen from imidazoquinoline amines, imidazopyridine amines, 6,7-fused cycloalkylimidazopyridine amines, imidazonaphthyridine amines, oxazoloquinoline amines, thiazoloquinoline amines, 1,2-bridged imidazoquinoline amines, and pharmaceutically acceptable salts thereof. In one optional embodiment, the invention provides systems and methods which are particularly advantageous for topical application to the cervix for treatment of cervical conditions such as cervical dysplasias including dysplasia associated with human papillomavirus (HPV). [0002]
  • The present invention is also directed to medicament delivery arrangements and methods of use. Some aspects of the invention are directed to the delivery of a pharmacological agent to a selected location with minimal delivery to regions surrounding the selected location. In some optional embodiments the invention is particularly advantageous for topical delivery of a pharmacological agent to the uterine cervix. [0003]
    • BACKGROUND OF THE INVENTION
  • Many imidazoquinoline amine, imidazopyridine amine, 6,7-fused cycloalkylimidazopyridine amine, 1,2-bridged imidazoquinoline amine, thiazolo- and oxazolo-quinolinamines and pyridinamines, imidazonaphthyridine and tetrahydroimidazonaphthyridine amine compounds have demonstrated potent immunostimulating, antiviral and antitumor (including anticancer) activity, and have also been shown to be useful as vaccine adjuvants to enhance the protective immune system response to vaccines. These compounds are hereinafter sometimes collectively referred to as the “IRM” (immune response modifier) compounds of the invention. An IRM compound may be selected from the group comprising imidazoquinoline amines, imidazopyridine amines, 6,7-fused cycloalkylimidazopyridine amines, imidazonaphthyridine amines, oxazoloquinoline amines, [0004] thiazoloquinoline amines 1,2-bridged imidazoquinoline amines, and pharmaceutically acceptable salts thereof. Methods for preparing such IRMs and pharmaceutical compositions containing them are disclosed in, for example, U.S. Pat. Nos. 4,689,338; 5,389,640; 5,268,376; 4,929,624; 5,266,575; 5,352,784; 5,494,916; 5,482,936; 5,346,905; 5,395,937; 5,238,944; 5,525,612; 5,175,296; 5,693,811; 5,741,908; 5,939,090; 6,110,929; 4,988,815; 5,376,076; and PCT Publications WO 99/29693; WO 00/76505; WO 00/76518; and WO 00/76519. The entire disclosure of each of these patents and patent applications is incorporated herein by reference.
  • The immunostimulating, antiviral and antitumor activities of these compounds have been discussed in detail, and certain specific diseases have been identified as being susceptible to treatment therewith, including basal cell carcinoma, eczema, essential thrombocythaemia, hepatitis B, multiple sclerosis, neoplastic diseases, psoriasis, rheumatoid arthritis, type I herpes simplex, type II herpes simplex, and warts. One of these IRM compounds, known as imiquimod, has been commercialized in a topical formulation, Aldara™, for the treatment of anogenital warts associated with human papillomavirus. [0005]
  • The mechanism for the antiviral and antitumor activity of these IRM compounds is thought to be due in substantial part to enhancement of the immune response due to induction of various important cytokines (e.g., interferons, interleukins, tumor necrosis factor, etc.). Such compounds have been shown to stimulate a rapid release of certain monocyte/macrophage-derived cytokines and are also capable of stimulating B cells to secrete antibodies which play an important role in these IRM compounds' antiviral and antitumor activities. One of the predominant immunostimulating responses to these compounds is the induction of interferon (IFN)-α production, which is believed to be very important in the acute antiviral and antitumor activities seen. Moreover, up regulation of cytokines such as, for example, tumor necrosis factor (TNF), IL-1 and IL-6 also have potentially beneficial activities and are believed to contribute to the antiviral and antitumor properties of these compounds. [0006]
  • Although some of the beneficial effects of IRMs are known, the ability to provide therapeutic benefit via topical application of an IRM for treatment of a particular condition at a particular location may be hindered due to tissue irritation, formulation wash away, poor permeation or undesired systemic delivery of the topically applied compound. Accordingly, there is a need for new methods, formulations, and systems to provide the greatest therapeutic benefit from this class of compounds. [0007]
  • Topical administration of a pharmacological agent to a tissue surface can provide localized therapeutic benefit without concomitant systemic effects. However, topical application is often difficult or impossible due to the anatomical location of the tissue. In some cases, application of the agent to a general anatomical region that includes or surrounds the target tissue may be an alternative to direct topical application. But, if the agent has irritating properties, this alternative disadvantageously carries with it the possibility of irritating tissues surrounding the target tissue. In addition, even if the agent is non-irritating, regional application typically requires use of a greater volume or concentration of the agent to achieve a therapeutic result equivalent to that achieved by direct application to the target tissue. [0008]
  • The uterine cervix is one example of a target tissue to which it is difficult to apply a topical agent. Relative to a standing position, the cervix is typically located at the uppermost portion of the vaginal cavity. However, while the cervix is located at the uppermost portion of the vaginal cavity, age, the stage of the estrous cycle, pregnancy, and other factors cause variability of the location of the cervix between different women and in the same woman at different stages of life. [0009]
  • Certain cervical conditions can be advantageously treated by topical administration of a pharmacological agent. Cervical dysplasia is an example of a pathological condition that can be effectively treated by direct delivery of medication to the surface of the cervix where the abnormal cells are typically found. Unfortunately, most currently available applicators for vaginal drug delivery are inadequate for applying a medication to the surface of the cervix. And, since cervical dysplasia can lead to cervical cancer, an applicator that is less than optimal is not an acceptable option. [0010]
  • Most presently available vaginal applicators are for application to the vaginal cavity generally and not for direct application to the cervix. In general, the length and configuration of the applicators are insufficient to ensure delivery of an agent to the uppermost portion of the vaginal cavity. Delivery to the middle or lower portion of the vagina does not ensure that an agent will reach the cervical tissue in the upper portion of the vagina. In addition, with the exception of certain body orientations, gravity tends to drain agents away from the cervix. Normal discharge and flow of fluids, both menstrual and non-menstrual, also drain away from the cervix. Thus, any applicator that is not capable of repeatedly delivering an appropriate amount of agent to the uppermost end of the vaginal cavity risks less than optimal treatment. [0011]
  • Overcoming the inaccuracy of present vaginal applicators, when used for cervical delivery of an agent, by delivering an excess volume or concentration of the medication may be unacceptable due to the risk of undesired effects to surrounding tissues. However, delivery of reduced volumes or concentrations to avoid irritation to surrounding tissue risks the serious consequences of ineffective treatment. [0012]
  • Accordingly, there is continuing need for improved delivery systems and methods for topical application of a pharmacological agent. [0013]
    • SUMMARY OF THE INVENTION
  • One aspect of the invention includes a system for treating a condition associated with a mucosal surface. The system comprises an immune response modifier (IRM) compound chosen from imidazoquinoline amines, imidazopyridine amines, 6,7-fused cycloalkylimidazopyridine amines, 1,2-bridged imidazoquinoline amines, and pharmaceutically acceptable salts thereof. The system also comprises an applicator device for applying the IRM compound to the mucosal surface. [0014]
  • Another aspect of the invention includes a system comprising an immune response modifier (IRM) compound chosen from imidazoquinoline amines, imidazopyridine amines, 6,7-fused cycloalkylimidazopyridine amines, imidazonaphthyridine amines, oxazoloquinoline amines, thiazoloquinoline amines, 1,2-bridged imidazoquinoline amines, and pharmaceutically acceptable salts thereof. The system also includes an applicator device for applying to the mucosal surface the IRM compound. [0015]
  • For example, the IRM compound may be 1-(2-methylpropyl)-1H-imidazo[4,5-c]-quinolin-4-amine, or 4-amino-α,α-dimethyl-2-ethoxymethyl-1H-imidazo[4,5-c]quinoline-1-ethanol or 2-propyl[1,3]thiazolo[4,5-c]quinolin-4-amine. [0016]
  • The system may be used for treating a condition associated with the mucosal surface on a cervix, optionally, the vaginal part of the cervix. Exemplary conditions associated with the mucosal surface include cervical dysphasia and cervical intraepithelial neoplasia. [0017]
  • In an exemplary embodiment, the applicator device may comprise a hollow tube and a piston slidably received within the tube. [0018]
  • Yet another aspect of the invention includes a method for treating a condition associated with a mucosal surface. The method comprises providing an immune response modifier (IRM) chosen from imidazoquinoline amines, imidazopyridine amines, 6,7-fused cycloalkylimidazopyridine amines, imidazonaphthyridine amines, oxazoloquinoline amines, thiazoloquinolines amines, 1,2-bridged imidazoquinoline amines, and pharmaceutically acceptable salts thereof. The method also includes providing an applicator device for applying to the mucosal surface the IRM compound. In addition, the method further includes applying the IRM compound to the mucosal surface with an applicator device. [0019]
  • The method may involve inserting the applicator device into the vagina, positioning a distal end of the applicator device adjacent to the vaginal part of the cervix, and applying the IRM compound to the vaginal part of the cervix. [0020]
  • At least some of the embodiments disclosed herein provide medicament application systems and methods suitable for topical administration of an agent to a target tissue. The systems and methods could be advantageous for intravaginal delivery of a pharmacological formulation. For example, some embodiments provide effective topical application of a pharmacological agent to the cervix for treatment or prevention of conditions including, for example, cervical dysplasia. [0021]
  • Additional aspects will be set forth in part in the description which follows, and in part will be obvious from the description, or may be learned by practice of the invention. It will be appreciated that at several locations throughout the specification, guidance is provided through lists of examples. In each instance, the recited list serves only as a representative group; it is not meant that the list is exclusive. [0022]
  • It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive. [0023]
  • The accompanying drawings, which are incorporated in and constitute a part of this specification, illustrate several embodiments of the invention and together with the description, serve to explain the principles of the invention.[0024]
    • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1A is a top view of a treatment system including an applicator device and a container containing an IRM compound packaged together; [0025]
  • FIG. 1B is a top view of a treatment system with several pre-filled cartridges of the IRM compound; [0026]
  • FIG. 2 is an exploded perspective view of components of a intravaginal delivery device; [0027]
  • FIG. 3 is a proximal end-on view of an exemplary intravaginal delivery device; [0028]
  • FIG. 4 is a longitudinal cross-section view of an exemplary intravaginal delivery device taken through line [0029] 4-4 with the pushing member retracted proximally;
  • FIG. 5 is a longitudinal cross-section of an exemplary intravaginal delivery device with the pushing member advanced distally; [0030]
  • FIG. 6 is a close-up view of the proximal end of the intravaginal delivery device illustrated in FIG. 5; [0031]
  • FIG. 7 is a close-up view of the distal end of the intravaginal delivery device illustrated in FIG. 5; [0032]
  • FIG. 8 is an exploded perspective view of components of an optional alternative embodiment of an intravaginal delivery device according to the invention; [0033]
  • FIG. 9 is a longitudinal cross-section view of the intravaginal delivery device of FIG. 8 with the pushing member retracted proximally; [0034]
  • FIG. 10 is a longitudinal cross-section view of the intravaginal delivery device of FIG. 8 with the pushing member distally advanced; [0035]
  • FIG. 11 is a close-up view of the distal end of the intravaginal delivery device illustrated in FIG. 10; [0036]
  • FIG. 12 is a close-up view of the proximal end of the drug delivery device of FIG. 10; [0037]
  • FIG. 13 is a perspective view of an alternative proximal end for an intravaginal delivery device; [0038]
  • FIG. 14 is a perspective view of another alternative proximal end for an intravaginal delivery device; [0039]
  • FIG. 15 is a longitudinal cross section view of an exemplary intravaginal delivery device pre-filled with a formulation; [0040]
  • FIG. 16 is a graph comparing imiquimod transport across hairless mouse skin from three pharmaceutical formulations each containing 5% imiquimod; [0041]
  • FIG. 17 is a graph comparing imiquimod transport across hairless mouse skin from four pharmaceutical formulations containing varied concentrations of imiquimod and isostearic acid; [0042]
  • FIG. 18 is a graph comparing mean serum imiquimod concentration in rats after a single intravaginal dose of Formulation A or Formulation B; and [0043]
  • FIGS. 19A and 19B provide bar graphs of the pharmacokinetic comparison of imiquimod in rats after vaginal dosing of Formulation A or Formulation B.[0044]
    • DESCRIPTION OF THE EMBODIMENTS
  • Reference will now be made in detail to some exemplary embodiments of the invention, examples of which are illustrated in the accompanying drawings. Wherever possible, the same reference numbers will be used throughout the drawings to refer to the same or like parts. [0045]
  • The present invention may be, in part, directed to medicament applicators and methods for delivery of a pharmacological agent to a selected location. In some optional embodiments, the dispensers may be particularly suited for intravaginal delivery of a pharmacological agent. In optional embodiments, the disclosed dispensers may provide for topical application of the pharmacological agent to an itravaginal location, such as the cervix, for treatment of conditions including, for example, cervical dysplasia. In general, the dispensers may be used to deliver a pharmacological agent in a frequency and amount necessary to obtain a desired treatment result. [0046]
  • Throughout the specification, guidance may be provided through lists of examples. In each instance, the recited list serves only as a representative group. It is not meant, however, that the list is exclusive. [0047]
  • As used herein the term “pharmacological agent” includes any agent or combination of agents that can be used to diagnose, treat, cure, ameliorate, prevent or otherwise manage a condition of a patient. The term “condition” refers to any infectious, non-infectious, pathological, physiological, biochemical or other state of a patient's body that can be treated according to the invention. [0048]
  • Throughout the specification, unless otherwise stated, the terms “proximal” and “distal” are relative terms. The term “proximal” refers to a location nearest the user (for example, the user's hand that is operating the dispenser) and the term “distal” refers to a location farthest from the user. Thus, in a typical embodiment, the proximal end of the delivery device will be nearest to or grasped by the hand of the user and the distal end of the instrument will be located nearest to the tissue site at which the agent will be applied. [0049]
  • As used herein, a “mucosal associated condition” means an inflammatory, infectious, neoplastic or other condition that involves a mucosal surface or that is in sufficient proximity to a mucosal surface to be affected by a therapeutic or prophylactic agent topically applied to the mucosal surface. [0050]
  • Unless stated otherwise, the term “treat”, and derivatives such as “treatment”, “treating”, etc., are used herein generically to indicate administration of a pharmacological agent for any reason to a patient and is not intended to distinguish a preventative, therapeutic, diagnostic, palliative or other procedure. The term “therapeutically effective amount” means the amount of an agent administered to provide a desired therapeutic effect, such as cytokine induction, antiviral or antitumor activity. A “therapeutically effective amount” includes a single dose of an agent used in a course of therapy over a period of time to achieve a desired therapeutic effect. [0051]
  • Some optional embodiments of devices and methods of the invention may be advantageous for delivering an agent to the uterine cervix through the vagina to treat (i.e., prevent, diagnose, ameliorate, etc.) a cervical condition. In certain optional embodiments, the dispensers of the invention may be particularly advantageous for delivering an immune response modifier (IRM) to the cervix for a cervical condition. Examples of immune response modifiers suitable for the invention include those disclosed in, for example, U.S. Pat. Nos. 4,689,338; 5,389,640; 5,268,376; 4,929,624; 5,266,575; 5,352,784; 5,494,916; 5,482,936; 5,346,905; 5,395,937; 5,238,944; 5,525,612; 5,175,296; 5,693,811; 5,741,908; 5,939,090; 6,110,929; 4,988,815; 5,376,076; and PCT Publications WO 99/29693; WO 00/76505; WO 00/76518; and WO 00/76519. The entire disclosure of each of these patents and patent applications is incorporated herein by reference. Some optional IRMs suitable for the invention include 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine (imiquimod) and compounds and formulations such as disclosed in co-pending U.S. Ser. No. 09/479,578 and PCT Publication WO 00/06577. The entire disclosure of each of these patents and applications are incorporated herein by reference. [0052]
  • In general, the “user” of the disclosed dispensers (also referred to herein as applicators) include health care providers who apply the agent to a patient or the patient themselves for self-administration of the agent. [0053]
  • In some optional embodiments, the dispensers can provide for accurate delivery of a predetermined amount of the pharmacological agent to a selected location with reduced likelihood of inadvertent delivery to surrounding tissues. Typically, a predetermined amount is a therapeutically effective amount for a single dose. Accurate application of the agent to a selected location can advantageously reduce the amount of the agent necessary to achieve a therapeutic result while minimizing the possibility of irritation to tissues adjacent to the selected site of application. [0054]
  • In the case of intravaginal applications, the dispenser may reduce undesired side effects caused by an agent. For example, when delivery of an agent is desired only to the cervix, such as for a cervical condition, delivery of the agent to locations other than the upper portion of the vaginal cavity can unnecessarily expose the lower vaginal cavity and other surrounding tissues to the agent. This not only exposes non-targeted tissues to the agent, but also to potential tissue irritation that can be caused by the agent or other components in a pharmacological formulation. [0055]
  • The intravaginal dispensers may optionally provide for accurate delivery of a volume of an agent (or formulation thereof that is smaller than volumes typically used for administering other intravaginal medications. In some optional embodiments, the intravaginal dispensers may provide for delivery of about 0.01-10 ml, in other optional embodiments about 0.5 to 4 ml and typically about 1.0 ml. [0056]
  • The dispensers can be pre-filled with a therapeutically effective amount of a particular agent or filled by the user at the time of administration. In the latter situation, the dispensers can be configured to receive the agent from a source of the agent (e.g., aluminum tube, plastic tube, etc.) that can mount to the dispenser for filling. Some optional dispensers may typically provide for a fixed maximum volume of the agent. Alternatively, or additionally, the dispensers can have incremental markings for filling with amounts less than the maximum volume of the dispenser. [0057]
  • In an optional embodiment, a pre-filled dispenser may be provided to eliminate the possibility of filling the delivery device with an incorrect amount of the agent. In one optional embodiment, the dispensers may be pre-filled with a formulation including an amount of immune response modifier (IRM) compound for a single treatment. The dispenser, whether pre-filled or not, may be packaged in an outer wrap, such as a foil wrap, which maintains sterility and can act as a moisture barrier. [0058]
  • The dispenser may be formed through known methods including injection molding processes that form a plastic applicator from polymer materials such as high density polyethylene, low density polyethylene, linear low density polyethylene, or polypropylene. [0059]
  • FIG. 1A shows a [0060] treatment system 400 including an applicator device 10 and a container 401 of a formulation packaged together in packaging 402. The device 10 could be configured to be filled with formulation contained in the container 401 by placing them in flow communication with one another.
  • FIG. 1B shows a [0061] treatment system 400 where the formulation is a contained in pre-filled cartridges 401 a-401 d capable of being loaded in the dispensing device 10 one at a time.
  • FIGS. 2 and 4 show an optional embodiment of an [0062] intravaginal delivery device 10 according to the invention. As illustrated, device 10 may include a distal end 1, a proximal end 2 and a longitudinal axis X-X passing therethrough. FIG. 2 is an exploded perspective view of components of device 10 including elongate tube 3 having a delivery end 4, an operating end 5 and a lumen 6 passing therethrough. Operating end 5 can include handle arrangement 7 such as opposing flanges 8 a and 8 b for holding device 10 during use. In some embodiments, elongate tube 3 may have a length dimension of about 6 cm to about 24 cm, typically, about 10 cm to about 18 cm.
  • Pushing [0063] member 11 may be slidably received within lumen 6 of elongate tube 3 and may include a pushing end 12 and a driving end 13. Pushing end 12 may include a platform 14 for placement of a user's thumb or finger to distally advance pushing member 11 within lumen 6. Piston 15 may be mountable to driving end 13 of pushing member 11 and may have a distal tip 16 opposite end 17. A cap 18 may be removably mounted to the distal end 4 of device 10 using known arrangements such as threads or friction fit, for example.
  • FIG. 3 is a distal end view of [0064] device 10 and FIG. 4 is a longitudinal cross-section of device 10 taken through line 4-4 of FIG. 3. In FIG. 4, piston 15 is shown mounted to the driving end 13 of pushing member 11 and located at a first position that provides a chamber 20 for containing or receiving a predetermined amount of a pharmacological agent.
  • In some optional embodiments, [0065] chamber 20 will provide for a volume of a pharmacological agent of about 5 ml to 0.1 ml, typically about 2 ml to 0.5 ml and optionally about 1.0 ml. In an optional embodiment, the driving end 13 of pushing member 11 may be removably nested into bore 19 of piston 15. Thus, in this optional embodiment, if pushing member 11 is retracted proximally the driving end 13 of pushing member 11 may pull free from bore 19 and piston 15 will not be retracted proximally with pushing member 11. This optional aspect may prevent aspiration of an agent after expulsion of the agent from chamber 20 and may also prevent aspiration of tissue into the delivery end 4 of tube 3 if pushing member 11 is retracted proximally.
  • In addition, in some optional embodiments, [0066] lumen 6 may include a stop 40, such as protuberance 41 which may protrude into lumen 6 to prevent proximal retraction of piston 15. Whether device 10 is pre-filled with an agent or filled by the user at the time of use, the position of stop 40 may provide a fixed maximum volume of chamber 20 to contain a predetermined amount of an agent. This stop can advantageously prevent a user from exceeding a particular dose of an agent if the device 10 is filled with the agent by the user prior to use.
  • [0067] Cap 18 is shown mounted at delivery end 4. Cap 18 can be friction fit to the external surface 35 of delivery end 4. Alternatively, or in addition, cap 18 can include a stem 18 a which is friction fit into the distal end 1 of lumen 6. Distal end 1 of lumen 6 could alternatively have female threads (not shown) which can threadedly receive male threads (not shown) which can be present on the exterior surface of stem 18 a. Cap 18 can also include a tab 18 b which provides for easier gripping of cap 18 when removing from tube 3.
  • [0068] Cap 18, could optionally include texturing, such as knurls, ridges, etc., to facilitate removal. Markings, such as a raised arrow, can optionally be added to the cap 18 to indicate the direction to unscrew for removal to contribute to the ease of use of the device.
  • In FIG. 5, pushing [0069] member 11 has been distally advanced to a position that would cause expulsion of a pharmacological agent from chamber 20. In the optional illustrated embodiment, when pushing member 11 is distally advanced, the distal tip 16 of piston 15 protrudes beyond the distal end 4 of elongate tube 3. In addition, distal tip 16 can be convex shaped or domed outwardly to further ensure complete expulsion of an agent from chamber 20.
  • FIG. 6 is a close-up view of an optional embodiment of a proximal end [0070] 2 of delivery device 10. In the illustrated embodiment, platform 14 of pushing member 11 forms a shoulder 25 at the junction with the pushing end 12 of pushing member 11. When pushing member 11 is distally advanced within lumen 6, shoulder 25 may affirmatively stop by abutting against the operating end 5 of elongate tube 3 which may indicate complete delivery of a pharmacological agent from chamber 20 of device 10.
  • FIG. 7 is a close-up of an optional embodiment of a [0071] distal end 1 of delivery device 10. As illustrated, the distal end of chamber 20 of lumen 6 may include a converging taper 30. The external surface 31 of piston 15 may also have a converging taper 32 that may extend to distal tip 16. The corresponding converging tapers 30 and 32 may facilitate complete delivery of a pharmacological agent contained within chamber 20 when pushing member 11 is advanced distally. Piston 15 also may include a sealing ring 33 such as circumferential flange 34 which may fit snugly against lumen 6 to assure that a significant portion, preferably all, of the pharmacological agent is removed from lumen 6 as piston 15 is advanced distally. Thus, lumen 6 may have at least two different diameters, a lumen diameter LD and a delivery diameter DD. A typical lumen diameter LD may be about 5 to about 15 mm and a typical delivery diameter may be about 2 to about 10 mm. In an example of a delivery device 10 with a maximum chamber volume of about 1 ml, the length of elongate tube 3 can be about 12-20 cm, LD can be about 10 mm and DD can be about 6 mm.
  • The [0072] external surface 35 of distal end 1 of elongate tube 3 may also have a converging taper 36 to facilitate insertion of the distal end 1 of device 10 into the vagina. After expulsion of an agent from chamber 20, converging taper 36 may also ensure that all of the dispensed agent remains at the site of delivery. For example, when delivering an agent to the cervix, the vaginal wall surrounding the distal end 1 can drape closely around the distal tip 1 to wipe off any of the agent remaining on the tip as compared to applicators having a square-ended (i.e., right cylinder) tip or square-ended tip with rounded corners.
  • In use, the user can place the thumb and middle finger proximal to flanges [0073] 8 a and 8 b of handle arrangement 7 to hold device 10 at a selected location while the user's index finger is placed on platform 14 to distally advance pushing member 11 such that distal tip 16 of piston 15 expels the pharmacological agent from chamber 20 to deliver the agent to an intravaginal location, such as the mucosal surface of the cervix.
  • FIG. 8 is an exploded perspective view of the components of an optional alternative embodiment of an [0074] intravaginal delivery device 100. As illustrated, delivery device 100 may include a proximal end 101, a distal end 102 and a longitudinal axis X-X passing therethrough. Elongate tube 103 may have a delivery end 104, an operating end 105 and a lumen 106 passing therethrough. A cap 108 can be slidably or threadedly mounted to distal end 102 of device 100 as described above for cap 18 of device 10.
  • The operating [0075] end 105 of elongate tube 103 may include a handle arrangement 107 including tip 118 to facilitate handling of device 100 during use. In the optional illustrated embodiment, lip 118 may extend continuously around the circumference of the operating end 105. However, it will be appreciated that lip 118 need not be continuous and, in other embodiments, lip 118 can be omitted.
  • Pushing [0076] member 111 can be slidably received into lumen 106 and may include a pushing end 113, driving end 114 and a shaft 115 extending therebetween. The pushing end 113 can include a platform 116 for placement of a user's thumb or finger to distally advance pushing member 111 during use. Platform 116 can have a concave surface 117 to better conform to the tip of a user's finger or thumb. Piston 120 can be fixedly mounted to driving end 114 of pushing member 111 or driving end 114 can be removably nested into bore 122 a at end 122. Piston 120 may include a distal tip 121. In some embodiments, distal tip 121 can be convexed distally or domed outwardly to further ensure complete expulsion of the agent.
  • FIG. 9 is a longitudinal cross-section view of [0077] device 100 showing chamber 130 for containing or receiving a predetermined amount of a pharmacological agent when pushing member 111 is proximally retracted within lumen 106 of elongate tube 103. FIG. 10 illustrates that when pushing member 111 is distally advanced, the distal tip 121 of piston 120 may extend beyond the distal end 102 of elongate tube 103.
  • FIG. 11 is a close-up view of the [0078] distal end 102 of the view of device 100 illustrating that chamber 130 may include a converging taper 131 at the distal end 102 of lumen 106. The optional converging taper 131 of chamber 130 may be configured to match with a corresponding converging taper 132 in a distal portion of piston 120. The converging surfaces 131 and 132 may facilitate complete expulsion of a pharmacological agent contained within chamber 130.
  • [0079] Piston 120 also can include a sealing ring 133 such as circumferential flange 134 which may fit snugly against lumen 106 to ensure complete expulsion of the agent as piston 120 is advanced distally. The external surface 135 of the distal end 102 of elongate tube 103 may be tapered 136 for reasons discussed above.
  • As with [0080] device 10, in some optional embodiments, lumen 106 can include a stop 140 such as protuberance 141 which may protrude into lumen 106 to prevent proximal retraction of piston 120. Whether device 100 is pre-filled with an agent or filled by the user at the time of use, the position of stop 140 may provide a fixed maximum volume of chamber 130 to contain a predetermined amount of an agent.
  • FIG. 12 is a close-up view of an optional embodiment of a [0081] proximal end 101 of device 100 of FIG. 10 illustrating that when pushing member 111 is fully advanced distally, platform 116 of pushing end 113 may be recessed within the operating end 105 of elongate tube 103. This feature reduces the likelihood that some or all of the pharmacological agent dispensed from chamber 130 will be aspirated back into the chamber 130 after delivery by inadvertent proximal retraction of pushing member 111 after the pharmacological agent has been expelled.
  • Also, in some optional embodiments, the operating [0082] end 105 of elongate tube 103 and the pushing end 113 of pushing member 111 can be constructed to provide audible and/or tactile feedback to the user when expulsion of the agent is complete. According to this optional embodiment, the operating end 105 of lumen 106 can include a projecting surface 145 such as ridge 146 at a location proximal to platform 116 when pushing member 111 is fully advanced distally. Platform 116 may be sized such that as platform 116 is pushed distally past ridge 146 a click can be heard and the movement past ridge 146 creates a tactile click to inform the user of complete expulsion of the agent. Ridge 146 may also act to “lock” pushing member 111 in the distally advanced portion and may prevent proximal retraction of pushing member 111.
  • It will be appreciated that in addition to lumen diameter L[0083] D and delivery diameter DD, lumen 106 also has a diameter PO at operating end 105. Lumen 106 thus may have a taper 150 extending between diameter PO and LD. In an example of a delivery device 100 having a maximum chamber volume of about 1 ml, the length of elongate tube 103 is about 15 to about 17 cm, LD is about 11-15 mm and DD is about 7-12 mm.
  • In an optional alternative embodiment, the region of [0084] elongate tube 103, shown as having parallel sides (see e.g., FIG. 9) extending from the proximal end to the distal end, can alternatively have a converging taper from the proximal end to distal end. This may advantageously provide for filling the delivery device with a pharmacological agent from the proximal end of elongate tube rather than the distal end. That is, without a taper as just described, attempting to push the piston into place distally along a non-tapered tube, after loading the formulation could be hindered by air that can be trapped between the piston seal and wall of the lumen. By tapering the elongate lumen as described, a gap may be maintained between the piston and the wall that may allow for air to escape as the piston is advanced distally. Such a taper could occur gradually over the length of the elongate tube, or there can be an abrupt taper near where the piston is to be placed for setting a predetermined volume at the distal end of the elongate tube.
  • FIG. 13 illustrates another optional embodiment of the operating end of an elongate tube suitable for an [0085] intravaginal delivery device 10, 100 according to the invention. According to this embodiment, the operating end 201 of elongate tube 200 may include a configuration which provides an indicator 203 of the orientation of device 200 around longitudinal axis X-X. Thus, in the embodiment of FIG. 13, opposing sides 204 and 205 are linear giving the operating end an oval cross-sectional configuration. In this embodiment, lip 206 may extend around the perimeter of the operating end 201. It will be appreciated, however, that the lip may be completely absent or discontinuous around the perimeter.
  • FIG. 14 illustrates another optional embodiment of the operating end of an [0086] elongate tube 300 suitable for an intravaginal delivery device according to the invention. In this embodiment, the operating end 301 of elongate tube 300 may include a configuration which also provides an indicator 303 for the orientation of device 300 around longitudinal axis X-X. Operating end 301 may include corners 304 a-304 d. The walls 305 a-305 d of operating end 301 between corners 304 a-304 d form a converging taper moving from operating end diameter PO to lumen diameter LD. In the illustrated embodiment, the proximal aspect of each of walls 305 a-305 d may include a concave void 306 a-306 d extending distally into the surface of the walls 305 a-305 d, respectively. In addition, the platform 350 of the pushing member (not visible) may have a distally concave surface 351 and four corners 352 a-352 d configured to mate with the corners 304 a-304 d of walls 305 a-305 d. A lip or flanges (not shown in this embodiment) may or may not be present around the proximal edge of the operating end 301 as described for device 10 and 110.
  • The intravaginal delivery device may provide for accurate delivery of a volume of an agent that is less than the volumes typically used for other vaginal medications. Many vaginal applicators are designed to deliver about 5 ml of an agent and the application is not localized but rather it is delivered to the vaginal cavity in general. [0087]
  • In optional embodiments, such as that shown in FIG. 15, the [0088] applicator 10 may be pre-filled with a product P to eliminate the possibility of incorrect filling of the applicator. However, if the device is to be filled at the time of use, structure such as stops in the device, may set a maximum volume that can help to eliminate the chance of exceeding a predetermined dosage.
  • Any of the above-mentioned applicators may have a length sufficient to allow the distal end of the applicator to be located at, or very close to, the cervix while a portion of the applicator passes through the vagina and proximal end is positioned outside the vagina. The length of the applicator may be configured to assure delivery of an IRM compound to the uppermost end of the vaginal cavity while the proximal end is outside the vagina. For example, the length of the applicator may be sufficient to accommodate anatomical variability among women, so that treatment of women with longer vaginal cavities will not be compromised. [0089]
  • In use, the intravaginal delivery device could be held at the proximal end between the thumb and middle finger and the platform of the pushing member depressed (i.e., advanced distally) with the index finger to deliver the agent. [0090]
  • In optional embodiments, the pushing member may be pre-positioned within the lumen of the elongate tube, ready for use. If the delivery device is to be filled prior to use, the distal end of the elongate tube can include female threads to fit with male threads of a medicament source, such as an aluminum tube, to provide a threaded seal while transferring the medicament from the source to the chamber of the delivery device. [0091]
  • The dispensers can be packaged in an overwrap pouch that provides for asepsis as well as a moisture barrier. The overwrap pouch can be made from any material suitable for protecting the pharmacological agent such as foils or foil laminates (e.g., a metal and plastic layer). In some embodiments, the overwrap can protect against moisture loss from the formulation or oxidation of the formulation. [0092]
  • The applicator device could be part of a system or component used in a method involving additional parts or components. In one optional embodiment, the systems and methods include an immune response modifier (IRM) compound to treat or prevent conditions associated with a mucosal surface. For example, the IRM compound could be in a formulation which can be applied to the mucosal surface of the cervix to treat cervical conditions including cervical dysplasias such as cervical intraepithelial neoplasia. [0093]
  • In some optional embodiments, the certain formulations may be used for application of an IRM compound to a mucosal surface. In some optional embodiments, the formulations can enhance therapeutic efficiency of the IRM by facilitating mucosal permeation or increasing the duration of contact of the IRM with the mucosal surface. The pharmaceutical formulation may contain a preservative system that renders the formulations suitable for packaging in multiple-use containers. [0094]
  • IRM Compounds [0095]
  • As noted above, many of the imidazoquinoline amine, imidazopyridine amine, 6,7-fused cycloalkylimidazopyridine amine, 1,2-bridged imidazoquinoline amine, thiazolo- and oxazolo-quinolinamines and pyridinamines, imidazonaphthyridine and tetrahydroimidazonaphthyridine amine IRM compounds of the present invention have demonstrated significant immunomodulating activity. Some optional immune response modifier compounds of the invention include 1H-imidazo[4,5-c]quinolin-4-amines defined by one of Formulas I-V below: [0096]
    Figure US20020058674A1-20020516-C00001
  • wherein [0097]
  • R[0098] 11 is selected from the group consisting of alkyl of one to ten carbon atoms, hydroxyalkyl of one to six carbon atoms, acyloxyalkyl wherein the acyloxy moiety is alkanoyloxy of two to four carbon atoms or benzoyloxy, and the alkyl moiety contains one to six carbon atoms, benzyl, (phenyl)ethyl and phenyl, said benzyl, (phenyl)ethyl or phenyl substituent being optionally substituted on the benzene ring by one or two moieties independently selected from the group consisting of alkyl of one to four carbon atoms, alkoxy of one to four carbon atoms and halogen, with the proviso that if said benzene ring is substituted by two of said moieties, then said moieties together contain no more than six carbon atoms;
  • R[0099] 21 is selected from the group consisting of hydrogen, alkyl of one to eight carbon atoms, benzyl, (phenyl)ethyl and phenyl, the benzyl, (phenyl)ethyl or phenyl substituent being optionally substituted on the benzene ring by one or two moieties independently selected from the group consisting of alkyl of one to four carbon atoms, alkoxy of one to four carbon atoms and halogen, with the proviso that when the benzene ring is substituted by two of said moieties, then the moieties together contain no more than six carbon atoms; and
  • each R[0100] 1 is independently selected from the group consisting of alkoxy of one to four carbon atoms, halogen, and alkyl of one to four carbon atoms, and n is an integer from 0 to 2, with the proviso that if n is 2, then said R1 groups together contain no more than six carbon atoms;
    Figure US20020058674A1-20020516-C00002
  • wherein [0101]
  • R[0102] 12 is selected from the group consisting of straight chain or branched chain alkenyl containing two to ten carbon atoms and substituted straight chain or branched chain alkenyl containing two to ten carbon atoms, wherein the substituent is selected from the group consisting of straight chain or branched chain alkyl containing one to four carbon atoms and cycloalkyl containing three to six carbon atoms; and cycloalkyl containing three to six carbon atoms substituted by straight chain or branched chain alkyl containing one to four carbon atoms; and
  • R[0103] 22 is selected from the group consisting of hydrogen, straight chain or branched alkyl containing one to eight carbon atoms, benzyl, (phenyl)ethyl and phenyl, the benzyl, (phenyl)ethyl or phenyl substituent being optionally substituted on the benzene ring by one or two moieties independently selected from the group consisting of straight chain or branched chain alkyl containing one to four carbon atoms, straight chain or branched chain alkoxy containing one to four carbon atoms, and halogen, with the proviso that when the benzene ring is substituted by two such moieties, then the moieties together contain no more than six carbon atoms; and
  • each R[0104] 2 is independently selected from the group consisting of straight chain or branched chain alkoxy containing one to four carbon atoms, halogen, and straight chain or branched chain alkyl containing one to four carbon atoms, and n is an integer from zero to 2, with the proviso that if n is 2, then said R2 groups together contain no more than six carbon atoms;
    Figure US20020058674A1-20020516-C00003
  • wherein [0105]
  • R[0106] 23 is selected from the group consisting of hydrogen, straight chain or branched chain alkyl of one to eight carbon atoms, benzyl, (phenyl)ethyl and phenyl, the benzyl, (phenyl)ethyl or phenyl substituent being optionally substituted on the benzene ring by one or two moieties independently selected from the group consisting of straight chain or branched chain alkyl of one to four carbon atoms, straight chain or branched chain alkoxy of one to four carbon atoms, and halogen, with the proviso that when the benzene ring is substituted by two such moieties, then the moieties together contain no more than six carbon atoms; and
  • each R[0107] 3 is independently selected from the group consisting of straight chain or branched chain alkoxy of one to four carbon atoms, halogen, and straight chain or branched chain alkyl of one to four carbon atoms, and n is an integer from zero to 2, with the proviso that if n is 2, then said R3 groups together contain no more than six carbon atoms;
    Figure US20020058674A1-20020516-C00004
  • wherein [0108]
  • R[0109] 14 is —CHRxRy wherein Ry is hydrogen or a carbon-carbon bond, with the proviso that when Ry is hydrogen Rx is alkoxy of one to four carbon atoms, hydroxyalkoxy of one to four carbon atoms, 1-alkynyl of two to ten carbon atoms, tetrahydropyranyl, alkoxyalkyl wherein the alkoxy moiety contains one to four carbon atoms and the alkyl moiety contains one to four carbon atoms, 2-, 3-, or 4-pyridyl, and with the further proviso that when Ry is a carbon-carbon bond Ry and Rx together form a tetrahydrofuranyl group optionally substituted with one or more substituents independently selected from the group consisting of hydroxy and hydroxyalkyl of one to four carbon atoms;
  • R[0110] 24 is selected from the group consisting of hydrogen, alkyl of one to four carbon atoms, phenyl, and substituted phenyl wherein the substituent is selected from the group consisting of alkyl of one to four carbon atoms, alkoxy of one to four carbon atoms, and halogen; and
  • R[0111] 4 is selected from the group consisting of hydrogen, straight chain or branched chain alkoxy containing one to four carbon atoms, halogen, and straight chain or branched chain alkyl containing one to four carbon atoms;
    Figure US20020058674A1-20020516-C00005
  • wherein [0112]
  • R[0113] 15 is selected from the group consisting of: hydrogen; straight chain or branched chain alkyl containing one to ten carbon atoms and substituted straight chain or branched chain alkyl containing one to ten carbon atoms, wherein the substituent is selected from the group consisting of cycloalkyl containing three to six carbon atoms and cycloalkyl containing three to six carbon atoms substituted by straight chain or branched chain alkyl containing one to four carbon atoms; straight chain or branched chain alkenyl containing two to ten carbon atoms and substituted straight chain or branched chain alkenyl containing two to ten carbon atoms, wherein the substituent is selected from the group consisting of cycloalkyl containing three to six carbon atoms and cycloalkyl containing three to six carbon atoms substituted by straight chain or branched chain alkyl containing one to four carbon atoms; hydroxyalkyl of one to six carbon atoms; alkoxyalkyl wherein the alkoxy moiety contains one to four carbon atoms and the alkyl moiety contains one to six carbon atoms; acyloxyalkyl wherein the acyloxy moiety is alkanoyloxy of two to four carbon atoms or benzoyloxy, and the alkyl moiety contains one to six carbon atoms; benzyl; (phenyl)ethyl; and phenyl; said benzyl, (phenyl)ethyl or phenyl substituent being optionally substituted on the benzene ring by one or two moieties independently selected from the group consisting of alkyl of one to four carbon atoms, alkoxy of one to four carbon atoms, and halogen, with the proviso that when said benzene ring is substituted by two of said moieties, then the moieties together contain no more than six carbon atoms;
    Figure US20020058674A1-20020516-C00006
  • wherein [0114]
  • R[0115] S and RT are independently selected from the group consisting of hydrogen, alkyl of one to four carbon atoms, phenyl, and substituted phenyl wherein the substituent is selected from the group consisting of alkyl of one to four carbon atoms, alkoxy of one to four carbon atoms, and halogen;
  • X is selected from the group consisting of alkoxy containing one to four carbon atoms, alkoxyalkyl wherein the alkoxy moiety contains one to four carbon atoms and the alkyl moiety contains one to four carbon atoms, hydroxyalkyl of one to four carbon atoms, haloalkyl of one to four carbon atoms, alkylamido wherein the alkyl group contains one to four carbon atoms, amino, substituted amino wherein the substituent is alkyl or hydroxyalkyl of one to four carbon atoms, azido, chloro, hydroxy, 1-morpholino, 1-pyrrolidino, alkylthio of one to four carbon atoms; and [0116]
  • R[0117] 5 is selected from the group consisting of hydrogen, straight chain or branched chain alkoxy containing one to four carbon atoms, halogen, and straight chain or branched chain alkyl containing one to four carbon atoms;
  • or a pharmaceutically acceptable salt of any of the foregoing. [0118]
  • [0119] Preferred 6,7 fused cycloalkylimidazopyridine amine IRM compounds are defined by Formula VI below:
    Figure US20020058674A1-20020516-C00007
  • wherein [0120]
  • m is 1, 2, or 3; [0121]
  • R[0122] 16 is selected from the group consisting of hydrogen; cyclic alkyl of three, four, or five carbon atoms; straight chain or branched chain alkyl containing one to ten carbon atoms and substituted straight chain or branched chain alkyl containing one to ten carbon atoms, wherein the substituent is selected from the group consisting of cycloalkyl containing three to six carbon atoms and cycloalkyl containing three to six carbon atoms substituted by straight chain or branched chain alkyl containing one to four carbon atoms; fluoro- or chloroalkyl containing from one to ten carbon atoms and one or more fluorine or chlorine atoms; straight chain or branched chain alkenyl containing two to ten carbon atoms and substituted straight chain or branched chain alkenyl containing two to ten carbon atoms, wherein the substituent is selected from the group consisting of cycloalkyl containing three to six carbon atoms and cycloalkyl containing three to six carbon atoms substituted by straight chain or branched chain alkyl containing one to four carbon atoms; hydroxyalkyl of one to six carbon atoms; alkoxyalkyl wherein the alkoxy moiety contains one to four carbon atoms and the alkyl moiety contains one to six carbon atoms; acyloxyalkyl wherein the acyloxy moiety is alkanoyloxy of two to four carbon atoms or benzoyloxy, and the alkyl moiety contains one to six carbon atoms, with the proviso that any such alkyl, substituted alkyl, alkenyl, substituted alkenyl, hydroxyalkyl, alkoxyalkyl, or acyloxyalkyl group does not have a fully carbon substituted carbon atom bonded directly to the nitrogen atom; benzyl; (phenyl)ethyl; and phenyl; said benzyl, (phenyl)ethyl or phenyl substituent being optionally substituted on the benzene ring by one or two moieties independently selected from the group consisting of alkyl of one to four carbon atoms, alkoxy of one to four carbon atoms, and halogen, with the proviso that when said benzene ring is substituted by two of said moieties, then the moieties together contain no more than six carbon atoms;
  • and [0123]
  • —CHRxRy
  • wherein [0124]  
  • R[0125] y is hydrogen or a carbon-carbon bond, with the proviso that when Ry is hydrogen Rx is alkoxy of one to four carbon atoms, hydroxyalkoxy of one to four carbon atoms, 1-alkynyl of two to ten carbon atoms, tetrahydropyranyl, alkoxyalkyl wherein the alkoxy moiety contains one to four carbon atoms and the alkyl moiety contains one to four carbon atoms, 2-, 3-, or 4-pyridyl, and with the further proviso that when Ry is a carbon-carbon bond Ry and Rx together form a tetrahydrofuranyl group optionally substituted with one or more substituents independently selected from the group consisting of hydroxy and hydroxyalkyl of one to four carbon atoms,
  • [0126] R 26 is selected from the group consisting of hydrogen, straight chain or branched chain alkyl containing one to eight carbon atoms, straight chain or branched chain hydroxyalkyl containing one to six carbon atoms, morpholinoalkyl, benzyl, (phenyl)ethyl and phenyl, the benzyl, (phenyl)ethyl or phenyl substituent being optionally substituted on the benzene ring by a moiety selected from the group consisting of methyl, methoxy, and halogen; and
  • —C(R[0127] S)(RT)(X) wherein RS and RT are independently selected from the group consisting of hydrogen, alkyl of one to four carbon atoms, phenyl, and substituted phenyl wherein the substituent is selected from the group consisting of alkyl of one to four carbon atoms, alkoxy of one to four carbon atoms, and halogen;
  • X is selected from the group consisting of alkoxy containing one to four carbon atoms, alkoxyalkyl wherein the alkoxy moiety contains one to four carbon atoms and the alkyl moiety contains one to four carbon atoms, haloalkyl of one to four carbon atoms, alkylamido wherein the alkyl group contains one to four carbon atoms, amino, substituted amino wherein the substituent is alkyl or hydroxyalkyl of one to four carbon atoms, azido, alkylthio of one to four carbon atoms, and morpholinoalkyl wherein the alkyl moiety contains one to four carbon atoms, and [0128]
  • R[0129] 6 is selected from the group consisting of hydrogen, fluoro, chloro, straight chain or branched chain alkyl containing one to four carbon atoms, and straight chain or branched chain fluoro- or chloroalkyl containing one to four carbon atoms and at least one fluorine or chlorine atom;
  • and pharmaceutically acceptable salts thereof. [0130]
  • Preferred imidazopyridine amine IRM compounds are defined by Formula VII below: [0131]
    Figure US20020058674A1-20020516-C00008
  • wherein [0132]
  • R[0133] 17 is selected from the group consisting of hydrogen; —CH2RW wherein RW is selected from the group consisting of straight chain, branched chain, or cyclic alkyl containing one to ten carbon atoms, straight chain or branched chain alkenyl containing two to ten carbon atoms, straight chain or branched chain hydroxyalkyl containing one to six carbon atoms, alkoxyalkyl wherein the alkoxy moiety contains one to four carbon atoms and the alkyl moiety contains one to six carbon atoms, and phenylethyl; and —CH═CRZRZ wherein each RZ is independently straight chain, branched chain, or cyclic alkyl of one to six carbon atoms;
  • R[0134] 27 is selected from the group consisting of hydrogen, straight chain or branched chain alkyl containing one to eight carbon atoms, straight chain or branched chain hydroxyalkyl containing one to six carbon atoms, alkoxyalkyl wherein the alkoxy moiety contains one to four carbon atoms and the alkyl moiety contains one to six carbon atoms, benzyl, (phenyl)ethyl and phenyl, the benzyl, (phenyl)ethyl or phenyl substituent being optionally substituted on the benzene ring by a moiety selected from the group consisting of methyl, methoxy, and halogen; and morpholinoalkyl wherein the alkyl moiety contains one to four carbon atoms;
  • R[0135] 67 and R77 are independently selected from the group consisting of hydrogen and alkyl of one to five carbon atoms, with the proviso that R67 and R77 taken together contain no more than six carbon atoms, and with the further proviso that when R77 is hydrogen then R67 is other than hydrogen and R27 is other than hydrogen or morpholinoalkyl, and with the further proviso that when R67 is hydrogen then R77 and R27 are other than hydrogen;
  • and pharmaceutically acceptable salts thereof. [0136]
  • [0137] Preferred 1,2-bridged imidazoquinoline amine IRM compounds are defined by Formula VIII below:
    Figure US20020058674A1-20020516-C00009
  • wherein [0138]
  • Z is selected from the group consisting of: [0139]
  • —(CH[0140] 2)p— wherein p is 1 to 4;
  • —(CH[0141] 2)a—C(RDRE)(CH2)b—, wherein a and b are integers and a+b is 0 to 3, RD is hydrogen or alkyl of one to four carbon atoms, and RE is selected from the group consisting of alkyl of one to four carbon atoms, hydroxy, —ORF wherein RF is alkyl of one to four carbon atoms, and —NRGR′G wherein RG and R′G are independently hydrogen or alkyl of one to four carbon atoms; and
  • —(CH[0142] 2)a—(Y)—(CH2)b— wherein a and b are integers and a+b is 0 to 3, and Y is O, S, or —NRJ— wherein RJ is hydrogen or alkyl of one to four carbon atoms;
  • and wherein q is 0 or 1 and R[0143] 8 is selected from the group consisting of alkyl of one to four carbon atoms, alkoxy of one to four carbon atoms, and halogen,
  • and pharmaceutically acceptable salts thereof. [0144]
  • Suitable thiazolo- and oxazolo-quinolinamine and pyridinamine compounds include compounds of Formula IX: [0145]
    Figure US20020058674A1-20020516-C00010
  • wherein: [0146]
  • R[0147] 19 is selected from the group consisting of oxygen, sulfur and selenium;
  • R[0148] 29 is selected from the group consisting of
  • -hydrogen; [0149]
  • -alkyl; [0150]
  • -alkyl-OH; [0151]
  • -haloalkyl; [0152]
  • -alkenyl; [0153]
  • -alkyl-X-alkyl; [0154]
  • -alkyl-X-alkenyl; [0155]
  • -alkenyl-X-alkyl; [0156]
  • -alkenyl-X-alkenyl; [0157]
  • -alkyl-N(R[0158] 59)2;
  • -alkyl-N[0159] 3;
  • -alkyl-O—C(O)—N(R[0160] 59)2;
  • -heterocyclyl; [0161]
  • -alkyl-X-heterocyclyl; [0162]
  • -alkenyl-X-heterocyclyl; [0163]
  • -aryl [0164]
  • -alkyl-X-aryl; [0165]
  • -alkenyl-X-aryl; [0166]
  • -heteroaryl; [0167]
  • -alkyl-X-heteroaryl; and [0168]
  • -alkenyl-X-heteroaryl; [0169]
  • R[0170] 39 and R49 are each independently:
  • -hydrogen; [0171]
  • —X-alkyl; [0172]
  • -halo; [0173]
  • -haloalkyl; [0174]
  • —N(R[0175] 59)2;
  • or when taken together, R[0176] 39 and R49 form a fused aromatic, heteroaromatic, cycloalkyl or heterocyclic ring;
  • X is selected from the group consisting of —O—, —S—, —NR[0177] 59—, —C(O)—, —C(O)O—, —OC(O)—, and a bond; and
  • each R[0178] 59 is independently H or C1-8alkyl;
  • Suitable imidazonaphthyridine and tetrahydroimidazomaphthyridine IRM compounds are those of Formulae X and XI below: [0179]
    Figure US20020058674A1-20020516-C00011
  • wherein [0180]
  • A is ═N—CR═CR—CR═; ═CR—N═CR—CR═; ═CR—CR═N—CR═; or ═CR—CR═CR—N═; [0181]
  • R[0182] 110 is selected from the group consisting of:
  • -hydrogen; [0183]
  • —C[0184] 1-20alkyl or C2-20alkenyl that is unsubstituted or substituted by one or more substituents selected from the group consisting of:
  • -aryl; [0185]
  • -heteroaryl; [0186]
  • -heterocyclyl; [0187]
  • —O—C[0188] 1-20alkyl,
  • —O—(C[0189] 1-20alkyl)0-1-aryl;
  • —O—(C[0190] 1-20alkyl)0-1-heteroaryl;
  • —O—(C[0191] 1-20alkyl)0-1-heterocyclyl;
  • —C[0192] 1-20alkoxycarbonyl;
  • —S(O)[0193] 0-2—C1-20alkyl;
  • —S(O)[0194] 0-2—(C1-20alkyl)0-1-aryl;
  • —S(O)[0195] 0-2—(C1-20alkyl)0-1-heteroaryl;
  • —S(O)[0196] 0-2—(C1-20alkyl)0-1-heterocyclyl;
  • —N(R[0197] 310)2;
  • —N[0198] 3;
  • oxo; [0199]
  • -halogen; [0200]
  • —NO[0201] 2;
  • —OH; and [0202]
  • —SH; and [0203]
  • —C[0204] 1-20alkyl-NR310—Q—X—R410 or —C2-20alkenyl-NR310-Q—X—R410 wherein Q is —CO— or —SO2—; X is a bond, —O— or —NR310- and R410 is aryl; heteroaryl; heterocyclyl; or —C120alkyl or C2-20alkenyl that is unsubstituted or substituted by one or more substituents selected from the group consisting of:
  • -aryl; [0205]
  • -heteroaryl; [0206]
  • -heterocyclyl; [0207]
  • —O—C[0208] 1-20alkyl,
  • —O—(C[0209] 1-20alkyl)0-1-aryl;
  • —O—(C[0210] 1-20alkyl)0-1-heteroaryl;
  • —O—(C[0211] 1-20alkyl)0-1-heterocyclyl;
  • —C[0212] 1-20alkoxycarbonyl;
  • —S(O)[0213] 0-2—C1-20alkyl;
  • —S(O)[0214] 0-2—(C1-20 alkyl) 0-1-aryl;
  • —S(O)[0215] 0-2—(C1-20alkyl)0-1-heteroaryl;
  • —S(O)[0216] 0-2—(C1-20alkyl)0-1-heterocyclyl;
  • —N(R[0217] 310)2;
  • —NR[0218] 310—CO—O—C1-20alkyl;
  • —N[0219] 3;
  • oxo; [0220]
  • -halogen; [0221]
  • —NO[0222] 2;
  • —OH; and [0223]
  • —SH; or R[0224] 410 is
    Figure US20020058674A1-20020516-C00012
  • wherein Y is —N— or —CR—; [0225]
  • R[0226] 210 is selected from the group consisting of:
  • -hydrogen; [0227]
  • —C[0228] 110alkyl;
  • —C[0229] 2-10alkenyl;
  • -aryl; [0230]
  • —C[0231] 1-10alkyl-O—C1-10-alkyl;
  • —C[0232] 1-10alkyl-O—C2-10alkenyl; and
  • —C[0233] 1-10alkyl or C2-10alkenyl substituted by one or more substituents selected from the group consisting of:
  • —OH; [0234]
  • -halogen; [0235]
  • —N(R[0236] 310)2;
  • —CO—N(R[0237] 310)2;
  • —CO—C[0238] 1-10alkyl;
  • —N[0239] 3;
  • -aryl; [0240]
  • -heteroaryl; [0241]
  • -heterocyclyl; [0242]
  • —CO-aryl; and [0243]
  • —CO-heteroaryl; [0244]
  • each R[0245] 310 is independently selected from the group consisting of hydrogen and C1-10alkyl; and
  • each R is independently selected from the group consisting of hydrogen, C[0246] 1-10alkyl, C1-10alkoxy, halogen and trifluoromethyl,
  • or a pharmaceutically acceptable salt thereof. [0247]
    Figure US20020058674A1-20020516-C00013
  • wherein [0248]
  • B is —NR—C(R)[0249] 2—C(R)2—C(R)2—; —C(R)2—NR—C(R)2—C(R)2—;
  • —C(R)[0250] 2—C(R)2—NR—C(R)2— or —C(R)2—C(R)2—C(R)2—NR—;
  • R[0251] 111 is selected from the group consisting of:
  • -hydrogen; [0252]
  • —C[0253] 1-20alkyl or C2-20alkenyl that is unsubstituted or substituted by one or more substituents selected from the group consisting of:
  • -aryl; [0254]
  • -heteroaryl; [0255]
  • -heterocyclyl; [0256]
  • —O—C[0257] 1-20alkyl;
  • —O—(C[0258] 1-20alkyl)0-1-aryl;
  • —O—(C[0259] 1-20alkyl)0-1-heteroaryl;
  • —O—(C[0260] 1-20alkyl)0-1-heterocyclyl;
  • —C[0261] 1-20alkoxycarbonyl;
  • —S(O)[0262] 0-2—C1-20alkyl;
  • —S(O)[0263] 0-2—(C1-20alkyl)0-1-aryl;
  • —S(O)[0264] 0-2—(C1-20alkyl)0-1-heteroaryl;
  • —S(O)[0265] 0-2—(C1-20alkyl)0-1-heterocyclyl;
  • —N(R[0266] 311)2;
  • —N[0267] 3;
  • oxo; [0268]
  • -halogen; [0269]
  • —NO[0270] 2;
  • —OH; and [0271]
  • —SH; and [0272]
  • —C[0273] 1-20alkyl-NR311—Q—X—R411 or —C2-20alkenyl-NR311—Q—X—R411 wherein Q is —CO— or —SO2—; X is a bond, —O— or —NR311- and R411 is aryl; heteroaryl; heterocyclyl; or —C1-20alkyl or C2-20alkenyl that is unsubstituted or substituted by one or more substituents selected from the group consisting of:
  • -aryl; [0274]
  • -heteroaryl; [0275]
  • -heterocyclyl; [0276]
  • —O—C[0277] 1-20alkyl,
  • —O—(C[0278] 1-20alkyl)0-1aryl;
  • —O—(C[0279] 1-20alkyl)0-1-heteroaryl;
  • —O—(C[0280] 1-20alkyl)0-1-heterocyclyl;
  • —C[0281] 1-20alkoxycarbonyl;
  • —S(O)[0282] 0-2—C1-20alkyl;
  • —S(O)[0283] 0-2—(C1-20alkyl)0-1-aryl;
  • —S(O)[0284] 0-2—(C1-20alkyl)0-1-heteroaryl;
  • —S(O)[0285] 0-2—(C1-20alkyl)0-1-heterocyclyl;
  • —N(R[0286] 311)2;
  • —N R[0287] 311—CO—O—C1-20alkyl;
  • —N[0288] 3;
  • oxo; [0289]
  • -halogen; [0290]
  • —NO[0291] 2;
  • —OH; and [0292]
  • —SH; or R[0293] 411 is
    Figure US20020058674A1-20020516-C00014
  • wherein Y is —N— or —CR—; [0294]
  • R[0295] 211 is selected from the group consisting of:
  • -hydrogen; [0296]
  • —C[0297] 1-10alkyl;
  • —C[0298] 2-10alkenyl;
  • aryl [0299]
  • [0300] 13 C1-10alkyl-O—C1-10-alkyl;
  • —C[0301] 1-10alkyl-O—C2-10alkenyl; and
  • —C[0302] 1-10alkyl or C2-10alkenyl substituted by one or more substituents selected from the group consisting of:
  • —OH; [0303]
  • -halogen; [0304]
  • —N(R[0305] 311)2;
  • —CO—N(R[0306] 311)2;
  • —CO—C[0307] 1-10alkyl;
  • —N[0308] 3;
  • -aryl; [0309]
  • -heteroaryl; [0310]
  • -heterocyclyl; [0311]
  • —CO-aryl; and [0312]
  • —CO-heteroaryl; [0313]
  • each R[0314] 311 is independently selected from the group consisting of hydrogen and C1-10alkyl; and
  • each R is independently selected from the group consisting of hydrogen, C[0315] 1-10alkyl, C1-10alkoxy, halogen and trifluoromethyl, and pharmaceutically acceptable salts thereof.
  • The compounds recited above are disclosed in the patents and applications noted above in the background, all of which are incorporated herein by reference. [0316]
  • The substituents R[0317] 11-R111 above are generally designated “1-substituents” herein. The preferred 1-substituents are alkyl containing one to six carbon atoms and hydroxyalkyl containing one to six carbon atoms. Optionally, the 1-substituent is 2-methylpropyl or 2-hydroxy-2-methylpropyl.
  • The substituents R[0318] 21-R211 above are generally designated “2-substituents” herein. Optional 2-substituents are hydrogen, alkyl of one to six carbon atoms, alkoxyalkyl wherein the alkoxy moiety contains one to four carbon atoms and the alkyl moiety contains one to four carbon atoms, and hydroxyalkyl of one to four carbon atoms. Optionally, the 2-substituent is hydrogen, methyl, butyl, propyl hydroxymethyl, ethoxymethyl or methoxyethyl.
  • In instances where n can be zero, one, or two, n is preferably zero or one. [0319]
  • IRM Pharmaceutical Formulations [0320]
  • The amount of an IRM compound that will be therapeutically effective in a specific situation will depend on such things as the activity of the particular compound, the mode of administration, the particular formulation and the condition being treated. As such, it is not practical to identify specific administration amounts herein; however, those skilled in the art will be able to determine appropriate therapeutically effective amounts based on the guidance provided herein, information available in the art pertaining to these compounds, and routine testing. [0321]
  • The pharmaceutical formulations described below can be used for topical administration of an IRM. Many of the formulations provided are particularly advantageous for topical administration to a mucosal surface. In some embodiments, the formulations can affect the pharmacokinetics of the IRM such that reduced concentrations of the IRM provide similar pharmacodynamic affects as that of other formulations having a greater IRM concentration. [0322]
  • Generally, a pharmaceutical formulation of the invention includes an IRM, a fatty acid, a preservative system and an optional viscosity enhancing agent such as a carbomer. The IRMs can be prepared using methods previously described in the patents listed in the background section above as well as U.S. Pat. Nos. 4,988,815; 5,367,076; 5,175,296; 5,395,937; and 5,741,908, the disclosures which are incorporated herein by reference. Unless otherwise specified, all percentages are weight percentages based on the total composition weight. [0323]
  • The amount of an IRM present in a pharmaceutical formulation of the invention will be an amount effective to treat a targeted condition, to prevent recurrence of the condition, or to promote immunity against the condition. The amount of IRM is preferably about 0.1% to about 9% by weight based on the total formulation weight. Optionally, the IRM amount does not exceed about 5% by weight and most preferably is about 0.1 to about 3% by weight for mucosal surface applications. [0324]
  • Typically, a pharmaceutical formulation of the invention is an oil in water emulsion. The oil component of the formulation includes an IRM and a fatty acid. The fatty acid is present in the formulation in an amount sufficient to solubilize the IRM. This is generally about 2% to about 45%, typically about 10% to about 30%, and preferably about 15% to about 18% based on the total weight of the formulation. Fatty acids such as isostearic acid are suitable for the formulations. Alternatively, the IRM can be solubilized in linear chain carboxylic acids of six to eight carbon atoms. [0325]
  • A pharmaceutical formulation of the invention can also include an emulsifier such as a non-ionic surfactant. Suitable surfactants include, for example, [0326] polysorbate 60, sorbitan monostearate, polyglyceryl-4 oleate, polyoxyethylene(4)lauryl ether, etc. For some formulations, surfactants such as Poloxamers (e.g., Pluronic F68 available from BASF, Ludwigschafen, Germany) and sorbitan trioleate (e.g., Span 85 available from Sigma Chemical Co., St. Louis, Mo.), alone or in combination, are preferred. The non-ionic surfactant is typically present in an amount of about 0.5% to about 10% of total formulation weight. In preferred embodiments, the total emulsifier content does not exceed about 5% of total formulation weight, and is more preferably about 3.5% of total formulation weight.
  • A formulation of the invention can also include a viscosity enhancing agent such as a carbomer, preferably having mucoadhesive properties. The carbomer can be present in an amount of about 0.1% to about 8%, preferably about 0.5% to about 4%, more preferably about 0.5 to about 3%, and most preferably about 1.0% of total formulation weight. Suitable carbomers include polyacrylic acids such as Carbopol 934P, Carbopol 971 P, Carbopol 940 and Carbopol 974P available from B. F. Goodrich. A preferred carbomer is Carbopol 974P. [0327]
  • In some optional embodiments, the formulation can also include a chelating agent. The chelating agent functions to chelate metal ions. If present, unchelated metal ions can suppress gel formation by suppressing ionization which facilitates gel formation in a carbomer containing formulation. An optional chelating agent is disodium ethylenediaminetetraacetate (EDTA) in a concentration of about 0.0001 to about 0.5%, typically about 0.0005 to about 0.1% per total formulation weight. [0328]
  • A preservative such as methylparaben, sorbic acid, propylene glycol, etc. can also be added. In one optional embodiment, methylparaben and sorbic acid are each provided at concentrations of about 0.05% to about 0.3%, preferably about 0.15% of total formulation weight and propylene glycol is present in amounts up to about 30%, preferably about 5%. It was discovered that this combination of preservatives advantageously meets the Preservation Effectiveness Test (PET), 1997 European Pharmacopeia, Test 5.1.3 Efficacy Antimicrobial Preservation—Topical Preparations—A Criteria. This renders the formulation suitable for use in a multi-dose dispenser without adversely affecting the stability of the formulation. The methylparaben and sorbic acid can be solubilized in propylene glycol prior to adding to the formulation. [0329]
  • The remainder of the pharmaceutical formulation can be comprised of water to provide a formulation that can be washed away from the mucosal surface by normal physiological clearing mechanisms. [0330]
  • In addition to providing mucoadhesive properties to the formulation, the carbomer also increases viscosity by forming a stabilizing gel. Many factors, such as the amount of oil phase, the drug load, and the amount of carbomer used will affect the pH at which gelation occurs. In some formulations, the presence of metal ions and surfactants increases the pH at which the carbomer will form a gel. Thus, in the absence of a chelating agent, or in the presence of increased surfactant levels, the pH at which the carbomer will gel can be increased. Thus it may be necessary to add an organic or inorganic base or other substance to facilitate gel formation. Suitable inorganic bases include, for example, KOH, NaOH, etc. The pH for a pharmaceutical formulation of the invention is typically about pH 3.0 to about pH 7.0, preferably about pH 4.0 to about pH 6.0. [0331]
  • Mucosal Surface Applications [0332]
  • According to the invention, the compositions can be applied topically, particularly to non-cornified epithelial surfaces such as mucosal surfaces. Mucosal surfaces include mucosal membranes such as buccal, gingival, nasal, tracheal, bronchial, gastrointestinal, rectal, urethral, ureteral, vaginal, cervical, uterine, etc. Depending on the IRM concentration, formulation composition, and mucosal surface, the therapeutic affect of the IRM may extend only to the superficial layers of the mucosal surface or to tissues deep to the surface. [0333]
  • In one embodiment, the disclosed IRMs can be topically applied to the vaginal or supravaginal region of the cervix for treatment of dysplastic conditions such as cervical intraepithelial neoplasia. In some embodiments, the above described formulations are particularly advantageous for cervical application of an IRM for a period of time sufficient to obtain a desired therapeutic effect without undesired systemic absorption of the IRM. [0334]
  • Cervical Intraepithelial Neoplasia (CIN) [0335]
  • Approximately 16,000 new cases of invasive cancer of the cervix are diagnosed each year in the U.S. despite extensive screening of women to detect predictive cellular changes. There are also about 3,000 deaths due to cervical cancer in the U.S. alone and this is usually secondary to not detecting the primary cancerous lesion in a timely manner. [0336]
  • The Papanicoulaou Test (Pap smear) is the screening test which has been accepted since the 1950s as the method to detect abnormal cells of the cervix, including inflammation and dysplasia, which includes cervical cancer. This screening test has been widely adopted in industrialized countries and has had a profound impact on mortality associated with cervical cancers. An abnormal Pap smear prompts close observation for disease progression with the potential for the therapeutic interventions of destruction or excision of cancerous or pre-cancerous tissues. These excisional treatments are expensive, uncomfortable and associated with failure rates which range from 2 to 23% and with higher failure rates reported for the more advanced lesions. Failure rates have recently been documented to approximate 10% following laser treatment. [0337]
  • The etiologic agent for cervical cancer was originally thought to be the herpes virus. However, there was a gradual shift from this focus on herpes virus to the human papillomavirus (HPV) when it was shown that the cytopathic effects of HPV in experimental systems very closely mimicked what was seen in human disease. Improved experimental methods over the recent past have allowed the characterization of a full spectrum of HPV subtypes, which has resulted in the conclusion that the high risk HPV types (e.g., [0338] HPV 16, 18, and less frequently 31, 33, 35, 45) are very likely the exclusive initiating factor (i.e., oncogenic agent) for cervical dysplasia and subsequent cancers. The mechanism of HPV transformation of the normal cell to a dysplastic cell is associated with the HPV encoded oncoproteins (E6 and E7) from the high risk genotypes binding the cell's tumor suppressor gene products p53 and Rb resulting in disruption of the cell cycle control mechanism in which p53 and Rb play an important role. In addition, the application of these molecular methods has resulted in the epidemilogic observation that HPV is isolated from approximately 93% of cervical tumors, which has further strengthened the generally accepted conclusion that HPV infection is the most important initiating agent for cervical cancer.
  • Exposure to HPV is common in sexually active women, but it does not invariably lead to dysplasia or cancer in most of the exposed women. Infected women who harbor persistent viral DNA have about five times the chance of persistent dysplasia compared to women who are able to eradicate the virus. The importance of cell-mediated immune (CMI) response to HPV infection is illustrated by the observation that the antibody mediated immune response is not effective in eliminating established infections as is demonstrated by the fact that patients with invasive cervical dancer often exhibit high antibody levels against the viral E6 and E7 proteins. This particular antibody response probably reflects extensive antigen exposure in the face of increasing tumor burden. In contrast to the apparently inconsequential effect of the humoral immune response, the cell-mediated immune response (Th-1-Type Response) appears to be effective in controlling tumor progression. Regression of intraepithelial lesions is accompanied by a cellular infiltrate consisting of CD4[0339] + T-CELLS, CD8+ T-CELLS, natural killer cells (NK) and macrophages. This inflammatory infiltrate was usually associated with tumor regression which is in contrast to women who lack the ability to mount this inflammatory response and who experience disease progression. In addition, patients with a defect in cell-mediated immunity have increased cervical cancer rates, whereas those with defects in the production of antibody do not exhibit the same susceptibility.
  • In one optional embodiment, the inventors foresee the topical application of IRMs for the non-invasive treatment of cervical conditions including cervical intraepithelial neoplasia (CIN). [0340]
  • Intravaginal Applicators for an IRM [0341]
  • To obtain a beneficial therapeutic or prophylactic effect for a cervical condition, intravaginal application of a herein disclosed IRM is preferred. The IRM can be applied via a dosing formulation or dispenser which ensures contact of the IRM with the mucosal surface of the cervix for a period of time sufficient to provide the desired therapeutic effect. Any of the dispensers (i.e., applicators) described herein and/or shown in the drawings could be used to apply the IRM. [0342]
  • In addition to the applicators already described, an IRM can be formulated as a suppository and administered intravaginally using a suppository applicator. A suitable suppository applicator includes known cardboard tube applicators for dispensing medications to the vaginal cavity. Formulations according to the invention can also be administered using a barrel type applicator, such as those described herein and/or shown in the drawings. An example of a suitable barrel type applicator can be found in U.S. Pat. No. 5,282,789, the disclosure of which is incorporated herein by reference. [0343]
  • In optional embodiment, an IRM can be administered directly to the cervical mucosa. In one such embodiment, the IRM can be topically applied to the cervical mucosa by using a direct cervical applicator, as previously described or using a cervical cap. One example of a suitable cervical cap is found in U.S. Pat. No. 4,858,624, the disclosure of which is incorporated herein by reference. Suitable IRM formulations for direct cervical applications are disclosed above and in the Examples below. In general, an IRM formulated pursuant to any of formulations A-J in the Examples below can be placed into the concave region of the cervical cap which is then applied directly over the cervix. These formulations might also be applied with other types of applicator devices including those shown in the drawings and described herein. Optionally, the IRM is formulated to include a viscosity agent, such as a carbomer, to enhance the residence time of the IRM on the cervix. [0344]
  • The following Examples are provided to further describe IRM formulations and methods according to the invention. The examples, however, are not intended to limit the formulations and methods. [0345]
    • EXAMPLES Example 1
  • Evaluation of the Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) OF 1-(2-methylpropyl)-1H-imadazo[4,5-c]quinolin-4-amine (imiquimod) Applied to the Cervix. [0346]
  • Methods [0347]
  • This was a single dose, randomized, double-blind, placebo controlled dose escalation study which evaluated five doses of imiquimod. 50, 100, 150, 200 and 250 mg of imiquimod in a cream formulation were applied to the cervix for eight hours. The ingredients of the formulation of the imiquimod cream used for this study (Formulation A) is presented in Table I below. Each dose group was composed of 8 subjects (6 active and 2 placebo), with two subjects treated as dose leaders, and the remaining six subjects were treated after an acceptable response by the dose leaders. Safety was assessed by adverse events (AE's), laboratory tests, and colposcopy with photodocumentation of the cervix at pre-dose and 24 hours post-dose, and 48 hours post-dose if required. Systemic exposure (PK) was determined by measuring imiquimod and metabolites through 48 hours post-dose and the PD response was determined by serum analysis for the cytokines: tumor necrosis factor-α (TNF-α), interferon-α (IFN-α), interleukin-1 receptor agonist (IL-1RA), interleukin-6 (IL-6), neopterin (NPT) and 2′5′ oligoadenlyate synthetase (2′5′ AS) during dosing and selected times during the 48 hours post-dose. Statistical tests to evaluate AE's and demographics, laboratory tests, vital signs and ECG's were Fisher's Exact, Wilcoxon Rank-Sum and Kruskall Wallis Tests respectively. Cytokine changes between dose groups were compared using Wilcoxon Rank-Sum and changes from baseline were evaluated using Spearman Rank Correlation. [0348]
  • Results [0349]
  • Thirty-nine generally healthy, surgically sterilized, 18-50 year-old females within 25% of ideal body weight were included in the study. All women had normal baseline colposcopy results with normal and borderline dyskariosis on cervical histology. AE's were reported in each of the 39 subjects with mild temperature elevation the most common event (92%). There were no differences among groups with respect to subjects who experienced one or more events, or in AE's attributed as possibly or probably related to drug. (Two serious AE's occurred which were intercurrent events associated with a fractured ankle and its surgical repair.) There were statistically significant changes in some laboratory parameters and pulse rates that were not considered clinically significant. There were no differences in ECG's or physical exams. Pelvic and colposcopic examinations revealed few reactions with 2 of 6 receiving 250 mg experiencing cervical changes of minor small vesicles or smaller ulcer. These reactions resolved within 48 hours. No quantifiable (>5 ng/ml) serum levels of imiquimod were detected. Significant changes from baseline were seen in IFN and IL-6 in the 250 mg group and in NPT. 2′5′ AS and IL-1RA in the 150 mg, 200 mg, and 250 mg groups. [0350]
  • The study showed that single doses of imiquimod up to 250 mg applied to the cervix for 8 hours in healthy volunteers is safe with minimal systemic exposure. Cervical application of a dose ≧150 mg increases the systemic concentration of certain cytokines. [0351]
    TABLE 1
    Components Formulation A (% w/w)
    Imiquimod 5.0
    Isostearic Acid 25.0 
    Benzyl Alcohol 2.0
    Cetyl Alcohol 2.2
    Stearyl Alcohol 3.1
    White Petrolatum 3.0
    Polysorbate 60 3.4
    Sorbitan Monostearate 0.6
    Glycerin 2.0
    Methyl Paraben 0.2
    Propyl Paraben  0.02
    Water 52.98
    Xanthan Gum 0.5
    PH 5.1
    Viscosity (cps) 0.33 × 105
    • Example 2
  • Preparation of Pharmaceutical Formulation B [0352]
  • This example describes a novel formulation for a vaginal application, that is a stable formulation, with a high viscosity, and well preserved to pass the EP preservative effectiveness test (PET) criteria. The w/w % of ingredients of this formulation (Formulation B) are shown in Table 2 below. [0353]
  • Imiquimod was dissolved in isostearic acid with Span 85. Pluronic F68, EDTA, Carbopol 974P, propylene glycol, sorbic acid, and methylparaben were dissolved in water. After emulsification to form an oil-in-water emulsion, sodium hydroxide was added to achieve a pH of about 5.2. The pH range for this formulation can be about 4.8 to 6.0. [0354]
    TABLE 2
    Components Formulation B (% w/w)
    Imiquimod 5
    Isostearic acid 28
    Pluronic F68 2.98
    Purified water 43.78
    Carbopol 974P 1.7
    Disodium EDTA 0.05
    Propylene glycol 15
    Sorbic acid 0.15
    Methylparaben 0.15
    Span 85 2.02
    5N NaOH 1.17
    PH 5.1
    Viscosity (cps) 6.4 × 105
    • Example 3
  • Preparation of Pharmaceutical Formulations C-F [0355]
  • Pharmaceutical Formulations C-F were prepared with the components recited below in Table 3. The method for preparing Formulations C-F was the same as that disclosed for preparing Formulation B in Example 2. [0356]
    TABLE 3
    Formulation Formulation Formulation Formulation
    C D E F
    Components (% w/w) (% w/w) (% w/w) (% w/w)
    Imiquimod 1.0 1.0 3.0 3.0
    Isostearic acid 5.6 28.0 16.8 28.0
    Pluronic F68 1.79 1.79 1.79 1.79
    Purified water 69.05 48.30 56.25 46.75
    Carbopol 974P 2.8 2.10 2.5 1.80
    Disodium 0.05 0.05 0.05 0.05
    EDTA
    PG* 15.0 15.0 15.0 15.0
    Sorbic acid 0.15 0.15 0.15 0.15
    Methylparaben 0.15 0.15 0.15 0.15
    Span 85 1.21 1.21 1.21 1.21
    5N NaOH 3.2 2.26 3.1 2.1
    pH 5.1 5.2 5.2 5.3
    Viscosity (cps) 5.8 × 105 8.8 × 105 11.0 × 105 10.0 × 105
    • Example 4
  • Imiquimod Transport Across Hairless Mouse Skin from Two Formulations A and B. Both at 5% w/w, Imiquimod [0357]
  • FIG. 16 is a graph of the results of imiquimod penetration studies of Formulations A and B, of Examples 1 and 2, using hairless mouse skin according to the procedure described in U.S. Pat. No. 5,238,944, the entire disclosure of which is incorporated herein by reference. [0358]
  • In brief, hairless mouse skin was removed from female hairless mice that were 5 to 7 weeks old (available from Charles River). The skin was maintained on ice until used. The mouse skin was mounted on a diffusion cell of the type shown in U.S. Pat. No. 5,238,944. The mouse skin was mounted with the epidermal side up between upper and lower portions of the cell which are held together by means of ball joint clamp. [0359]
  • The portion of the cell below the mounted skin was completely filled with 0.1 N HCl receptor fluid such that the receptor fluid contacted the skin. The receptor fluid was stirred using a magnetic stir bar and a magnetic stirrer. [0360]
  • Approximately 100[0361] ± 5 mg formulation to be tested was applied to the epidermal (upper) side of the skin to cover in an even layer only the area of skin that would be in contact with the receptor fluid when the skin was mounted in the diffusion cell. The formulations were applied to the skin prior to the time the receptor fluid was added to the cell below the skin.
  • The cell was then placed in a constant temperature (31° C.) chamber. To maintain constant temperature, the chamber utilized a heat exchanger coupled to a constant temperature bath, with a fan to circulate air. The receptor fluid was stirred by means of a magnetic stirring bar throughout the experiment to ensure a uniform sample and a reduced diffusion barrier layer on the dermal side of the skin. At specified time intervals (1, 2, 4, 6, 8, 12 and 24 hours), the entire volume of receptor fluid was removed and immediately replaced with fresh receptor fluid. The withdrawn receptor fluid was analyzed for imiquimod content by conventional high pressure chromatography as follows: [0362]
  • Detector: UV at 258 nm; Mobile Phase: 25/75 acetonitrile/water containing 1% triethylamine, 0.2% 1-octane sulfonate with the pH adjusted to 2.0 with H[0363] 3PO4; Stationary Phase: C8 Zorbax RX-C8 5μ; Flow Rate: 2 ml/min; Run Time: approximately 10 minutes.
  • Cumulative amount of penetration was plotted versus time to obtain the steady state rate. [0364]
    • Example 5
  • Imiquimod Transport Across Nude Mouse Skin from Formulations C-F at 1% w/w and 3% w/w Imiquimod with Varied Concentrations of Isostearic Acid (USA). [0365]
  • Table 4 below provides the imiquimod concentration, isostearic acid concentration, viscosity, pH and steady state rate (μg/hour) of Formulations C-F across nude mouse skin. [0366]
  • The results are graphed in FIG. 17. The procedure used to study skin penetration was the same as that disclosed in Example 4. [0367]
    TABLE 4
    IRM ISA
    Formu- Concentration Concentration Viscosity Steady State
    lation (% w/w) (% w/w) (× 10−5 cps) Rate (μg/hr)
    C 1% 5.6% 5.8 18.1
    D 1%  28% 8.8 26.1
    E 3% 16.8%  11   39.9
    F 3%  28% 10   71.5
    • Example 6
  • Pharmacokinetics Comparison of Imiquimod in Rats After Single Dose Vaginal Application of Formulation a and Formulation B [0368]
  • Serum imiquimod concentration versus time profiles were compared in ovariectomized rats after single intravaginal doses of Formulation A or Formulation B. The two 5% w/w formulations were dosed to provide a dose level of 35 mg/kg. After dosing, each rat was collared to prevent removal of the formulation by licking. After about six hours, the vagina was lavaged and the collars removed. Blood samples were collected at pre-dose and at 0.5, 1, 2, 3, 4 and 24 hours post-dose. Due to the higher viscosity of Formulation B, intravaginal administration to the rats was considerably easier and retention of Formulation B was superior to Formulation A. [0369]
  • Serum was analyzed by HPLC for imiquimod. Mean serum imiquimod concentrations versus time are depicted in FIG. 18. The time to achieve maximum serum concentrations of imiquimod (T[0370] max) was similar (1 hr) for both formulations. However, the maximum imiquimod concentration (Cmax) for Formulation B was approximately 1.6 times greater than for Formulation A and the respective area under the curve versus time (AUC) was 3.3 times greater (FIGS. 19A and 19B). Based upon these data, the rate and extent of absorption of imiquimod was greater from Formulation B than from Formulation A.
    • Example 7
  • Preparation of Pharmaceutical Formulation G [0371]
  • The w/w % of the ingredients for Formulation G are shown in Table 5. [0372]
  • An oil phase was prepared as follows. Imjquimod (20.0 g) was slowly added with stirring to isostearic acid (3000 g). The mixture was stirred and heated, as necessary, up to 55° C. to facilitate dissolution of the imiquimod. After dissolution was complete the heat was turned off. Sorbitan trioleate (200 g) was added and thoroughly mixed. Carbomer 974 was slowly added with mixing. The mixing was continued until the carbomer was uniformly dispersed in the oil phase. The oil phase was then allowed to cool to a temperature of less than 30° C. [0373]
  • An aqueous phase was prepared as follows. Sorbic acid (30.0 g) and methylparaben (40.0 g) were added with stirring to propylene glycol (1000 g). The resulting mixture was stirred and heated gently (<45° C.) until a solution was obtained. The heat source was removed. Polaxamer 188 (500 g) was added to the solution. The resulting mixture was stirred until the polaxamer was thoroughly wet. The resulting slurry was then added to a solution of edetate disodium (10.0 g) in purified water (13950 g). The resulting mixture was stirred until a clear solution was obtained. [0374]
  • A sodium hydroxide solution was prepared by dissolving sodium hydroxide pellets (50 g) in purified water (1000 g). [0375]
  • The oil phase was added to the aqueous phase and then the sodium hydroxide solution was added. The resulting mixture was mixed for a minimum of 30 minutes until a smooth and shiny cream was obtained. The pH was determined and adjusted, if necessary, to 5.6-5.8 with sodium hydroxide solution. [0376]
    • Example 8
  • Preparation of Pharmaceutical Formulations H-J [0377]
  • Pharmaceutical formulations H-J were prepared using the method of Example 7. The w/w % of the ingredients in the formulations is shown in Table 5 below. [0378]
    TABLE 5
    Formulation G H I J
    Component (% w/w) (% w/w) (% w/w) (% w/w)
    Isostearic Acid (874) 15.00  15.00  15.00  18.00 
    Imiquimod 0.10 0.50 1.50 3.00
    Sorbitan Trioleate 1.00 1.00 1.00 1.00
    Propylene Glycol 5.00 5.00 5.00 5.00
    Sorbic Acid 0.15 0.15 0.15 0.15
    Methylparaben 0.20 0.20 0.20 0.20
    Purified Water 75.00  74.60  73.60  69.10 
    Edetate Disodium 0.05 0.05 0.05 0.05
    Polaxamer 188 2.50 2.50 2.50 2.50
    Carbomer 974 1.00 1.00 1.00 1.00
    Sodium Hydroxide qs qs qs Os
    Total % w/w 100    100    100    100   
  • Accordingly, from the foregoing discussion, it will appreciated that the imidazoquinoline amines, imidazopyridine amines, 6,7-fused cycloalkylimidazopyridine amines, and 1,2-bridged imidazoquinoline amines of the present invention can be beneficial for treating mucosal associated conditions including cervical dysplasias. In addition, the disclosed pharmaceutical formulations can be particularly advantageous for topical application of an IRM to a mucosal surface. [0379]
  • From the foregoing detailed description and examples, it will be evident that modifications and variations can be made in the compounds, formulations, devices, systems, and methods disclosed herein. Other embodiments will be apparent to those skilled in the art. It is intended that the specification and examples be considered as exemplary only. [0380]

Claims (58)

What is claimed is:
1. A system for treating a condition associated with a mucosal surface, the system comprising:
an immune response modifier (IRM) compound chosen from imidazoquinoline amines, imidazopyridine amines, 6,7-fused cycloalkylimidazopyridine amines, 1,2-bridged imidazoquinoline amines, and pharmaceutically acceptable salts thereof; and
an applicator device for applying to the mucosal surface the IRM compound.
2. The system of claim 1, wherein the IRM compound is 1-(2-methylpropyl)-1H-imidazo[4,5-c]-quinolin-4-amine.
3. The system of claim 1, wherein the IRM compound is 4-amino-α,α-dimethyl-2-ethoxymethyl-1H-imidazo[4,5-c]quinoline-1-ethanol.
4. The system of claim 1, wherein the system further comprises a pharmaceutical formulation comprising:
the IRM compound;
at least one fatty acid; and
a preservative system comprising propylene glycol.
5. The system of claim 1, wherein the applicator device is pre-filled with a therapeutically effective amount of the IRM compound.
6. The system of claim 1, wherein the IRM compound is contained in a container separate from the device.
7. The system of claim 1, further comprising measuring marks on the applicator device for assisting a user in determining the amount of the IRM compound in the applicator device.
8. The system of claim 1, wherein the condition associated with the mucosal surface is cervical dysplasia.
9. The system of claim 1, wherein the mucosal surface is on a cervix.
10. The system of claim 9, wherein the mucosal surface is on the vaginal part of the cervix.
11. The system of claim 10, wherein the condition associated with the mucosal surface is cervical intraepithelial neoplasia.
12. The system of claim 1, wherein the applicator device comprises:
a hollow tube comprising a distal delivery end and a proximal end; and
a piston slidably received within the tube.
13. The system of claim 12, further comprising a member configured to cause movement of the piston toward the distal end.
14. The system of claim 13, wherein the device is configured to limit retraction movement of the member toward the proximal end when the piston is located adjacent to the distal end.
15. The system of claim 13, wherein the piston is removably coupled to the member.
16. The system of claim 13, wherein the member is slidably received in the hollow tube.
17. The system of claim 12, further comprising a stop limiting retraction movement of the piston toward the proximal end.
18. The system of claim 12, wherein the piston comprises a portion extending from the distal end when the piston is positioned at its farthest location away from the proximal end.
19. The system of claim 12, wherein the distal end is tapered on its outer surface.
20. The system of claim 13, wherein the member has a length shorter than the distance between the proximal end and the piston when the piston is positioned at its furthest location away from the proximal end.
21. A system for treating a condition associated with a mucosal surface, the system comprising:
an immune response modifier (IRM) compound chosen from imidazoquinoline amines, imidazopyridine amines, 6,7-fused cycloalkylimidazopyridine amines, imidazonaphthyridine amines, oxazoloquinoline amines, thiazoloquinoline amines, 1,2-bridged imidazoquinoline amines, and pharmaceutically acceptable salts thereof; and
an applicator device for applying to the mucosal surface the IRM compound.
22. The system of claim 21, wherein the IRM compound is 1-(2-methylpropyl)-1H-imidazo[4,5-c]-quinolin-4-amine.
23. The system of claim 21, wherein the IRM compound is 4-amino-α,α-dimethyl-2-ethoxymethyl-1H-imidazo[4,5-c]quinoline-1-ethanol.
24. The system of claim 21, wherein the IRM compound is 2-propyl[1,3]thiazolo[4,5-c]quinolin-4-amine.
25. The system of claim 21, wherein the system further comprises a pharmaceutical formulation comprising:
the IRM compound;
at least one fatty acid; and
a preservative system comprising propylene glycol.
26. The system of claim 21, wherein the applicator device is pre-filled with a therapeutically effective amount of the IRM compound.
27. The system of claim 21, wherein the IRM compound is contained in a container separate from the device.
28. The system of claim 21, further comprising measuring marks on the applicator device for assisting a user in determining the amount of the IRM compound in the applicator device.
29. The system of claim 21, wherein the condition associated with the mucosal surface is cervical dysplasia.
30. The system of claim 21, wherein the mucosal surface is on a cervix.
31. The system of claim 30, wherein the mucosal surface is on the vaginal part of the cervix.
32. The system of claim 31, wherein the condition associated with the mucosal surface is cervical intraepithelial neoplasia.
33. The system of claim 21, wherein the applicator device comprises:
a hollow tube comprising a distal delivery end and a proximal end; and
a piston slidably received within the tube.
34. The system of claim 33, further comprising a member configured to cause movement of the piston toward the distal end.
35. The system of claim 34, wherein the device is configured to limit retraction movement of the member toward the proximal end when the piston is located adjacent to the distal end.
36. The system of claim 34, wherein the piston is removably coupled to the member.
37. The system of claim 34, wherein the member is slidably received in the hollow tube.
38. The system of claim 33, further comprising a stop limiting retraction movement of the piston toward the proximal end.
39. The system of claim 33, wherein the piston comprises a portion extending from the distal end when the piston is positioned at its farthest location away from the proximal end.
40. The system of claim 33, wherein the distal end is tapered on its outer surface.
41. The system of claim 34, wherein the member has a length shorter than the distance between the proximal end and the piston when the piston is positioned at its furthest location away from the proximal end.
42. A method for treating a condition associated with a mucosal surface, the method comprising:
providing an immune response modifier (IRM) compound chosen from imidazoquinoline amines, imidazopyridine amines, 6,7-fused cycloalkylimidazopyridine amines, imidazonaphthyridine amines, oxazoloquinoline amines, thiazoloquinoline amines, 1,2-bridged imidazoquinoline amines, and pharmaceutically acceptable salts thereof;
providing an applicator device for applying to the mucosal surface the IRM compound; and
applying the IRM compound to the mucosal surface with the applicator device.
43. The method of claim 42, wherein the IRM compound is 1-(2-methylpropyl)-1H-imidazo[4,5-c]-quinolin-4-amine.
44. The method of claim 42, wherein the IRM compound is 4-amino-α,α-dimethyl-2-ethoxymethyl-1H-imidazo[4,5-c]quinoline-1-ethanol.
45. The method of claim 42, wherein the IRM compound is 2-propyl[1,3]thiazolo[4,5-c]quinolin-4-amine.
46. The method of claim 42, wherein the applicator device is pre-filled with a therapeutically effective amount of the IRM compound.
47. The method of claim 42, further comprising filling the applicator device with the IRM compound, wherein the IRM compound is contained in a container separate from the device.
48. The method of claim 47, wherein the applicator device comprises measuring marks and wherein the method further comprises using the marks to determine the amount of the IRM compound in the applicator device.
49. The method of claim 42, further comprising:
inserting the applicator device into the vagina;
positioning a distal end of the applicator device adjacent to the mucosal surface; and
applying the IRM compound to the mucosal surface, wherein the mucosal surface is on a cervix.
50. The method of claim 42, further comprising positioning a distal end of the applicator device adjacent to the vaginal part of the cervix, and applying the IRM compound to the mucosal surface, wherein the mucosal surface is on the vaginal part of the cervix.
51. The method of claim 42, wherein the condition associated with the mucosal surface is cervical intraepithelial neoplasia.
52. The method of claim 42, wherein the applicator device comprises a hollow tube comprising a distal delivery end and a proximal end, and a piston slidably received within the tube and wherein the method comprises moving the piston in the tube to cause dispensing of the IRM compound via the distal end.
53. The method of claim 52, wherein the applicator device further comprises a member configured to cause movement of the piston toward the distal end, and wherein the method comprises moving the member to cause the movement of the piston.
54. The method of claim 53, further comprising limiting retraction movement of the member toward the proximal end when the piston is located adjacent to the distal end.
55. The method of claim 53, wherein the piston is removably coupled to the member and wherein the method further comprises uncoupling the member from the piston.
56. The method of claim 53, further comprising sliding the member in the hollow tube.
57. The method of claim 52, further comprising limiting retraction movement of the piston toward the proximal end.
58. The method of claim 52, further comprising extending a portion of the piston from the distal end when the piston is positioned at its farthest location away from the proximal end.
US09/886,012 1999-01-08 2001-06-22 Systems and methods for treating a mucosal surface Abandoned US20020058674A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US09/886,012 US20020058674A1 (en) 1999-01-08 2001-06-22 Systems and methods for treating a mucosal surface
US10/238,662 US6706728B2 (en) 1999-01-08 2002-09-10 Systems and methods for treating a mucosal surface

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US11525399P 1999-01-08 1999-01-08
US09/479,578 US6245776B1 (en) 1999-01-08 2000-01-07 Formulations and methods for treatment of mucosal associated conditions with an immune response modifier
US21342000P 2000-06-22 2000-06-22
US09/676,339 US6486168B1 (en) 1999-01-08 2000-09-29 Formulations and methods for treatment of mucosal associated conditions with an immune response modifier
US09/886,012 US20020058674A1 (en) 1999-01-08 2001-06-22 Systems and methods for treating a mucosal surface

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US09/676,339 Continuation-In-Part US6486168B1 (en) 1999-01-08 2000-09-29 Formulations and methods for treatment of mucosal associated conditions with an immune response modifier

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/238,662 Continuation US6706728B2 (en) 1999-01-08 2002-09-10 Systems and methods for treating a mucosal surface

Publications (1)

Publication Number Publication Date
US20020058674A1 true US20020058674A1 (en) 2002-05-16

Family

ID=27494004

Family Applications (2)

Application Number Title Priority Date Filing Date
US09/886,012 Abandoned US20020058674A1 (en) 1999-01-08 2001-06-22 Systems and methods for treating a mucosal surface
US10/238,662 Expired - Fee Related US6706728B2 (en) 1999-01-08 2002-09-10 Systems and methods for treating a mucosal surface

Family Applications After (1)

Application Number Title Priority Date Filing Date
US10/238,662 Expired - Fee Related US6706728B2 (en) 1999-01-08 2002-09-10 Systems and methods for treating a mucosal surface

Country Status (1)

Country Link
US (2) US20020058674A1 (en)

Cited By (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010004853A1 (en) * 1999-12-28 2001-06-28 Yasunari Kato Accelerator with attachment of pedal arm
US6525064B1 (en) 2000-12-08 2003-02-25 3M Innovative Properties Company Sulfonamido substituted imidazopyridines
US6534654B2 (en) 1996-06-21 2003-03-18 3M Innovative Properties Company Process for preparing imidazoquinolinamines
US6545016B1 (en) 2000-12-08 2003-04-08 3M Innovative Properties Company Amide substituted imidazopyridines
US6545017B1 (en) 2000-12-08 2003-04-08 3M Innovative Properties Company Urea substituted imidazopyridines
US20030130299A1 (en) * 1999-06-10 2003-07-10 Stephen L. Crooks Method for the treatment of periodontal disease
US20030135843A1 (en) * 2001-12-20 2003-07-17 International Business Machines Corporation Testing measurements
US20030133913A1 (en) * 2001-08-30 2003-07-17 3M Innovative Properties Company Methods of maturing plasmacytoid dendritic cells using immune response modifier molecules
US20030161797A1 (en) * 2002-02-22 2003-08-28 3M Innovative Properties Company Method of reducing and treating UVB-induced immunosuppression
US20030186440A1 (en) * 1999-02-11 2003-10-02 3M Innovative Properties Company Maturation of dendritic cells with immune response modifying compounds
US20030199538A1 (en) * 2001-11-29 2003-10-23 3M Innovative Properties Company Pharmaceutical formulation comprising an immune response modifier
US6660735B2 (en) 2000-12-08 2003-12-09 3M Innovative Properties Company Urea substituted imidazoquinoline ethers
US6664265B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Amido ether substituted imidazoquinolines
US6667312B2 (en) 2000-12-08 2003-12-23 3M Innovative Properties Company Thioether substituted imidazoquinolines
US6677349B1 (en) 2001-12-21 2004-01-13 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
US6677348B2 (en) 2000-12-08 2004-01-13 3M Innovative Properties Company Aryl ether substituted imidazoquinolines
US6677347B2 (en) 2000-12-08 2004-01-13 3M Innovative Properties Company Sulfonamido ether substituted imidazoquinolines
US6699878B2 (en) 1997-12-11 2004-03-02 3M Innovative Properties Company Imidazonaphthyridines
US20040077678A1 (en) * 2000-12-08 2004-04-22 3M Innovative Properties Company Urea substituted imidazoquinoline ethers
US20040102471A1 (en) * 2000-12-08 2004-05-27 3M Innovative Properties Company Thioether substituted imidazoquinolines
US20040132079A1 (en) * 2002-12-11 2004-07-08 3M Innovative Properties Company Assays relating to Toll-like receptor activity
US20040132766A1 (en) * 2002-09-26 2004-07-08 Griesgraber George W. 1H-imidazo dimers
US20040141950A1 (en) * 2002-12-30 2004-07-22 3M Innovative Properties Company Immunostimulatory combinations
US20040162309A1 (en) * 2003-02-13 2004-08-19 3M Innovative Properties Company Methods and compositions related to IRM compounds and toll-like receptor 8
US6780873B2 (en) 1999-06-10 2004-08-24 3M Innovative Properties Company Urea substituted imidazoquinolines
US20040167154A1 (en) * 1999-06-10 2004-08-26 3M Innovative Properties Company Urea substituted imidazoquinolines
US20040171086A1 (en) * 2003-02-27 2004-09-02 3M Innovative Properties Company Selective modulation of TLR-mediated biological activity
US20040176367A1 (en) * 2003-03-07 2004-09-09 3M Innovative Properties Company 1-Amino 1H-imidazoquinolines
US20040181130A1 (en) * 2003-03-13 2004-09-16 3M Innovative Properties Company Methods for diagnosing skin lesions
US20040180919A1 (en) * 2003-03-13 2004-09-16 3M Innovative Properties Company Methods of improving skin quality
US6797718B2 (en) 2002-06-07 2004-09-28 3M Innovative Properties Company Ether substituted imidazopyridines
US20040197865A1 (en) * 2002-12-11 2004-10-07 3M Innovative Properties Company Gene expression systems and recombinant cell lines
US20040202720A1 (en) * 2003-04-10 2004-10-14 3M Innovative Properties Company Delivery of immune response modifier compounds using metal-containing particulate support materials
US20040235881A1 (en) * 2001-06-15 2004-11-25 Mitra Sumita B. Immune response modifiers for the treatment of periodontal disease
US20040265351A1 (en) * 2003-04-10 2004-12-30 Miller Richard L. Methods and compositions for enhancing immune response
US20050054640A1 (en) * 2003-03-07 2005-03-10 Griesgraber George W. 1-Amino 1H-imidazoquinolines
US20050070460A1 (en) * 2003-08-05 2005-03-31 3M Innovative Properties Company Infection prophylaxis using immune response modifier compounds
US6916925B1 (en) 1999-11-05 2005-07-12 3M Innovative Properties Co. Dye labeled imidazoquinoline compounds
US20060040946A1 (en) * 2003-11-17 2006-02-23 Biomarin Pharmaceutical Inc. Methods and compositions for the treatment of metabolic disorders
US20060100229A1 (en) * 2003-10-03 2006-05-11 Hays David S Pyrazolopyridines and analogs thereof
US7091214B2 (en) 2002-12-20 2006-08-15 3M Innovative Properties Co. Aryl substituted Imidazoquinolines
US20060189644A1 (en) * 2003-08-14 2006-08-24 Wightman Paul D Lipid-modified immune response modifiers
US20060195067A1 (en) * 2003-08-25 2006-08-31 Wolter James T Delivery of immune response modifier compounds
US20060216333A1 (en) * 2003-09-02 2006-09-28 Miller Richard L Methods related to the treatment of mucosal associated conditions
US7179253B2 (en) 2003-03-13 2007-02-20 3M Innovative Properties Company Method of tattoo removal
WO2007045901A1 (en) * 2005-10-21 2007-04-26 Nilufer Smith Innovations Limited Improvements in and relating to disposable dispensers for personal use
US20070099901A1 (en) * 2003-11-25 2007-05-03 3M Innovative Properties Company Hydroxylamine and oxime substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
US20070167476A1 (en) * 2003-12-29 2007-07-19 Kshirsagar Tushar A Piperazine, [1,4]Diazepane, [1,4]Diazocane, and [1,5]Diazocane fused imidazo ring compounds
US20070243215A1 (en) * 2004-10-08 2007-10-18 Miller Richard L Adjuvant for Dna Vaccines
US20070287724A1 (en) * 2004-06-18 2007-12-13 3M Innovative Properties Company Substituted Imidazoquinolines, Imidazopyridines, and Imidazonaphthyridines
US20080015184A1 (en) * 2004-06-14 2008-01-17 3M Innovative Properties Company Urea Substituted Imidazopyridines, Imidazoquinolines, and Imidazonaphthyridines
US20080114019A1 (en) * 2003-08-12 2008-05-15 Coley Pharmaceutical Group, Inc. Hydroxylamine Substituted Imidazoquinolines
US20080119572A1 (en) * 2003-03-25 2008-05-22 Graceway Pharmaceuticals. Llc Treatment for basal cell carcinoma
US7393859B2 (en) 1999-06-10 2008-07-01 Coley Pharmaceutical Group, Inc. Amide substituted imidazoquinolines
US20080188513A1 (en) * 2004-12-30 2008-08-07 Taked Pharmaceutical Company Limited 1-(2-Methylpropyl)-1H-Imidazo[4,5-C](1,5]Naphthyridin-4-Amine Ethanesulfonate and 1-(2-Methylpropyl)-1H-Imidazo[4,5-C](1,5]Naphthyridin-4-Amine Methanesulfonate
US20080193487A1 (en) * 2004-10-08 2008-08-14 Johannes-Gutenberg-Universitaet Mainz Preparation for Vaccination, Vaccination Method and Use of a Vaccination Preparation
US20080193474A1 (en) * 2005-04-25 2008-08-14 Griesgraber George W Immunostimulatory Compositions
US7427629B2 (en) 2002-08-15 2008-09-23 3M Innovative Properties Company Immunostimulatory compositions and methods of stimulating an immune response
US20090005376A1 (en) * 2004-09-02 2009-01-01 3M Innovative Properties Company 1-Alkoxy 1H-Imidazo Ring Systems and Methods
US20090042925A1 (en) * 2003-11-14 2009-02-12 Coley Pharmaceutical Group, Inc. Oxime substituted imidazoquinolines
US20090124652A1 (en) * 2004-12-30 2009-05-14 Takeda Pharmaceutical Company Limited Polymorphs of 1-(2-Methylpropyl)-1H-Imidazo[4,5-C][1,5]Naphthyridin-4-Amine Ethane-Sulfonate
US20090163532A1 (en) * 2005-02-04 2009-06-25 Coley Pharmaceutical Group, Inc. Aqueous Gel Formulations Containing Immune Response Modifiers
US20100056557A1 (en) * 2004-12-30 2010-03-04 Bernd Benninghoff Treatment for cutaneous metastases
US20100087797A1 (en) * 2008-10-07 2010-04-08 Christcot Medical Company Method and apparatus for inserting a rectal suppository
US20100158928A1 (en) * 2006-12-22 2010-06-24 Doris Stoermer Immune response modifier compositions and methods
US7897597B2 (en) 2003-08-27 2011-03-01 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted imidazoquinolines
US7897609B2 (en) 2004-06-18 2011-03-01 3M Innovative Properties Company Aryl substituted imidazonaphthyridines
US7906506B2 (en) 2006-07-12 2011-03-15 3M Innovative Properties Company Substituted chiral fused [1,2] imidazo [4,5-c] ring compounds and methods
US7915281B2 (en) 2004-06-18 2011-03-29 3M Innovative Properties Company Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and method
US7923429B2 (en) 2003-09-05 2011-04-12 3M Innovative Properties Company Treatment for CD5+ B cell lymphoma
US7939526B2 (en) 2003-12-04 2011-05-10 3M Innovative Properties Company Sulfone substituted imidazo ring ethers
US7943609B2 (en) 2004-12-30 2011-05-17 3M Innovative Proprerties Company Chiral fused [1,2]imidazo[4,5-C] ring compounds
US7943636B2 (en) 2005-04-01 2011-05-17 3M Innovative Properties Company 1-substituted pyrazolo (3,4-C) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases
US7943610B2 (en) 2005-04-01 2011-05-17 3M Innovative Properties Company Pyrazolopyridine-1,4-diamines and analogs thereof
US7968563B2 (en) 2005-02-11 2011-06-28 3M Innovative Properties Company Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods
US8003126B2 (en) 2004-11-17 2011-08-23 Biomarin Pharmaceutical Inc. Stable tablet formulation
US8017779B2 (en) 2004-06-15 2011-09-13 3M Innovative Properties Company Nitrogen containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
US8026366B2 (en) 2004-06-18 2011-09-27 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
US8034938B2 (en) 2004-12-30 2011-10-11 3M Innovative Properties Company Substituted chiral fused [1,2]imidazo[4,5-c] ring compounds
US8088790B2 (en) 2005-11-04 2012-01-03 3M Innovative Properties Company Hydroxy and alkoxy substituted 1H-imidazoquinolines and methods
US8110582B2 (en) 2003-03-04 2012-02-07 3M Innovative Properties Company Prophylactic treatment of UV-induced epidermal neoplasia
US8143270B2 (en) 2004-09-02 2012-03-27 3M Innovative Properties Company 2-amino 1H-in-imidazo ring systems and methods
US8158794B2 (en) 2005-02-23 2012-04-17 3M Innovative Properties Company Hydroxyalkyl substituted imidazoquinoline compounds and methods
US8178677B2 (en) 2005-02-23 2012-05-15 3M Innovative Properties Company Hydroxyalkyl substituted imidazoquinolines
US8178539B2 (en) 2006-09-06 2012-05-15 3M Innovative Properties Company Substituted 3,4,6,7-tetrahydro-5H-1,2a,4a,8-tetraazacyclopenta[cd]phenalenes and methods
US8188111B2 (en) 2005-09-09 2012-05-29 3M Innovative Properties Company Amide and carbamate derivatives of alkyl substituted N-[4-(4-amino-1H-imidazo[4,5-c]quinolin-1-yl)butyI]methanesulfonamides and methods
US8329721B2 (en) 2006-03-15 2012-12-11 3M Innovative Properties Company Hydroxy and alkoxy substituted 1H-imidazonaphthyridines and methods
US8343993B2 (en) 2005-02-23 2013-01-01 3M Innovative Properties Company Hydroxyalkyl substituted imidazonaphthyridines
US8378102B2 (en) 2005-02-09 2013-02-19 3M Innovative Properties Company Oxime and hydroxylamine substituted thiazolo[4,5-c] ring compounds and methods
US8476292B2 (en) 2005-09-09 2013-07-02 3M Innovative Properties Company Amide and carbamate derivatives of N-{2-[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c] quinolin-1-Yl]-1,1-dimethylethyl}methanesulfonamide and methods
US8541438B2 (en) 2004-06-18 2013-09-24 3M Innovative Properties Company Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
US8557838B2 (en) 2004-12-17 2013-10-15 Medicis Pharmaceutical Corporation Immune response modifier formulations containing oleic acid and methods
BE1020555A5 (en) * 2012-10-10 2013-12-03 Euro Medical Bvba RESEARCH METHOD.
US8598192B2 (en) 2003-11-14 2013-12-03 3M Innovative Properties Company Hydroxylamine substituted imidazoquinolines
US8658666B2 (en) 2005-02-11 2014-02-25 3M Innovative Properties Company Substituted imidazoquinolines and imidazonaphthyridines
US8691837B2 (en) 2003-11-25 2014-04-08 3M Innovative Properties Company Substituted imidazo ring systems and methods
US8697873B2 (en) 2004-03-24 2014-04-15 3M Innovative Properties Company Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
US8735421B2 (en) 2003-12-30 2014-05-27 3M Innovative Properties Company Imidazoquinolinyl sulfonamides
US8802853B2 (en) 2003-12-29 2014-08-12 3M Innovative Properties Company Arylalkenyl and arylalkynyl substituted imidazoquinolines
US8846710B2 (en) 2005-02-23 2014-09-30 3M Innovative Properties Company Method of preferentially inducing the biosynthesis of interferon
US8871782B2 (en) 2003-10-03 2014-10-28 3M Innovative Properties Company Alkoxy substituted imidazoquinolines
US9107958B2 (en) 2011-06-03 2015-08-18 3M Innovative Properties Company Hydrazino 1H-imidazoquinolin-4-amines and conjugates made therefrom
US9145410B2 (en) 2003-10-03 2015-09-29 3M Innovative Properties Company Pyrazolopyridines and analogs thereof
US9216178B2 (en) 2011-11-02 2015-12-22 Biomarin Pharmaceutical Inc. Dry blend formulation of tetrahydrobiopterin
US9242980B2 (en) 2010-08-17 2016-01-26 3M Innovative Properties Company Lipidated immune response modifier compound compositions, formulations, and methods
US9475804B2 (en) 2011-06-03 2016-10-25 3M Innovative Properties Company Heterobifunctional linkers with polyethylene glycol segments and immune response modifier conjugates made therefrom
US9546184B2 (en) 2005-02-09 2017-01-17 3M Innovative Properties Company Alkyloxy substituted thiazoloquinolines and thiazolonaphthyridines
US9662481B2 (en) 2008-10-07 2017-05-30 Cristcot Llc Method and apparatus for inserting a rectal suppository
US10149967B2 (en) 2012-10-19 2018-12-11 Cristcot Llc Suppository insertion device, suppository, and method of manufacturing a suppository
US10441397B2 (en) * 2011-09-16 2019-10-15 Boston Scientific Scimed, Inc. Medical device and method for conducting a surgery through a body opening
US10472420B2 (en) 2006-02-22 2019-11-12 3M Innovative Properties Company Immune response modifier conjugates
WO2022006259A1 (en) * 2020-07-01 2022-01-06 Revelation Biosciences, Inc. Immunostimulatory compositions and methods
US11298515B2 (en) 2016-05-12 2022-04-12 Cristcot Llc Single-use suppository insertion device and method
US11306083B2 (en) 2017-12-20 2022-04-19 3M Innovative Properties Company Amide substituted imidazo[4,5-C]quinoline compounds with a branched chain linking group for use as an immune response modifier

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006091720A2 (en) * 2000-12-08 2006-08-31 3M Innovative Properties Company Compositions and methods for targeted delivery of immune response modifiers
US20040127861A1 (en) * 2002-12-26 2004-07-01 Bradley Pharmaceuticals, Inc. Method and apparatus for dispensing a composition
WO2004087049A2 (en) * 2003-03-25 2004-10-14 3M Innovative Properties Company Selective activation of cellular activities mediated through a common toll-like receptor
WO2004096144A2 (en) * 2003-04-28 2004-11-11 3M Innovative Properties Company Compositions and methods for induction of opioid receptors
WO2004110992A2 (en) * 2003-06-06 2004-12-23 3M Innovative Properties Company Process for imidazo[4,5-c] pyridin-4-amines
US6943255B2 (en) * 2003-06-06 2005-09-13 3M Innovative Properties Company Process for imidazo[4,5-c]pyridin-4-amines
JP2007505629A (en) * 2003-09-17 2007-03-15 スリーエム イノベイティブ プロパティズ カンパニー Selective regulation of TLR gene expression
US7442179B1 (en) * 2003-09-23 2008-10-28 Just Troy M Pre-fill applicator
US20090075980A1 (en) * 2003-10-03 2009-03-19 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and Analogs Thereof
US20050096259A1 (en) * 2003-10-31 2005-05-05 3M Innovative Properties Company Neutrophil activation by immune response modifier compounds
US20050226878A1 (en) * 2003-12-02 2005-10-13 3M Innovative Properties Company Therapeutic combinations and methods including IRM compounds
US8940755B2 (en) * 2003-12-02 2015-01-27 3M Innovative Properties Company Therapeutic combinations and methods including IRM compounds
JP2007517055A (en) * 2003-12-30 2007-06-28 スリーエム イノベイティブ プロパティズ カンパニー Enhanced immune response
US20050201959A1 (en) * 2004-03-11 2005-09-15 Vvii Newco 2003, Inc. Methods and compositions for altering skin coloration
JP2007532572A (en) * 2004-04-09 2007-11-15 スリーエム イノベイティブ プロパティズ カンパニー Methods, compositions and preparations for delivering immune response modifiers
EP1755665A4 (en) * 2004-04-28 2010-03-03 3M Innovative Properties Co Compositions and methods for mucosal vaccination
US20050267145A1 (en) * 2004-05-28 2005-12-01 Merrill Bryon A Treatment for lung cancer
EP1786450A4 (en) * 2004-08-27 2009-11-11 3M Innovative Properties Co Hiv immunostimulatory compositions
US20090270443A1 (en) * 2004-09-02 2009-10-29 Doris Stoermer 1-amino imidazo-containing compounds and methods
JP2008523076A (en) * 2004-12-08 2008-07-03 スリーエム イノベイティブ プロパティズ カンパニー Immunomodulatory compositions, combinations and methods
RU2007137960A (en) 2005-03-14 2009-04-20 Меда Аб (Se) METHOD FOR TREATING ACTIN KERATOSIS (OPTIONS) AND 2-METHYL-1- (2-METHYL PROPYL) -1H-IMIDAZO [4,5-c]] 1,5] NAPHTIRIDIN-4-AMINE AS A MEANS OF TREATMENT OF ACTINIC KERO
CN101304748A (en) 2005-08-22 2008-11-12 加利福尼亚大学董事会 TLR agonist
US20070081962A1 (en) * 2005-10-06 2007-04-12 Amit Munshi Novel delivery of immune response modifiers for removal of chronic tattoos
US8846697B2 (en) 2006-05-31 2014-09-30 The Regents Of The University Of California Purine analogs
MX2009000507A (en) * 2006-07-14 2009-06-12 Stiefel Res Australia Pty Ltd Fatty acid pharmaceutical foam.
EP1889609B1 (en) * 2006-07-18 2019-05-22 Meda AB Immune response modifier foam formulations
CA2659733A1 (en) * 2006-07-31 2008-02-07 3M Innovative Properties Company Sterilized topical compositions of 1-(2-methylpropyl)-1h-imidazo[4,5-c]quinolin-4-amine
US7666160B2 (en) 2006-12-29 2010-02-23 Kimberly-Clark Worldwide, Inc. Delivery device
DK2510946T3 (en) 2007-02-07 2015-11-02 Univ California Conjugates of synthetic fluorescent agonists and their applications
BRPI0907191A2 (en) * 2008-01-15 2015-07-14 Dow Pharmaceutical Sciences Solution, method of preparing a solution, method of increasing imiquimod skin penetration or an analog of imiquimod
EA201001264A1 (en) * 2008-02-07 2011-04-29 Дзе Регентс Оф Дзе Юниверсити Оф Калифорния METHOD FOR TREATING URINARY BUBBLE DISEASES WITH TLR7 Activator
US20100160368A1 (en) 2008-08-18 2010-06-24 Gregory Jefferson J Methods of Treating Dermatological Disorders and Inducing Interferon Biosynthesis With Shorter Durations of Imiquimod Therapy
AU2009335943A1 (en) 2008-12-19 2013-10-24 Medicis Pharmaceutical Corporation Lower dosage strength imiquimod formulations and short dosing regimens for treating actinic keratosis
WO2010088924A1 (en) 2009-02-06 2010-08-12 Telormedix Sa Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration
MX2011008500A (en) * 2009-02-11 2011-09-26 Univ California Toll-like receptor modulators and treatment of diseases.
ES2653313T3 (en) * 2009-07-13 2018-02-06 Medicis Pharmaceutical Corporation Imiquimod formulations with lower dosage concentration and short dosage regimens for the treatment of genital and perianal warts
WO2011127924A2 (en) 2010-04-16 2011-10-20 Charité - Universitätsmedizin Berlin Agent for locally treating cervical dysplasias
US11697851B2 (en) 2016-05-24 2023-07-11 The Regents Of The University Of California Early ovarian cancer detection diagnostic test based on mRNA isoforms

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US545102A (en) 1895-08-27 Stjegical
US652848A (en) 1898-07-11 1900-07-03 Joseph Benson Hill Applicator.
US1711341A (en) 1927-03-01 1929-04-30 Cook Jesse Franklin Applicator for medicaments
US1794221A (en) 1929-09-09 1931-02-24 Lack Mfg Company Applicator
US2518486A (en) 1948-03-06 1950-08-15 Ortho Pharma Corp Single dose dispenser
US2616423A (en) 1951-03-26 1952-11-04 Yervant H Kurkjian Plunger type disposable medicament container
US2705496A (en) 1953-06-18 1955-04-05 Hoffmann La Roche Applicator
US2826198A (en) 1956-03-16 1958-03-11 Wilton E Van Sickle Medicinal applicator
US3220413A (en) 1961-04-03 1965-11-30 Sunnen Joseph Applicator
US3314941A (en) 1964-06-23 1967-04-18 American Cyanamid Co Novel substituted pyridodiazepins
US3424158A (en) 1966-06-21 1969-01-28 Jules Silver Combination plastic mold,suppository package,dispenser and method for providing and using the same
US3506008A (en) 1968-03-25 1970-04-14 Ortho Pharma Corp Medical applicator
CS148629B1 (en) 1970-12-10 1973-03-29
US3917624A (en) 1972-09-27 1975-11-04 Pfizer Process for producing 2-amino-nicotinonitrile intermediates
US3900033A (en) 1973-03-07 1975-08-19 Ortho Pharma Corp Dilator for cervical canal
IL73534A (en) 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
ZA848968B (en) 1983-11-18 1986-06-25 Riker Laboratories Inc 1h-imidazo(4,5-c)quinolines and 1h-imidazo(4,5-c)quinolin-4-amines
SE8502933D0 (en) 1985-06-13 1985-06-13 Leo Ab Pipette
US4826830A (en) 1985-07-31 1989-05-02 Jui Han Topical application of glyciphosphoramide
US4858624A (en) 1988-02-24 1989-08-22 Vance Products Incorporated D/B/A/ Cook Urological Incorporated And Cook Ob/Gyn Device and method for intravaginal, barrier-type prevention of conception and infection
US5238944A (en) 1988-12-15 1993-08-24 Riker Laboratories, Inc. Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
US5037986A (en) 1989-03-23 1991-08-06 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo[4,5-c]quinolin-4-amines
US4929624A (en) 1989-03-23 1990-05-29 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo(4,5-c)quinolin-4-amines
US4988815A (en) 1989-10-26 1991-01-29 Riker Laboratories, Inc. 3-Amino or 3-nitro quinoline compounds which are intermediates in preparing 1H-imidazo[4,5-c]quinolines
DK0553202T3 (en) 1990-10-05 1995-07-03 Minnesota Mining & Mfg Process for the preparation of imidazo (4,5-c) quinoline-4-amines
US5175296A (en) 1991-03-01 1992-12-29 Minnesota Mining And Manufacturing Company Imidazo[4,5-c]quinolin-4-amines and processes for their preparation
US5389640A (en) 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US5268376A (en) 1991-09-04 1993-12-07 Minnesota Mining And Manufacturing Company 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US5266575A (en) 1991-11-06 1993-11-30 Minnesota Mining And Manufacturing Company 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines
ZA932947B (en) 1992-04-28 1993-10-27 Schering Plough Healthcare Applicator for semisolid medications
IL105595A0 (en) 1992-05-15 1993-09-22 Akzo Nv Applicator for introducing a cream-type substance into a woman's vagina
US5282789A (en) 1992-09-15 1994-02-01 Niemand Industries, Inc. Disposable medicine applicator
US5395937A (en) 1993-01-29 1995-03-07 Minnesota Mining And Manufacturing Company Process for preparing quinoline amines
US5773413A (en) 1993-06-04 1998-06-30 Demeter Biotechnologies, Ltd. Method of combating mammalian neoplasias, and lytic peptides therefor
DK0708772T3 (en) 1993-07-15 2000-09-18 Minnesota Mining & Mfg Imidazo [4,5-c] pyridin-4-amines
US5352784A (en) 1993-07-15 1994-10-04 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines
US5648516A (en) 1994-07-20 1997-07-15 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines
US5782801A (en) 1997-01-31 1998-07-21 Caillouette; James C. Controlled application of contained screening or treatment fluid to tissue such as cervical or vaginal tissue
US5644063A (en) 1994-09-08 1997-07-01 Minnesota Mining And Manufacturing Company Imidazo[4,5-c]pyridin-4-amine intermediates
US5482936A (en) 1995-01-12 1996-01-09 Minnesota Mining And Manufacturing Company Imidazo[4,5-C]quinoline amines
US5585612A (en) 1995-03-20 1996-12-17 Harp Enterprises, Inc. Method and apparatus for voting
JPH09208584A (en) 1996-01-29 1997-08-12 Terumo Corp Amide derivative, pharmaceutical preparation containing the same, and intermediate for synthesizing the same
IL126971A0 (en) 1996-05-09 1999-09-22 Pharma Pacific Pty Ltd Interferon compositions
US5693811A (en) 1996-06-21 1997-12-02 Minnesota Mining And Manufacturing Company Process for preparing tetrahdroimidazoquinolinamines
US5741908A (en) 1996-06-21 1998-04-21 Minnesota Mining And Manufacturing Company Process for reparing imidazoquinolinamines
US5939090A (en) 1996-12-03 1999-08-17 3M Innovative Properties Company Gel formulations for topical drug delivery
WO1998030562A1 (en) 1997-01-09 1998-07-16 Terumo Kabushiki Kaisha Novel amide derivatives and intermediates for the synthesis thereof
UA67760C2 (en) 1997-12-11 2004-07-15 Міннесота Майнінг Енд Мануфакчурінг Компані Imidazonaphthyridines and use thereof to induce the biosynthesis of cytokines
US6110929A (en) 1998-07-28 2000-08-29 3M Innovative Properties Company Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
JP2000119271A (en) 1998-08-12 2000-04-25 Hokuriku Seiyaku Co Ltd 1H-imidazopyridine derivative
MXPA01006876A (en) 1999-01-08 2002-04-24 3M Innovative Properties Co Formulations and methods for treatment of mucosal associated conditions with an immune response modifier.
US6541485B1 (en) 1999-06-10 2003-04-01 3M Innovative Properties Company Urea substituted imidazoquinolines
US6331539B1 (en) 1999-06-10 2001-12-18 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
US6451810B1 (en) 1999-06-10 2002-09-17 3M Innovative Properties Company Amide substituted imidazoquinolines

Cited By (244)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6613902B2 (en) 1996-06-21 2003-09-02 3M Innovative Properties Company Process for preparing imidazoquinolinamines
US7026482B2 (en) 1996-06-21 2006-04-11 Gerster John F Process for preparing imidazoquinolinamines
US6534654B2 (en) 1996-06-21 2003-03-18 3M Innovative Properties Company Process for preparing imidazoquinolinamines
US6897314B2 (en) 1996-06-21 2005-05-24 3M Innovative Properties Company Process for preparing imidazoquinolinamines
US6624305B2 (en) 1996-06-21 2003-09-23 3M Innovative Properties Company Process for preparing imidazoquinolinamines
US6797716B2 (en) 1997-12-11 2004-09-28 3M Innovative Properties Company Imidazonaphthyridines
US6949646B2 (en) 1997-12-11 2005-09-27 3M Innovative Properties Co. Imidazonaphthyridines
US6894165B2 (en) 1997-12-11 2005-05-17 3M Innovative Properties Company Imidazonaphthyridines
US6699878B2 (en) 1997-12-11 2004-03-02 3M Innovative Properties Company Imidazonaphthyridines
US6747040B2 (en) 1997-12-11 2004-06-08 3M Innovative Properties Company Imidazonaphthyridines
US20050107421A1 (en) * 1997-12-11 2005-05-19 3M Innovative Properties Company Imidazonaphthyridines
US20030186440A1 (en) * 1999-02-11 2003-10-02 3M Innovative Properties Company Maturation of dendritic cells with immune response modifying compounds
US6897221B2 (en) 1999-06-10 2005-05-24 3M Innovative Properties Company Urea substituted imidazoquinolines
US6825350B2 (en) 1999-06-10 2004-11-30 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines and methods for the treatment of periodontal disease using these and other immune response modifiers
US7393859B2 (en) 1999-06-10 2008-07-01 Coley Pharmaceutical Group, Inc. Amide substituted imidazoquinolines
US20060106052A1 (en) * 1999-06-10 2006-05-18 3M Innovative Properties Company Method of using sulfonamide substituted imidazoquinolines
US20030130299A1 (en) * 1999-06-10 2003-07-10 Stephen L. Crooks Method for the treatment of periodontal disease
US6784188B2 (en) 1999-06-10 2004-08-31 3M Innovative Properties Company Urea substituted imidazoquinolines
US20090023722A1 (en) * 1999-06-10 2009-01-22 Coleman Patrick L Amide substituted imidazoquinolines
US20040167154A1 (en) * 1999-06-10 2004-08-26 3M Innovative Properties Company Urea substituted imidazoquinolines
US6780873B2 (en) 1999-06-10 2004-08-24 3M Innovative Properties Company Urea substituted imidazoquinolines
US7157453B2 (en) 1999-06-10 2007-01-02 3M Innovation Properties Company Urea substituted imidazoquinolines
US6916925B1 (en) 1999-11-05 2005-07-12 3M Innovative Properties Co. Dye labeled imidazoquinoline compounds
US20010004853A1 (en) * 1999-12-28 2001-06-28 Yasunari Kato Accelerator with attachment of pedal arm
US6667312B2 (en) 2000-12-08 2003-12-23 3M Innovative Properties Company Thioether substituted imidazoquinolines
US7049439B2 (en) 2000-12-08 2006-05-23 3M Innovative Properties Co. Urea substituted imidazoquinoline ethers
US20040077678A1 (en) * 2000-12-08 2004-04-22 3M Innovative Properties Company Urea substituted imidazoquinoline ethers
US20040092545A1 (en) * 2000-12-08 2004-05-13 3M Innovative Properties Company Sulfonamido ether substituted imidazoquinolines
US20040097542A1 (en) * 2000-12-08 2004-05-20 3M Innovative Properties Company Sulfonamido ether substituted imidazoquinolines
US20040097736A1 (en) * 2000-12-08 2004-05-20 3M Innovative Properties Company Thioether substituted imidazoquinolines
US20040102471A1 (en) * 2000-12-08 2004-05-27 3M Innovative Properties Company Thioether substituted imidazoquinolines
US7288550B2 (en) 2000-12-08 2007-10-30 3M Innovative Properties Company Thioether substituted imidazoquinolines
US6720333B2 (en) 2000-12-08 2004-04-13 3M Innovative Properties Company Amide substituted imidazopyridines
US7276515B2 (en) 2000-12-08 2007-10-02 Coley Pharmaceutical Group, Inc. Thioether substituted imidazoquinolines
US6921826B2 (en) 2000-12-08 2005-07-26 3M Innovative Properties Co. Thioether substituted imidazoquinolines
US20040138248A1 (en) * 2000-12-08 2004-07-15 3M Innovative Properties Company Aryl ether substituted imidazoquinolines
US7214675B2 (en) 2000-12-08 2007-05-08 3M Innovative Properties Company Urea substituted imidazoquinoline ethers
US20040157879A1 (en) * 2000-12-08 2004-08-12 3M Innovative Properties Company Urea substituted imidazopyridines
US6720422B2 (en) 2000-12-08 2004-04-13 3M Innovative Properties Company Amide substituted imidazopyridines
US6720334B2 (en) 2000-12-08 2004-04-13 3M Innovative Properties Company Urea substituted imidazopyridines
US20040067975A1 (en) * 2000-12-08 2004-04-08 3M Innovative Properties Company Amido ether substituted imidazoquinolines
US6696465B2 (en) 2000-12-08 2004-02-24 3M Innovative Properties Company Sulfonamido substituted imidazopyridines
US7132429B2 (en) 2000-12-08 2006-11-07 3M Innovative Properties Company Sulfonamido ether substituted imidazoquinolines
US7115622B2 (en) 2000-12-08 2006-10-03 3M Innovative Properties Company Amido ether substituted imidazoquinolines
US7078523B2 (en) 2000-12-08 2006-07-18 3M Innovative Properties Company Urea substituted imidazoquinoline ethers
US20040072859A1 (en) * 2000-12-08 2004-04-15 3M Innovative Properties Company Urea substituted imidazoquinoline ethers
US6677347B2 (en) 2000-12-08 2004-01-13 3M Innovative Properties Company Sulfonamido ether substituted imidazoquinolines
US6677348B2 (en) 2000-12-08 2004-01-13 3M Innovative Properties Company Aryl ether substituted imidazoquinolines
US20050209267A1 (en) * 2000-12-08 2005-09-22 3M Innovative Properties Company Thioether substituted imidazoquinolines
US6989389B2 (en) 2000-12-08 2006-01-24 3M Innovative Properties Co. Aryl ether substituted imidazoquinolines
US6969722B2 (en) 2000-12-08 2005-11-29 3M Innovative Properties Company Amide substituted imidazopyridines
US6525064B1 (en) 2000-12-08 2003-02-25 3M Innovative Properties Company Sulfonamido substituted imidazopyridines
US6664265B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Amido ether substituted imidazoquinolines
US20050234088A1 (en) * 2000-12-08 2005-10-20 3M Innovative Properties Company Urea substituted imidazoquinoline ethers
US6953804B2 (en) 2000-12-08 2005-10-11 3M Innovative Properties Co. Aryl ether substituted imidazoquinolines
US20050215581A1 (en) * 2000-12-08 2005-09-29 3M Innovative Properties Company Urea substituted imidazoquinoline ethers
US6660735B2 (en) 2000-12-08 2003-12-09 3M Innovative Properties Company Urea substituted imidazoquinoline ethers
US6949649B2 (en) 2000-12-08 2005-09-27 3M Innovative Properties Co. Thioether substituted imidazoquinolines
US6878719B2 (en) 2000-12-08 2005-04-12 3M Innovative Properties Company Sulfonamido substituted imidazopyridines
US20050209268A1 (en) * 2000-12-08 2005-09-22 3M Innovative Properties Company Thioether substituted imidazoquinolines
US6903113B2 (en) 2000-12-08 2005-06-07 3M Innovative Properties Company Urea substituted imidazopyridines
US7612083B2 (en) 2000-12-08 2009-11-03 Coley Pharmaceutical Group, Inc. Urea substituted imidazoquinoline ethers
US6545017B1 (en) 2000-12-08 2003-04-08 3M Innovative Properties Company Urea substituted imidazopyridines
US6545016B1 (en) 2000-12-08 2003-04-08 3M Innovative Properties Company Amide substituted imidazopyridines
US20040235881A1 (en) * 2001-06-15 2004-11-25 Mitra Sumita B. Immune response modifiers for the treatment of periodontal disease
US7226928B2 (en) 2001-06-15 2007-06-05 3M Innovative Properties Company Methods for the treatment of periodontal disease
US20030133913A1 (en) * 2001-08-30 2003-07-17 3M Innovative Properties Company Methods of maturing plasmacytoid dendritic cells using immune response modifier molecules
US20080275077A1 (en) * 2001-11-29 2008-11-06 Skwierczynski Raymond D Pharmaceutical formulations comprising an immune response modifier
US20030199538A1 (en) * 2001-11-29 2003-10-23 3M Innovative Properties Company Pharmaceutical formulation comprising an immune response modifier
US7968562B2 (en) 2001-11-29 2011-06-28 3M Innovative Properties Company Pharmaceutical formulations comprising an immune response modifier
US7299453B2 (en) 2001-12-20 2007-11-20 International Business Machines Corporation Testing measurements
US20030135843A1 (en) * 2001-12-20 2003-07-17 International Business Machines Corporation Testing measurements
US20050197358A1 (en) * 2001-12-21 2005-09-08 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
US6888000B2 (en) 2001-12-21 2005-05-03 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
US6677349B1 (en) 2001-12-21 2004-01-13 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
US20040106638A1 (en) * 2001-12-21 2004-06-03 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
US6924293B2 (en) 2001-12-21 2005-08-02 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
US7199131B2 (en) 2001-12-21 2007-04-03 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
US7030129B2 (en) 2002-02-22 2006-04-18 3M Innovative Properties Company Method of reducing and treating UVB-induced immunosuppression
US20030161797A1 (en) * 2002-02-22 2003-08-28 3M Innovative Properties Company Method of reducing and treating UVB-induced immunosuppression
US7220758B2 (en) 2002-06-07 2007-05-22 3M Innovative Properties Company Ether substituted imidazopyridines
US20050032830A1 (en) * 2002-06-07 2005-02-10 3M Innovative Properties Company Ether substituted imidazopyridines
US6797718B2 (en) 2002-06-07 2004-09-28 3M Innovative Properties Company Ether substituted imidazopyridines
US7125890B2 (en) 2002-06-07 2006-10-24 3M Innovative Properties Company Ether substituted imidazopyridines
US7427629B2 (en) 2002-08-15 2008-09-23 3M Innovative Properties Company Immunostimulatory compositions and methods of stimulating an immune response
US20040132766A1 (en) * 2002-09-26 2004-07-08 Griesgraber George W. 1H-imidazo dimers
US6818650B2 (en) 2002-09-26 2004-11-16 3M Innovative Properties Company 1H-imidazo dimers
US20050026947A1 (en) * 2002-09-26 2005-02-03 3M Innovative Properties Company 1H-imidazo dimers
US7112677B2 (en) 2002-09-26 2006-09-26 3M Innovative Properties Company 1H-imidazo dimers
US20040132079A1 (en) * 2002-12-11 2004-07-08 3M Innovative Properties Company Assays relating to Toll-like receptor activity
US20040197865A1 (en) * 2002-12-11 2004-10-07 3M Innovative Properties Company Gene expression systems and recombinant cell lines
US7091214B2 (en) 2002-12-20 2006-08-15 3M Innovative Properties Co. Aryl substituted Imidazoquinolines
US7598382B2 (en) 2002-12-20 2009-10-06 Coley Pharmaceutical Group, Inc. Aryl substituted imidazoquinolines
US7387271B2 (en) 2002-12-30 2008-06-17 3M Innovative Properties Company Immunostimulatory combinations
US10105426B2 (en) 2002-12-30 2018-10-23 Trustees Of Dartmouth College Immunostimulatory combinations
US8329197B2 (en) 2002-12-30 2012-12-11 3M Innovative Properties Company Ex vivo uses of immunostimulatory combinations
US20040141950A1 (en) * 2002-12-30 2004-07-22 3M Innovative Properties Company Immunostimulatory combinations
US20110002946A1 (en) * 2002-12-30 2011-01-06 Noelle Randolph J Immunostimulatory Combinations
US20040162309A1 (en) * 2003-02-13 2004-08-19 3M Innovative Properties Company Methods and compositions related to IRM compounds and toll-like receptor 8
US7375180B2 (en) 2003-02-13 2008-05-20 3M Innovative Properties Company Methods and compositions related to IRM compounds and Toll-like receptor 8
US20040171086A1 (en) * 2003-02-27 2004-09-02 3M Innovative Properties Company Selective modulation of TLR-mediated biological activity
US7485432B2 (en) 2003-02-27 2009-02-03 3M Innovative Properties Company Selective modulation of TLR-mediated biological activity
US8110582B2 (en) 2003-03-04 2012-02-07 3M Innovative Properties Company Prophylactic treatment of UV-induced epidermal neoplasia
US20050054640A1 (en) * 2003-03-07 2005-03-10 Griesgraber George W. 1-Amino 1H-imidazoquinolines
US7163947B2 (en) 2003-03-07 2007-01-16 3M Innovative Properties Company 1-Amino 1H-imidazoquinolines
US20040176367A1 (en) * 2003-03-07 2004-09-09 3M Innovative Properties Company 1-Amino 1H-imidazoquinolines
US7699057B2 (en) 2003-03-13 2010-04-20 3M Innovative Properties Company Methods for treating skin lesions
US8426457B2 (en) 2003-03-13 2013-04-23 Medicis Pharmaceutical Corporation Methods of improving skin quality
US20040180919A1 (en) * 2003-03-13 2004-09-16 3M Innovative Properties Company Methods of improving skin quality
US20040181130A1 (en) * 2003-03-13 2004-09-16 3M Innovative Properties Company Methods for diagnosing skin lesions
US20050165043A1 (en) * 2003-03-13 2005-07-28 3M Innovative Properties Company Method of treating scarring
US7179253B2 (en) 2003-03-13 2007-02-20 3M Innovative Properties Company Method of tattoo removal
US8835394B2 (en) 2003-03-25 2014-09-16 Medicis Pharmaceutical Corporation Treatment for basal cell carcinoma
US7696159B2 (en) 2003-03-25 2010-04-13 Graceway Pharmaceuticals, Llc Treatment for basal cell carcinoma
US20100197722A1 (en) * 2003-03-25 2010-08-05 Graceway Pharmaceuticals, Llc Treatment for basal cell carcinoma
US20080119572A1 (en) * 2003-03-25 2008-05-22 Graceway Pharmaceuticals. Llc Treatment for basal cell carcinoma
US7923560B2 (en) 2003-04-10 2011-04-12 3M Innovative Properties Company Delivery of immune response modifier compounds
US20040202720A1 (en) * 2003-04-10 2004-10-14 3M Innovative Properties Company Delivery of immune response modifier compounds using metal-containing particulate support materials
US9801947B2 (en) 2003-04-10 2017-10-31 3M Innovative Properties Company Methods and compositions for enhancing immune response
US20040265351A1 (en) * 2003-04-10 2004-12-30 Miller Richard L. Methods and compositions for enhancing immune response
US20050070460A1 (en) * 2003-08-05 2005-03-31 3M Innovative Properties Company Infection prophylaxis using immune response modifier compounds
US7648997B2 (en) 2003-08-12 2010-01-19 Coley Pharmaceutical Group, Inc. Hydroxylamine substituted imidazoquinolines
US8673932B2 (en) 2003-08-12 2014-03-18 3M Innovative Properties Company Oxime substituted imidazo-containing compounds
US20080114019A1 (en) * 2003-08-12 2008-05-15 Coley Pharmaceutical Group, Inc. Hydroxylamine Substituted Imidazoquinolines
US7799800B2 (en) 2003-08-14 2010-09-21 3M Innovative Properties Company Lipid-modified immune response modifiers
US20060189644A1 (en) * 2003-08-14 2006-08-24 Wightman Paul D Lipid-modified immune response modifiers
US8961477B2 (en) 2003-08-25 2015-02-24 3M Innovative Properties Company Delivery of immune response modifier compounds
US20060195067A1 (en) * 2003-08-25 2006-08-31 Wolter James T Delivery of immune response modifier compounds
US8263594B2 (en) 2003-08-27 2012-09-11 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted imidazoquinolines
US7897597B2 (en) 2003-08-27 2011-03-01 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted imidazoquinolines
US20060216333A1 (en) * 2003-09-02 2006-09-28 Miller Richard L Methods related to the treatment of mucosal associated conditions
US7923429B2 (en) 2003-09-05 2011-04-12 3M Innovative Properties Company Treatment for CD5+ B cell lymphoma
US8871782B2 (en) 2003-10-03 2014-10-28 3M Innovative Properties Company Alkoxy substituted imidazoquinolines
US9856254B2 (en) 2003-10-03 2018-01-02 3M Innovative Properties Company Alkoxy substituted imidazoquinolines
US9365567B2 (en) 2003-10-03 2016-06-14 3M Innovative Properties Company Alkoxy substituted imidazoquinolines
US9145410B2 (en) 2003-10-03 2015-09-29 3M Innovative Properties Company Pyrazolopyridines and analogs thereof
US7879849B2 (en) 2003-10-03 2011-02-01 3M Innovative Properties Company Pyrazolopyridines and analogs thereof
US20060100229A1 (en) * 2003-10-03 2006-05-11 Hays David S Pyrazolopyridines and analogs thereof
US7544697B2 (en) 2003-10-03 2009-06-09 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and analogs thereof
US7897767B2 (en) 2003-11-14 2011-03-01 3M Innovative Properties Company Oxime substituted imidazoquinolines
US20090042925A1 (en) * 2003-11-14 2009-02-12 Coley Pharmaceutical Group, Inc. Oxime substituted imidazoquinolines
US8598192B2 (en) 2003-11-14 2013-12-03 3M Innovative Properties Company Hydroxylamine substituted imidazoquinolines
US8067416B2 (en) 2003-11-17 2011-11-29 Merck Eprova Ag Methods and compositions for the treatment of metabolic disorders
US9993481B2 (en) 2003-11-17 2018-06-12 Biomarin Pharmaceutical Inc. Methods and compositions for the treatment of metabolic disorders
US7566714B2 (en) 2003-11-17 2009-07-28 Biomarin Pharmaceutical Inc. Methods and compositions for the treatment of metabolic disorders
US20080090832A1 (en) * 2003-11-17 2008-04-17 Biomarin Pharmaceutical Inc. Methods and compositions for the treatment of metabolic disorders
US20060040946A1 (en) * 2003-11-17 2006-02-23 Biomarin Pharmaceutical Inc. Methods and compositions for the treatment of metabolic disorders
US9433624B2 (en) 2003-11-17 2016-09-06 Biomarin Pharmaceutical Inc. Methods and compositions for the treatment of metabolic disorders
US20100009996A1 (en) * 2003-11-17 2010-01-14 Biomarin Pharmaceutical Inc. Methods and compositions for the treatment of metabolic disorders
US9765071B2 (en) 2003-11-25 2017-09-19 3M Innovative Properties Company Substituted imidazo ring systems and methods
US8691837B2 (en) 2003-11-25 2014-04-08 3M Innovative Properties Company Substituted imidazo ring systems and methods
US8778963B2 (en) 2003-11-25 2014-07-15 3M Innovative Properties Company Hydroxylamine and oxime substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
US9328110B2 (en) 2003-11-25 2016-05-03 3M Innovative Properties Company Substituted imidazo ring systems and methods
US20070099901A1 (en) * 2003-11-25 2007-05-03 3M Innovative Properties Company Hydroxylamine and oxime substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
US7939526B2 (en) 2003-12-04 2011-05-10 3M Innovative Properties Company Sulfone substituted imidazo ring ethers
US8802853B2 (en) 2003-12-29 2014-08-12 3M Innovative Properties Company Arylalkenyl and arylalkynyl substituted imidazoquinolines
US20070167476A1 (en) * 2003-12-29 2007-07-19 Kshirsagar Tushar A Piperazine, [1,4]Diazepane, [1,4]Diazocane, and [1,5]Diazocane fused imidazo ring compounds
US7888349B2 (en) 2003-12-29 2011-02-15 3M Innovative Properties Company Piperazine, [1,4]Diazepane, [1,4]Diazocane, and [1,5]Diazocane fused imidazo ring compounds
US8735421B2 (en) 2003-12-30 2014-05-27 3M Innovative Properties Company Imidazoquinolinyl sulfonamides
US8697873B2 (en) 2004-03-24 2014-04-15 3M Innovative Properties Company Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
US20080015184A1 (en) * 2004-06-14 2008-01-17 3M Innovative Properties Company Urea Substituted Imidazopyridines, Imidazoquinolines, and Imidazonaphthyridines
US8017779B2 (en) 2004-06-15 2011-09-13 3M Innovative Properties Company Nitrogen containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
US9938275B2 (en) 2004-06-18 2018-04-10 3M Innovative Properties Company Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
US9006264B2 (en) 2004-06-18 2015-04-14 3M Innovative Properties Company Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
US7897609B2 (en) 2004-06-18 2011-03-01 3M Innovative Properties Company Aryl substituted imidazonaphthyridines
US7915281B2 (en) 2004-06-18 2011-03-29 3M Innovative Properties Company Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and method
US20070287724A1 (en) * 2004-06-18 2007-12-13 3M Innovative Properties Company Substituted Imidazoquinolines, Imidazopyridines, and Imidazonaphthyridines
US8541438B2 (en) 2004-06-18 2013-09-24 3M Innovative Properties Company Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
US8026366B2 (en) 2004-06-18 2011-09-27 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
US7884207B2 (en) 2004-06-18 2011-02-08 3M Innovative Properties Company Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
US9550773B2 (en) 2004-06-18 2017-01-24 3M Innovative Properties Company Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
US8143270B2 (en) 2004-09-02 2012-03-27 3M Innovative Properties Company 2-amino 1H-in-imidazo ring systems and methods
US20090005376A1 (en) * 2004-09-02 2009-01-01 3M Innovative Properties Company 1-Alkoxy 1H-Imidazo Ring Systems and Methods
US7579359B2 (en) 2004-09-02 2009-08-25 3M Innovative Properties Company 1-alkoxy 1H-imidazo ring systems and methods
US20080193487A1 (en) * 2004-10-08 2008-08-14 Johannes-Gutenberg-Universitaet Mainz Preparation for Vaccination, Vaccination Method and Use of a Vaccination Preparation
US9017654B2 (en) 2004-10-08 2015-04-28 Johannes-Gutenberg-Universitaet Mainz Preparation for vaccination, vaccination method and use of a vaccination preparation
US20070243215A1 (en) * 2004-10-08 2007-10-18 Miller Richard L Adjuvant for Dna Vaccines
US8003126B2 (en) 2004-11-17 2011-08-23 Biomarin Pharmaceutical Inc. Stable tablet formulation
US8557838B2 (en) 2004-12-17 2013-10-15 Medicis Pharmaceutical Corporation Immune response modifier formulations containing oleic acid and methods
US8546383B2 (en) 2004-12-30 2013-10-01 3M Innovative Properties Company Chiral fused [1,2]imidazo[4,5-c] ring compounds
US20090124652A1 (en) * 2004-12-30 2009-05-14 Takeda Pharmaceutical Company Limited Polymorphs of 1-(2-Methylpropyl)-1H-Imidazo[4,5-C][1,5]Naphthyridin-4-Amine Ethane-Sulfonate
US7943609B2 (en) 2004-12-30 2011-05-17 3M Innovative Proprerties Company Chiral fused [1,2]imidazo[4,5-C] ring compounds
US8034938B2 (en) 2004-12-30 2011-10-11 3M Innovative Properties Company Substituted chiral fused [1,2]imidazo[4,5-c] ring compounds
US8461174B2 (en) 2004-12-30 2013-06-11 3M Innovative Properties Company Treatment for cutaneous metastases
US8207162B2 (en) 2004-12-30 2012-06-26 3M Innovative Properties Company Chiral fused [1,2]imidazo[4,5-c] ring compounds
US8350034B2 (en) 2004-12-30 2013-01-08 3M Innovative Properties Company Substituted chiral fused [1,2]imidazo[4,5-C] ring compounds
US20080188513A1 (en) * 2004-12-30 2008-08-07 Taked Pharmaceutical Company Limited 1-(2-Methylpropyl)-1H-Imidazo[4,5-C](1,5]Naphthyridin-4-Amine Ethanesulfonate and 1-(2-Methylpropyl)-1H-Imidazo[4,5-C](1,5]Naphthyridin-4-Amine Methanesulfonate
US20100056557A1 (en) * 2004-12-30 2010-03-04 Bernd Benninghoff Treatment for cutaneous metastases
US10071156B2 (en) 2005-02-04 2018-09-11 3M Innovative Properties Company Aqueous gel formulations containing immune response modifiers
US9248127B2 (en) * 2005-02-04 2016-02-02 3M Innovative Properties Company Aqueous gel formulations containing immune response modifiers
US20090163532A1 (en) * 2005-02-04 2009-06-25 Coley Pharmaceutical Group, Inc. Aqueous Gel Formulations Containing Immune Response Modifiers
US8378102B2 (en) 2005-02-09 2013-02-19 3M Innovative Properties Company Oxime and hydroxylamine substituted thiazolo[4,5-c] ring compounds and methods
US9546184B2 (en) 2005-02-09 2017-01-17 3M Innovative Properties Company Alkyloxy substituted thiazoloquinolines and thiazolonaphthyridines
US7968563B2 (en) 2005-02-11 2011-06-28 3M Innovative Properties Company Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods
US8658666B2 (en) 2005-02-11 2014-02-25 3M Innovative Properties Company Substituted imidazoquinolines and imidazonaphthyridines
US8178677B2 (en) 2005-02-23 2012-05-15 3M Innovative Properties Company Hydroxyalkyl substituted imidazoquinolines
US8846710B2 (en) 2005-02-23 2014-09-30 3M Innovative Properties Company Method of preferentially inducing the biosynthesis of interferon
US8158794B2 (en) 2005-02-23 2012-04-17 3M Innovative Properties Company Hydroxyalkyl substituted imidazoquinoline compounds and methods
US8343993B2 (en) 2005-02-23 2013-01-01 3M Innovative Properties Company Hydroxyalkyl substituted imidazonaphthyridines
US7943610B2 (en) 2005-04-01 2011-05-17 3M Innovative Properties Company Pyrazolopyridine-1,4-diamines and analogs thereof
US7943636B2 (en) 2005-04-01 2011-05-17 3M Innovative Properties Company 1-substituted pyrazolo (3,4-C) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases
US20080193474A1 (en) * 2005-04-25 2008-08-14 Griesgraber George W Immunostimulatory Compositions
US8188111B2 (en) 2005-09-09 2012-05-29 3M Innovative Properties Company Amide and carbamate derivatives of alkyl substituted N-[4-(4-amino-1H-imidazo[4,5-c]quinolin-1-yl)butyI]methanesulfonamides and methods
US8476292B2 (en) 2005-09-09 2013-07-02 3M Innovative Properties Company Amide and carbamate derivatives of N-{2-[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c] quinolin-1-Yl]-1,1-dimethylethyl}methanesulfonamide and methods
WO2007045901A1 (en) * 2005-10-21 2007-04-26 Nilufer Smith Innovations Limited Improvements in and relating to disposable dispensers for personal use
GB2431356B (en) * 2005-10-21 2011-02-09 Nilufer Smith Innovations Ltd Improvements in and relating to disposable dispensers for personal use
US20080249462A1 (en) * 2005-10-21 2008-10-09 Nilufer Smith Innovations Limited Disposable Dispensers for Personal Use
US8377957B2 (en) 2005-11-04 2013-02-19 3M Innovative Properties Company Hydroxy and alkoxy substituted 1H-imidazoquinolines and methods
US8088790B2 (en) 2005-11-04 2012-01-03 3M Innovative Properties Company Hydroxy and alkoxy substituted 1H-imidazoquinolines and methods
US10472420B2 (en) 2006-02-22 2019-11-12 3M Innovative Properties Company Immune response modifier conjugates
US8329721B2 (en) 2006-03-15 2012-12-11 3M Innovative Properties Company Hydroxy and alkoxy substituted 1H-imidazonaphthyridines and methods
US7906506B2 (en) 2006-07-12 2011-03-15 3M Innovative Properties Company Substituted chiral fused [1,2] imidazo [4,5-c] ring compounds and methods
US8178539B2 (en) 2006-09-06 2012-05-15 3M Innovative Properties Company Substituted 3,4,6,7-tetrahydro-5H-1,2a,4a,8-tetraazacyclopenta[cd]phenalenes and methods
US10144735B2 (en) 2006-12-22 2018-12-04 3M Innovative Properties Company Immune response modifier compositions and methods
US10005772B2 (en) 2006-12-22 2018-06-26 3M Innovative Properties Company Immune response modifier compositions and methods
US20100158928A1 (en) * 2006-12-22 2010-06-24 Doris Stoermer Immune response modifier compositions and methods
US8419712B2 (en) 2008-10-07 2013-04-16 Christcot Medical Company Method and apparatus for inserting a rectal suppository
US9662481B2 (en) 2008-10-07 2017-05-30 Cristcot Llc Method and apparatus for inserting a rectal suppository
US8192393B2 (en) 2008-10-07 2012-06-05 Christcot Medical Company Method and apparatus for inserting a rectal suppository
US20100087797A1 (en) * 2008-10-07 2010-04-08 Christcot Medical Company Method and apparatus for inserting a rectal suppository
US10525242B2 (en) 2008-10-07 2020-01-07 Cristcot Llc Method and apparatus for inserting a rectal suppository
US10821176B2 (en) 2010-08-17 2020-11-03 3M Innovative Properties Company Lipidated immune response modifier compound compositions, formulations, and methods
US11524071B2 (en) 2010-08-17 2022-12-13 3M Innovative Properties Company Lipidated immune response modifier compound compositions, formulations, and methods
US9795669B2 (en) 2010-08-17 2017-10-24 3M Innovative Properties Company Lipidated immune response modifier compound compositions, formulations, and methods
US10052380B2 (en) 2010-08-17 2018-08-21 3M Innovative Properties Company Lipidated immune response modifier compound compositions, formulations, and methods
US10383938B2 (en) 2010-08-17 2019-08-20 3M Innovative Properties Company Lipidated immune response modifier compound compositions, formulations, and methods
US12201688B2 (en) 2010-08-17 2025-01-21 Solventum Intellectual Properties Company Lipidated immune response modifier compound compositions, formulations, and methods
US9242980B2 (en) 2010-08-17 2016-01-26 3M Innovative Properties Company Lipidated immune response modifier compound compositions, formulations, and methods
US9107958B2 (en) 2011-06-03 2015-08-18 3M Innovative Properties Company Hydrazino 1H-imidazoquinolin-4-amines and conjugates made therefrom
US9475804B2 (en) 2011-06-03 2016-10-25 3M Innovative Properties Company Heterobifunctional linkers with polyethylene glycol segments and immune response modifier conjugates made therefrom
US10406142B2 (en) 2011-06-03 2019-09-10 3M Lnnovative Properties Company Hydrazino 1H-imidazoquinolin-4-amines and conjugates made therefrom
US9902724B2 (en) 2011-06-03 2018-02-27 3M Innovative Properties Company Heterobifunctional linkers with polyethylene glycol segments and immune response modifier conjugates made therefrom
US10723731B2 (en) 2011-06-03 2020-07-28 3M Innovative Properties Company Heterobifunctional linkers with polyethylene glycol segments and immune response modifier conjugates made therefrom
US9585968B2 (en) 2011-06-03 2017-03-07 3M Innovative Properties Company Hydrazino 1H-imidazoquinolin-4-amines and conjugates made therefrom
US10441397B2 (en) * 2011-09-16 2019-10-15 Boston Scientific Scimed, Inc. Medical device and method for conducting a surgery through a body opening
US9216178B2 (en) 2011-11-02 2015-12-22 Biomarin Pharmaceutical Inc. Dry blend formulation of tetrahydrobiopterin
BE1020555A5 (en) * 2012-10-10 2013-12-03 Euro Medical Bvba RESEARCH METHOD.
US10149967B2 (en) 2012-10-19 2018-12-11 Cristcot Llc Suppository insertion device, suppository, and method of manufacturing a suppository
US11224727B2 (en) 2012-10-19 2022-01-18 Cristcot Llc Suppository insertion device, suppository, and method of manufacturing a suppository
US12337130B2 (en) 2012-10-19 2025-06-24 Cristcot Llc Suppository insertion device, suppository, and method of manufacturing a suppository
US11298515B2 (en) 2016-05-12 2022-04-12 Cristcot Llc Single-use suppository insertion device and method
US12156984B2 (en) 2016-05-12 2024-12-03 Cristcot Llc Single-use suppository insertion device and method
US11306083B2 (en) 2017-12-20 2022-04-19 3M Innovative Properties Company Amide substituted imidazo[4,5-C]quinoline compounds with a branched chain linking group for use as an immune response modifier
WO2022006259A1 (en) * 2020-07-01 2022-01-06 Revelation Biosciences, Inc. Immunostimulatory compositions and methods

Also Published As

Publication number Publication date
US6706728B2 (en) 2004-03-16
US20030045543A1 (en) 2003-03-06

Similar Documents

Publication Publication Date Title
US6706728B2 (en) Systems and methods for treating a mucosal surface
US6245776B1 (en) Formulations and methods for treatment of mucosal associated conditions with an immune response modifier
US6486168B1 (en) Formulations and methods for treatment of mucosal associated conditions with an immune response modifier
US10071156B2 (en) Aqueous gel formulations containing immune response modifiers
EP1495758A2 (en) Formulations and methods for treatment of mucosal associated conditions with an immune response modifier
US9642998B2 (en) Pump systems and methods for storing and dispensing a plurality of precisely measured unit-doses of imiquimod cream
US20060216333A1 (en) Methods related to the treatment of mucosal associated conditions
AU2001270081A1 (en) Systems and methods for treating a mucosal surface
RU2349321C2 (en) Systems and methods of mucosa surface treatment
AU2006252154A1 (en) Systems and methods for treating a mucosal surface

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: EXPRESSLY ABANDONED -- DURING PUBLICATION PROCESS

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载